n-terminal functionalized amino acid derivatives capable of forming drug encapsulation microspheres,

专利摘要:
patent abstract: "N-terminal functionalized amino acid derivatives capable of forming drug encapsulation microspheres". The present invention relates to compounds and compositions which are characterized by the markush formulas (i), (ii), (iii), (iv), (v), and (vi) below, wherein at least one terminal amino group is also functionalized by carrying a group of type (i), (ii) or (iii). such compounds are obtained by reacting the terminal amino group with epoxides or acrylates carrying long-chain hydrocarbon groups. the resulting amphiphilic molecules (referred to as "appls" in the application) are considered to be useful as a drug delivery system, including nucleotide delivery to cells. formulas (i), (ii) and (iii) are: (i)(ii)(iii)(iv)(v)(vi) wherein m, n, p, r', r1, r2, r3, r4, r5, r8, z, w, y, and z are as defined here.
公开号:BR112014010050A2
申请号:R112014010050-0
申请日:2012-10-26
公开日:2020-06-30
发明作者:Yizhou Dong；Kevin Thomas Love；Robert S. Langer；Daniel Griffith Anderson；Delai Chen；Yi Chen；Arturo Jose Vegas；Akinleye Alabi；Yunlong Zhang
申请人:Massachusetts Institute Of Technology；
IPC主号:

专利说明:

[001] [001] The present application claims priority under 35 U.S.C. $119(e) for the United States Provisional Patent Application, U.S.S.N. 61/552,423, filed October 27, 2011, which is incorporated herein by reference. Government Support
[002] [002] This invention was made with government support under Grant No. R37 EBOO00244 granted by the National Institutes of Health. The government has certain rights in this invention. Background of the Invention
[003] [003] The ability to silence genes through RNA interference (RNAi) was reported by Mello and Fire in 1998. See Fire et al., Nature (1998) 391:806-811. Since then, scientists have rushed to take advantage of the enormous therapeutic potential driven by targeted gene reduction. This is evidenced by the fact that the first report of small interference RNA (SIRNA) mediated by RNAi in humans was reported only twelve years after the phenomenon was described in Caenorhabditis elegans. See Davis et al., Nature (2010) 464:1067-1070. It is well understood that the development of gene drugs is slowed by the inability to release nucleic acids effectively in vivo. When unprotected, genetic material injected into the bloodstream can be degraded by DNAases and RNAases, or, if not degraded, the genetic material can stimulate an immune response. See, for example, Whitehead and others,
[004] [004] To overcome delivery difficulties, nucleotides were complexed with a wide variety of delivery systems, including polymers, lipids, inorganic nanoparticles and viruses. See, for example, Peer et al., Nature Nanotechnology, (2007) 2:751-
[005] [005] Described herein are inventive compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide. , or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as "APPLs". Such APPLs are found to be useful for a variety of applications, such as, for example, improved nucleotide release.
[006] [006] Exemplary APPLs include, but are not limited to, compounds of formula (1), (11), (III), (IV), (V), and (VI), and salts thereof, as described herein: www
[007] [007] where m, n, p, R' ,R', R2, Rº, R$, R$, R$, Z, W, Y, and Z are as defined here, provided that the APPL comprises at least one case of a group of formula (i), (ii), or (iii):
[008] [008] each case of R' is independently hydrogen or optionally substituted alkyl;
[009] [009] X is O, S, NR, wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[0010] [0010] Yéo,S,NR", wherein R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
[0011] [0011] Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and
[0012] [0012] R!| optionally substituted C1-55 alkyl, optionally substituted C2-55 alkenyl, optionally substituted C1-55 alkynyl, optionally substituted heteroC1-55 alkyl, optionally substituted heteroC1-5,5 alkenyl, optionally substituted heteroC1-55 alkynyl
[0013] [0013] In certain embodiments, the formula (i) group represents a formula (i-a) group or a formula (i-b) group: Rx R Ro YRP O" No. i R-R.(i-a)(i-b).
[0014] [0014] In certain embodiments, the formula group (i-a) is a formula group (i-a1) or a formula group (i-a2):
[0015] [0015] In certain embodiments, the formula group (ib) is a formula group (i-b1) or a formula group (i-b2): RR: QD" RL" YR ” R (i-b1) ) (i-b2)
[0016] [0016] In certain embodiments, at least one case of R' is a group of formula: 6 to R (iv)
[0017] [0017] wherein L is an optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally arylene substituted, or op-
[0018] [0018] Rº and R' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , and a nitrogen protecting group;
[0019] [0019] provided that at least one case of Rº and R is a formula group: Rdv As Ú OR = fra ) (ii) o where:
[0020] [0020] each case of R' is independently hydrogen or optionally substituted alkyl;
[0021] [0021] XéoO, S, NR“, wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[0022] [0022] "Yéo,S, NR", wherein R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[0023] [0023] Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl
[0024] [0024] R" is optionally substituted C1-50 alkyl, optionally substituted C1-55 alkenyl, optionally substituted C1-55 alkynyl, optionally substituted heteroC1-50 alkyl, optionally substituted heteroC1-5,5 alkenyl, optionally substituted heteroC >2-55 alkynyl, or a polymer.
[0025] [0025] In certain embodiments, each case of R' is hydrogen.
[0026] [0026] In certain embodiments, L is an optionally substituted alkylene.
[0027] [0027] In certain modalities, the group of formula (iv) is of the formula: nº Ágor
[0028] [0028] where q is an integer between 1 and 50, inclusive.
[0029] [0029] In certain embodiments, each case of R' is a group of formula (iv).
[0030] [0030] An exemplary APPL of the present invention is composed (cCKK-E12): en mo TS aodos o (cKK-E12),
[0031] [0031] or a salt thereof.
[0032] [0032] In another aspect, compositions are provided which comprise an APPL or a salt thereof.
[0033] [0033] For example, in certain embodiments, a composition is provided which comprises an APPL or salt thereof and, optionally, an excipient, wherein the APPL is an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide , or structural isomer thereof, and wherein an amino or amide group of the APPL is conjugated to a group of formula (i), (ii), or (iii). In certain embodiments, the group of formula (i), (ii), or (iii) is attached to an amino group present on the APPL scaffold. In certain embodiments, the composition is a pharmaceutical composition, a cosmetic composition, a nutraceutical composition, or a composition with non-medical application. In certain embodiments, the composition for non-medical application is an emulsion or emulsifier useful as a food component, for quenching sting, for disinfecting surfaces, or for deoiling.
[0034] [0034] In certain embodiments, a composition also comprises an agent. In certain embodiments, the agent is an organic molecule, an inorganic molecule, nucleic acid, protein, peptide, polynucleotide, targeting agent, an isotopically labeled chemical compound, vaccine, an immunological agent, or an agent useful for bioprocessing, e.g. example, in the intracellular manufacture of proteins. In certain embodiments, the agent is a polynucleotide, and the polynucleotide is DNA or RNA. In certain embodiments, the RNA is RNA, dsRNA, siRNA, shRNA, miRNA, or antisense RNA. In certain embodiments, the agent and APPL are non-covalently linked, for example, for example, the agent and APPL are non-covalently complexed with each other. However, in certain embodiments, the agent and APPL are covalently linked.
[0035] [0035] In certain embodiments, the composition is in the form of a particle. In certain embodiments, the particle is a nanoparticle or microparticle. In certain embodiments, the particle is a micelle, liposome, or lipoplex. In certain embodiments, the particle encapsulates an agent, for example, an agent to be delivered.
[0036] [0036] In another aspect, there is provided a method of delivering a polynucleotide to a biological cell, comprising providing a composition comprising an APPL, or salt thereof, and a polynucleotide, and exposing a composition to the biological cell under sufficient conditions. to facilitate the release of the polynucleotide into the interior of the biological cell; wherein the APPL is an amino acid, a linear or cyclic peptide, or a linear or cyclic polypeptide, or structural isomer thereof, wherein an amino or amide group of the APPL is conjugated to a group of formula (i), ( ii), or (ili))). In certain embodiments, the polynucleotide is DNA or RNA. In certain embodiments, the RNA is RNA, dsRNA, siRNA, shRNA, miRNA, or antisense RNA. In certain embodiments, in the release of RNA into the cell, the RNA is able to interfere with the expression of a specific gene in the biological cell.
[0037] [0037] In yet another aspect, evaluation methods are provided. For example, in one embodiment, a method of evaluating a compound library is provided, the method comprising providing a plurality of different APPLs, or salts thereof, and performing at least one assay with the compound library to determine the presence or absence of a desired property; wherein the APPL is an amino acid, a linear or cyclic peptide, or a linear or cyclic polypeptide, or structural isomer thereof, wherein an amino or amide group of the APPL is conjugated to a group of formula (i), ( ii), or (ili))) In certain embodiments, the desired property is water solubility, solubility at different pH, ability to bind a polynucleotide, ability to bind heparin, ability to bind to small molecules, ability to bind protein, ability to form microparticles, ability to increase transfection efficiency, ability to support growth
[0038] [0038] In yet another aspect, methods of using the inventive APPLs for the treatment of various diseases, disorders, or conditions are provided. For example, in certain embodiments, there is provided a method of treating a disease, disorder, or condition from which the individual is suffering, comprising administering to an individual in need thereof an effective amount of an APPL, or salt thereof, in that APPL is an amino acid, linear or cyclic peptide, or linear or cyclic polypeptide, or structural isomer thereof, wherein an amino or amide group of APPL is conjugated to a group of formula (i), (ii), or (iii).
[0039] [0039] Details of one or more embodiments of the invention are mentioned here. Other aspects, objects, and advantages of the invention will be apparent from the Detailed Description, the Figures, the Examples, and the Claims. Definitions Chemical Definitions
[0040] [0040] Definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are identified according to the Periodic Table of Elements, CAS version, Handbook of Chemistry and Physics, 75th Edition, inside cover, and specific functional groups are generally defined as described here. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; There-
[0041] [0041] Compounds described herein may comprise one or more asymmetric centers, and thus may exist in various isomeric forms, for example enantiomers and/or diastereomers. For example, the compounds described herein may be in the form of a single enantiomer, diastereomer or geometric isomer, or they may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates, and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, E.-L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The invention further encompasses compounds as individual isomers substantially free of other isomers, and alternatively, mixtures of various isomers.
[0042] [0042] When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, "C1.;"alkyl" is intended to encompass, C1, C2, C3, Ca, Cs, C6, C1.6, C15, C1a, C13, C12) Ca-6, Cas, Caa4, Co3 , C36, Cas, Cas, Cas, Cas, E C5-6 alkyl.
[0043] [0043] As used herein, "alkyl" refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 50 carbon atoms ("C1.5.5 alkyl"). In some embodiments, an alkyl group has 1 to 40 carbon atoms ("C14o alkyl"). In some embodiments, an alkyl group has 1 to 30 carbon atoms ("C1-309 alkyl"). In some embodiments, an alkyl group has 1 to carbon atoms ("C1.2.5 alkyl""). In some embodiments, an alkyl group has 1 to 10 carbon atoms ("C16 alkyl"). In some embodiments, an alkyl group has 1 to 9 carbon atoms ("C16 alkyl"). , an alkyl group has 1 to 8 carbon atoms ("C1; alkyl").. In some embodiments, an alkyl group has 1 to 7 carbon atoms ("C1; alkyl"). In some embodiments, an alkyl group has 1 to 6 carbon atoms ("C1-6 alkyl"). In some embodiments, an alkyl group has 1 to 5 carbon atoms ("C,5 alkyl"). alkyl group has 1 to 4 carbon atoms ("C1, alkyl"). In some embodiments, an alkyl group has 1 to 3 carbon atoms ("C,-; alkyl"). alkyl group has 1 to 2 carbon atoms ("C, > alkyl"). In some embodiments, an alkyl group has 1 carbon atom ("C, alkyl"). In some embodiments, an alkyl group has 2 to 6 atoms of carbon ("C> «alkyl"). Examples of C;-;alkyl groups include methyl (C 1 ), ethyl (C 1 ), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C s ), tert-butyl (C 1 ), sec-butyl (C s ), iso- butyl (Ca), n-pentyl (Cs), 3-pentanyl (Cs), amyl (Cs), neopentyl (Cs), 3-methyl-2-butanyl (Cs), tertiary amyl (Cs), and n-hexyl (C;)) Additional examples of alkyl groups include n-heptyl (C;), n-octyl (C;) and the like. Unless otherwise specified, each case of an alkyl group is independently unsubstituted (an "unsubstituted alkyl") or substituted (an "substituted alkyl") with one or more substituents. In certain embodiments, the alkyl group is an unsubstituted C155 alkyl. In certain embodiments, the alkyl group is a substituted C150 alkyl.
[0044] [0044] As used herein, "heteroalkyl" refers to an alkyl group as defined herein that also includes at least one heteroalkyl
[0045] [0045] As used herein, "alkenyl" refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 50 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds) ("C>5o alkenyl"). In some embodiments, an alkenyl group has 2 to 40 carbon atoms ("C2 405 alkenyl"). In some embodiments, an alkenyl group has 2 to 30 carbon atoms ("C>2-35 alkenyl"). In some embodiments, an alkenyl group has 2 to 20 carbon atoms ("C>-20 alkenyl"). In some embodiments, an alkenyl group has 2 to 10 carbon atoms ("C>1st alkenyl"). In some embodiments, an alkenyl group has 2 to 9 carbon atoms ("C>+ alkenyl"). In some embodiments, an alkenyl group has 2 to 8 carbon atoms ("C>; alkenyl"). In some embodiments, an alkenyl group has 2 to 7 carbon atoms ("C>; alkenyl"). In some embodiments, an alkenyl group has 2 to 6 carbon atoms ("C>.; alkenyl"). In some embodiments, an alkenyl group has 2 to 5 carbon atoms ("C>-; alkenyl"). In some embodiments, an alkenyl group has 2 to 4 carbon atoms ("C>, alkenyl"). In some embodiments, an alkenyl group has 2 to 3 carbon atoms ("C2-3 alkenyl"). In some embodiments, an alkenyl group has 2 carbon atoms ("C, alkenyl"). One or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C₂, alkenyl groups include (C₁₋₆), 1-propenyl (C₃), 2-propenyl (C₃), 1-butenyl (C₄), 2-butenyl (C₁), butadienyl (C₁₋₆), and the like. Examples of groups C>; alkenyl include the aforementioned C₁, alkenyl groups as well as pentenyl (Cs), pentadienyl (Cs), hexenyl (Cs), and the like. Additional examples of alkenyl include heptenyl (C1), octenyl (Cs), octatrienyl (Cs), and the like. Unless otherwise specified, each case of an alkenyl group is independently unsubstituted (an "unsubstituted alkenyl") or substituted (a "substituted alkenyl") with one or more substituents. In certain embodiments, the alkenyl group is an unsubstituted C>5th alkenyl. In certain embodiments, the alkenyl group is a substituted C>2-500 alkenyl.
[0046] [0046] As used herein, "heteroalkenyl" refers to an alkenyl group as defined herein, which also includes at least one heteroatom (e.g., 1 to 25, e.g., 1, 2, 3, or 4 heteroatom). - mos) selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorous within (ie, inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain.
[0047] [0047] As used herein, "alkynyl" refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 50 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) and optionally one or more double bonds (e.g. 1, 2, 3, or 4 double bonds) ("Cx 50 alkynyl"). An alkynyl group that has one or more triple bonds and one or more double bonds is also referred to as an "ene-yene". In some embodiments, an alkynyl group has 2 to 40 carbon atoms ("C>-,49 alkynyl"). In some embodiments, an alkynyl group has 2 to 30 carbon atoms ("C>39 alkynyl"). In some embodiments, an alkynyl group has 2 to 20 carbon atoms ("C2-20o alkynyl"). In some embodiments, an alkynyl group has 2 to 10 carbon atoms ("C2-10o alkynyl"). In some embodiments, an alkynyl group has 2 to 9 carbon atoms ("C>, alkynyl"). In some embodiments, an alkynyl group has 2 to 8 carbon atoms ("C>; alkynyl"). In some embodiments, an alkynyl group has
[0048] [0048] As used herein, "heteroalkynyl" refers to an alkynyl group as defined herein that also includes at least one heteroatom (e.g., 1 to 25, e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorus within (ie, inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 50 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC> is alkynyl"). In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 40 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC > 10 alkynyl"). In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 30 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC>2 alkynyl"). In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 20 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC>2 2, alkynyl")). .. In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC>2 15 alkynyl") . In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC 1 , alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC, ; alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC>2; alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC>7; alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain ("heteroC,2; alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain ("heteroC, , alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom within the parent chain ("heteroC, ;3 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain ("heteroC₁₋₆alkynyl"). Unless otherwise specified, each case of a heteroalkynyl group is independently unsubstituted (an "unsubstituted heteroalkynyl") or substituted (a "substituted heteroalkynyl") with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted heteroC, 5th alkynyl. In certain embodiments, the heteroalkynyl group is a substituted heteroC, 5th alkynyl.
[0049] [0049] As used herein, "carbocyclyl" or "carbocyclic" refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms ("C3z-105 carbocyclyl") and zero heteroatoms. in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms ("C;3 ; carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms ("C;3 ; carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C3z-6 carbocyclyl"). In some embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms ("C₁₋₄ carbocyclyl"). In some embodiments, a carbocyclyl group has 5 to 6 ring carbon atoms ("Cs 5 carbocyclyl"). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms ("Cs 195 carbocyclyl"). C3z groups 6; Exemplary carbocyclyl include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (Ca), cyclobutenyl (Ca), cyclopentyl (Cs), cyclopentenyl (Cs), cyclohexyl (Cs), cyclohexenyl (Cs) , cyclohexadienyl (Cs), and the like. Exemplary C13z 68 carbocyclyl groups include, without limitation, the aforementioned C groups; ; carbocyclyl as well as cycloheptyl (C;), cycloheptenyl (C;), cycloheptadienyl (C;), cycloheptatrienyl (C;), cyclooctyl (C;), cyclooctenyl
[0050] [0050] In some embodiments, "carbocyclyl" or "carbocyclic" is referred to as a "cycloalkyl", that is, a saturated, monocyclic carbocyclyl group having 3 to 10 ring carbon atoms ("C3 1st cycloalkyl "). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C3z; cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C3 cycloalkyl"). In some embodiments, a cycloalkyl group has 4 to 6 ring carbon atoms ("C3;cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("C; cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("Cs 1st cycloalkyl"). E-examples of Cs groups; Cycloalkyl include cyclopentyl (Cs) and cyclohexyl (Cs). Examples of C3- groups; cycloalkyl include the aforementioned Cs groups; cCycloalkyl as well as cyclopropyl (C3) and cyclobutyl (Ca). Examples of C;3 groups; cycloalkyl include the aforementioned C;3 groups; cycloalkyl, as well as cycloheptyl (C₁) and cyclooctyl (C₁). Unless otherwise specified, each case of a cycloalkyl group is independently unsubstituted (an "unsubstituted cycloalkyl") or substituted (a "substituted cycloalkyl") with one or more substituents. In certain embodiments, the cycloalkyl group is an unsubstituted C3z 10 cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C13 cycloalkyl.
[0051] [0051] As used herein, "heterocyclyl" or "heterocyclic" refers to a radical of a 3- to 14-membered non-aromatic ring system having ring carbon atoms and 1 or more (e.g., 1, 2, 3 , or 4) ring heteroatoms, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorous ("3- to 14-membered heterocyclyl"). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valence permits. A heterocyclyl group can either be monocyclic ("monocyclic heterocyclyl") or polycyclic (e.g., a fused, bridged, or spiro ring system such as a bicyclic system ("bicyclic heterocyclyl") or tricyclic system ("tricyclic heterocyclyl")), and may be saturated or may contain one or more carbon-carbon double or triple bonds. Polycyclic heterocyclyl ring systems may include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which the heterocyclyl ring, as defined above, is fused to one or more carbocyclyl groups in which the point of attachment is on the carbocyclyl or heterocyclyl ring, or ring systems in which the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, where the point of attachment is on the heterocyclyl ring, and in such cases, the number of ring members continues to denote the number of ring members. ring in the heterocyclyl ring system. Unless otherwise specified, each case of heterocyclyl is independently unsubstituted (an "unsubstituted heterocyclyl") or substituted (a "substituted" heterocyclyl) with one or more substituents. In certain embodiments, the heterocyclyl group is a 3- to 14-membered unsubstituted heterocyclyl. In certain embodiments, the heterocyclyl group is a 3- to 14-membered substituted heterocyclyl.
[0052] [0052] In some embodiments, a heterocyclyl group is a 5- to 10-membered non-aromatic ring system having ring carbon atoms and 1 or more (e.g., 1, 2, 3, or 4) heteroatoms. ring, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorous ("5- to 10-membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5- to 8-membered non-aromatic ring system having ring carbon atoms and 1 or more (e.g., 1, 2, 3, or 4) ring heteroatoms, where each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorous ("5- to 8-membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5- to 6-membered non-aromatic ring system having ring carbon atoms and 1 or more (e.g., 1, 2, 3, or 4) ring heteroatoms, where each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorous ("5- to 6-membered heterocyclyl"). In some embodiments, the 5- to 6-membered heterocyclyl has 1 or more (eg, 1, 2, or 3) ring heteroatoms selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorus. In some embodiments, the 5- to 6-membered heterocycle has 1 or 2 ring heteroatoms selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorus. In some embodiments, the 5- to 6-membered heterocyclyl has 1 ring heteroatom selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorus.
[0053] [0053] Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azirdinyl, oxiranyl, thiorenyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, dioxanyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, triazinenyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl, oxepanyl and tiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydro-
[0054] [0054] As used herein, "aryl" refers to a radical of a monocyclic or polycyclic (eg, bicyclic or tricyclic) 4n+2 aromatic ring system (eg, having 6, 10, or 14 | ) shared electrons in a cyclic arrangement) having 6 to 14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ("Ce 11 aryl"). In some embodiments, an aryl group has 6 ring carbon atoms ("Cs aryl"; e.g., phenyl)). In some embodiments, an aryl group has 10 ring carbon atoms ("Cio aryl "; e.g., naphthyl such as 1-—naphthyl and 2—naphthyl))) In some embodiments, an aryl group has 14 ring carbon atoms ("Ca, aryl"; e.g., anthracyl). "Aryl" also includes ring systems in which the aryl ring, as defined above, is fused to one or more carbocyclyl or heterocyclyl groups in which the radical or point of attachment is on the aryl ring, and in such cases, the number of carbon atoms continues to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each case of an aryl group is independently unsubstituted (an "unsubstituted aryl") or substituted (a "substituted aryl") with one or more substituents. In certain embodiments, the aryl group is an unsubstituted Ce 11 aryl. In certain embodiments, the aryl group is a substituted aryl.
[0055] [0055] As used herein, "heteroaryl" refers to a radical of a 5- to 14-membered 4n+2 monocyclic or polycyclic (e.g., bicyclic or tricyclic) aromatic ring system (e.g., having 6, 10 , or 14 n shared electrons in a cyclic arrangement) having ring carbon atoms and 1 or more (e.g., 1, 2, 3 ring, or 4 heteroatoms) ring heteroatoms provided in the aromatic ring system, where each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorus ("5- to 14-membered heteroaryl"). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valence permits. Polycyclic heteroaryl ring systems may include one or more heteroatoms in one or both rings. "Heteroaryl" includes ring systems in which the heteroaryl ring, as defined above, is fused to one or more carbocyclyl or heterocyclyl groups in which the point of attachment is on the heteroaryl ring, and in such cases, the number of members of ring continue to designate the number of ring members in the heteroaryl ring system. "Heteroaryl" also includes ring systems in which the heteroaryl ring, as defined above, is fused to one or more aryl groups in which the point of attachment is on the aryl or heteroaryl ring, and in such cases, the number of ring members designates the number of ring members in the fused polycyclic ring system (aryl/heteroaryl). Polycyclic heteroaryl groups in which one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment may be either on the ring, i.e., or the ring carrying a heteroatom (e.g., 2- indolyl) or the ring that does not contain a heteroatom (e.g. 5-indolyl).
[0056] [0056] In some embodiments, a heteroaryl group is a 5- to 10-membered aromatic ring system having ring carbon atoms and 1 or more (e.g., 1, 2, 3, or 4) provided ring heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorous ("5- to 10-membered heteroaryl"). In some embodiments, a heteroaryl group is a 5- to 8-membered aromatic ring system having ring carbon atoms and 1 or more (e.g., 1, 2, 3, or 4) ring heteroatoms provided in the aromatic ring system, in which each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorus ("5- to 8-membered heteroaryl"). In some embodiments, a heteroaryl group is a 5- to 6-membered aromatic ring system having ring carbon atoms and 1 or more (e.g., 1, 2, 3, or 4) ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorous ("5- to 6-membered heteroaryl"). In some embodiments, the 5- to 6-membered heteroaryl has 1 or more (eg, 1, 2, or 3) ring heteroatoms selected from oxygen, sulfur, nitrogen, boron, silicon, or phosphorus.
[0057] [0057] Exemplary 5-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing 4 heteroatoms include, without limitation, tetrazolyl. Exemplary 6-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing 1 heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include, without limitation, phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl and phenazinyl.
[0058] [0058] As used herein, the term "partially unsaturated" refers to a ring moiety that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic groups (eg, aryl or heteroaryl moieties) as defined herein.
[0059] [0059] As used herein, the term "saturated" refers to a portion of a ring that does not contain a double or triple bond, that is, the ring contains all single bonds.
[0060] [0060] The affixing of the suffix "-ene" to a group indicates that the group is a divalent moiety, e.g. alkylene is the divalent moiety of alkyl, alkenylene is the divalent moiety of alkenyl, alkynylene is the divalent moiety of alkynyl, heteroalkylene is the divalent moiety of heteroalkyl, heteroalkenylene is the divalent moiety of heteroalkenyl, heteroalkynylene is the divalent moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl, heterocyclylene is the divalent moiety of heterocyclyl, arylene is the divalent moiety of aryl, and heteroarylene is the divalent moiety of heteroaryl.
[0061] [0061] As understood from the foregoing, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are, in certain embodiments, optionally substituted. Optionally substituted refers to a group that may be substituted or unsubstituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl substituted", "substituted" or "unsubstituted" heteroalkyl, "substituted" or "unsubstituted" heteroalkenyl, "substituted" or "unsubstituted" heteroalkynyl, "substituted" or "unsubstituted" carbocyclyl, heterocyclyl "substituted" or "unsubstituted", "substituted" or "unsubstituted" aryl or "substituted" or "unsubstituted" heteroaryl). In general, the term "substituted" means that at least one hydrogen present in a group is substituted with a permissible substituent, e.g. a substituent which on substitution results in a stable compound, e.g. a compound that does not spontaneously undergoes transformation such as by reorganization, cyclization, elimination, or other reaction. Unless otherwise noted, a "substituted" group has a substituent at one or more substitutable positions within the group, and when more than one position in any given structure is substituted, the substituent is either the same or different in each position. The term "substituted" is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein that satisfies the valencies of the heteroatoms and results in the formation of a stable moiety.
[0062] [0062] Exemplary carbon atom substituents include, but are not limited to, halogen, -CN, -NO,, -N3, -SOz2H, —SO3H, -OH, -—OR*, -ON(R),, <N(RP),, =N(Rº5)3X", =N(ORºS)R", -SeH, -SeR", —-SH, —SRº, —SSR“, -C(=O)R", -—-COsH, -CHO, — C(OR), COR -OC(=O)R%, -OCOR*º% -C(=O)N(R), - OC(FO)N(R"* )2, -NRPC(=O)R*, -NRºPCOR*, -NRPC(=O)N(R"*),, — CEENRP)R , -C(ENR)OR*, -OC(=NRº” )R*, -OC(=NR”)OR”, — CENRN(IR), —cOC(ENRINIR), —“<NRPPC(ENRPIN(IR), — C(=OINRPSO.R*, -NRSOR*, -) SOaN(R)2, =SO2R*, -SO20R”, —OSOR”, -S(=O)RY%, -OS(=O)R”%, —Si(Rº*);;, —OSi(Rº ); - CESIN(R ), =C(=0)SR*, -C(=S)SR*, -SC(=S)SR*, -SC(=0)SR”, —OC(= O)SR*, -SC(=0) OR”, -SC(=O0)R*, -P(=0).R*, -OP(=O0),R”, -P(=O)( R*),, -OP(=OXR*),, “OP(=O)(OR“),, -P(=O)AN(R""), - OP(=O)2N(R"* )2, -P(=O)(NR*)2, -OP(=O)(NRº")a, -NR”P(=O)(OR),, NRPPEONNR)2, -P(R)2 , -P(R)a, -OP(R")2, -OP(R")s, -B(R)2, -B(OR)2, -BRº(OR”), Cri-50 alkyl, C2.5o alkenyl, Ca509 alkynyl,
[0063] [0063] or two geminal hydrogens on a carbon atom are substituted with the group =O, =S, =NN(R”), =NNRº”"C(=O)R”, =NNRº*"C(=0 )OR*, =NNRº"S(=0),R*, =NRºº, or =NOR“;
[0064] [0064] Each case of R* is independently selected from C1-50o alkyl, Ca 50 alkenyl, C2,509 alkynyl, Cz 19 carbocyclyl, 3- to 14-membered heterocyclyl, Cc 11 aryl, and 5 to 5-membered heteroaryl 14-membered, or two R** groups are joined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted by O, 1, 2, 3, 4, or 5 R* groups:
[0065] [0065] each case of R** is independently selected from hydrogen, -OH, -OR*, —N(R%)2, =CN, -—C(=0)R”, -C(=O )N(R“),, — COR”, -SOR* , -C(=NRº)OR , -C(=NRON(RO)2, =SO2N(R“)», —SO2R“, -SO20R ”, -SOR*, -C(=S)N(R“)2, —=C(=O)SR“, -C(=S)SR", P(=O)R*, -P(= O)Rº*)2, -P(=O)AN(R)2, -P(=O)INR)2, C1-50 alkyl, Ca-50 alkenyl, C259 alkynyl, Ca-19 carbocyclyl, heterocyclyl 3 to 14 membered, Cs 11 aryl, and 5 to 14 membered heteroaryl, or two Rb groups are joined to form a 3 to 14 membered heterocyclyl or 5 to 14 membered heteroaryl ring, wherein each alkyl, al- kenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted by O, 1, 2, 3, 4, or 5 R* groups:
[0066] [0066] each case of R"* is independently selected from hydrogen, C1-5o alkyl, C2-509 alkenyl, C>2-59 alkynyl, Ca 195 carbocyclyl, 3- to 14-membered heterocyclyl, Cs 11 aryl , and 5 to 14 membered heteroaryl, or two Rºº groups are joined to form a 3 to 14 membered heterocyclyl or 5 to 14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with O, 1, 2, 3, 4, or 5 R** groups;
[0067] [0067] each case of Rº is independently selected from halogen, -CN, —=NO>, —N3, —=SO2H, —SOzH, —OH, =ORº, -ON(R)2, —NIR Ja, =N(RÍ)3'X”, -=N(ORº)RÍ, -SH, —<SRº, —SSRº, -C(=O)R“, —COH, COR“ COC(=O)R*º %, -OCOR“% -C(=O)N(IR, -OC(=O)N(R),, —NRÍC(=O)R*, -NRÍCOR”, -NRÍC(=O)N(R "), — C(ENROR*, -OC(ENRÍRE, -OC(eNRÍOR), -C(ENRINIR, — OC(=NRÍNIR)2, —NR'C(ENRÍNIR),-NRÍSORº, -SON(R), — SOR”, —SOOR*”, -OSORº, —S(=O)R*, —Si(R*)3, -—OSI(R*)3, — CESIN(R)2, =C(=0 )SR*”, -C(=S)SR*, -SC(=S)SR*, -P(=0).R”, — P(EONR*)a, -OP(=O)(R* )2, -OP(=0)(OR“)>, C1-50 alkyl, Case alkenyl, C> 59 alkynyl, C3 19 carbocyclyl, 3- to 10-membered heterocyclyl, Ce 19 aryl, 5-membered heteroaryl to 10 members, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with O, 1, 2, 3, 4, or 5 Rº groups, or two geminal Rº substituents may be joined to form =O or =S;
[0068] [0068] Each case of R* is independently selected from C1-50o alkyl, Ca.50 alkenyl, C2.59 alkynyl, Cz19 carbocyclyl, Cg1o aryl, 3- to 10-membered heterocyclyl, and 3- to 10-membered heteroaryl. bros, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R° groups;
[0069] [0069] each case of R* is independently selected from hydrogen, C1-509 alkyl, Ca.59 alkenyl, C2-59 alkynyl, Cz-19 carbocyclyl, 3- to 10-membered heterocyclyl, Csc15 aryl, and heteroaryl from 5a membered, or two RÉ groups are joined to form a 3 to 14 membered heterocyclyl or 5 to 14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with O , 1, 2, 3, 4, or 5 groups R°; and
[0070] [0070] each case of Rº is independently halogen, —-CN, —NO,>, —N3, -SO2H, -SO3H, —OH, -OC. 59 alkyl, -=ON(C1-50 alkyl), N(C1-50 alkyl)., -N(C1-50o alkyl)a'X, -NH(C1-50 alkyl)> X, -NHXC1-50 alkyl ) X, —-NH3X, —=N(OC1-50 alkyl)(C1-50 alkyl), -N(OH)(C1-50 alkyl)),) —YNH(OH), —SH, -SCi59 alkyl, -SS(Ci5o alkyl), — C(=O)(C1 50 alkyl), -CO2H, -CO(C1-50 alkyl), -OC(=O)(C1 505 alkyl), -OCOxXC1-55 alkyl ), -—C(=O)NH», —C(=O)N(C1-55 Is alkyl),, — OC(=O)NH(C1. 50th alkyl),) —NHC(=O)( (C150 alkyl),) -N(C159 alkyl)JC(=O)(C1509 alkyl), -NHCOX(C1509 alkyl), =-NHC(=O)N(C150 alkyl)., -NHC(= O)NH(C1-55 alkyl), =-NHC(=O)NH2, —C(=NH)O(C1-50 alkyl) — -OC(=NH)(Ci-50 alkyl), - OC(=NH)OC1-55 alkyl, — C(ENH)N(C1.55 alkyl), ., -C(=NH)NH(C1 55 alkyl), -=C(ENH)NH, — OC(= NH)N(C1.505 alkyl), α, -OC(NH)NH(C1-50 alkyl), -=OC(NH)NH1, —NHC(NH)N(C1-50 alkyl), α, -NHC (=NH)NH2z, -NHSO2(C1-509 alkyl), —SO2N(C1-50 alkyl), -SONH(C1 50 alkyl), =SONH2, -SO2C 150 alkyl, -SO2O0C1 509 alkyl, -OSO, C,56 alkyl, -SOC, 56 alkyl, -Si(C1 50 alkyl) >, -OSi(C1-. alkyl); -C(=S)N(C1-50o alkyl);, C(=SNH(C1-50 alkyl), C(=S)NH», “C(=O)S(C1-« alkyl), -C (=S)SC,1-6 alkyl, — SC(=S)SC,5 alkyl, -P(=O0)2(C1-50 alkyl), -P(=O)(C1-50 alkyl),, — OP(=O)(C1-50 alkyl), -OP(=O0)(OC1595 alkyl)., C1509 alkyl, C1509 alkenyl, C250 alkynyl, Ca-10 carbocyclyl, Cg-105 aryl, heterocyclyl 3 to 10 membered, 5 to 10 membered heteroaryl, or two R° geminal substituents may be joined to form =O or =S;
[0071] [0071] where X is a counterion.
[0072] [0072] As used herein, the term "halo" or "halogen" refers to a fluorine (fluorine, —F), chlorine (chlorine, —Cl), bromine (bromine, —Br), or iodine (io- , —/).
[0073] [0073] As used here, a "counterion" is a negative group.
[0074] [0074] Nitrogen atoms may be substituted or unsubstituted as valence permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, -OH, =-ORº, —N(R“)2», =CN, =C(=O0)R”*, -=C (=O)N(R“),, — COR”, -SO2R*, —C(eNRP)R*, -C(=NRº)OR*, -C(=NRºIN(Rº), — SO2N(RE) 2, -SO2R“”, -SO20R”, -SOR ”, -C(=S)N(R“)2, -C(=O)SR”, -C(ES)SRº, ——P(EO )LLR%, ——P(=O)R%), —-P(=O)N(RE), - P(=OX(NR)2, C1-50 alkyl, C>2 509 alkenyl, C2 59 alkynyl, Ca 19 carbocyclyl, 3 to 14 membered heterocyclyl, Cg-11 aryl, and 5 to 14 membered heteroaryl, or two Rº groups bonded to an N atom are joined to form a 3 to 14 membered heterocyclyl ring or 5- to 14-membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with O, 1, 2, 3, 4, or 5 R groups, and wherein R° , RP, Rº and Rºº are as defined above.
[0075] [0075] Nitrogen atoms may be substituted or unsubstituted as valence permits, and include secondary, tertiary, and quaternary primary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, -OH, -OR*, —N(R“)2, -CN, =C(=O0)R*, -C(=O )N(R“),, —
[0076] [0076] In certain embodiments, the substituent present on a nitrogen atom is a nitrogen protecting group (also referred to as an amino protecting group). Nitrogen protecting groups include, but are not limited to, -OH, -OR”, N(RP), —-C(=O)R%, —C(=O)N(R“), — COR”P”, —-SOR”, - C(ENRO RE, C(=NRºYº)JOR Y, cC(ENROIN(RO), -SON(R”), —SO2R“, -SO20R”, -SOR* , -C(=S)N(R“)2, —=C(=O)SR“, -C(=S)SR", C110 alkyl (e.g. aralkyl, heteroaralkyl), C> 19 alkenyl, C2 -10 alkynyl, Cz-19 carbocyclyl, 3- to 14-membered heterocyclyl, Cg-14 aryl, and 5- to 14-membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is inde - pendantly substituted with O, 1, 2, 3, 4, or 5 R$ groups, and wherein Rº , Rºº, Rºº and R$ are as defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated here by reference.
[0077] [0077] For example, nitrogen protecting groups such as amide groups (e.g. -C(=O)R*) include, but are not |i-
[0078] [0078] Nitrogen protecting groups such as carbamate groups (eg, -C(=0) OR”) include, but are not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc ), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxO-10, 10,10,10-Tetrahydrothioxanthyl)J-methyl — (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc ), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1--methylethyl carbamate (Ad-poc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl carbamate - 2,2-dibromoethyl (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TOBOC), 1-methyl-1-(4--biphenylyl)ethyl carbamate (Bpoc ), 1-(3,5-di-t-butylphenyl)-1--methylethyl carbamate (t-Bumeoc), 2-(2- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,Ndicyclohexylcarboxamido)ethyl, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-— nitrocinamyl (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate , p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methyltivetlay carbamate, 2--methylsulfonylethyl carbamate, 2-( p-toluenesulfonyl)ethyl, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate ( Peoc), 2-triphenylphosphoniumisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(di- hydroxyboryl)benzyl, b-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3- ,4-dimethoxy-6-nitrobenzyl, phenyl(o-nitrophenyl)methyl carbamate, tamyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, O-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborinyl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p-methoxyphenylazo carbamate )benzyl, 1-methylcyclobutyl carbamate, 1-—-methylcyclohexyl carbamate, 1-methyl carbamate -1-cyclopropylmethyl, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1- -methyl1-(4-pyridyl)ethyl, phenyl carbamate, pphenylazo)benzyl carbamate, 2,4,6-tritbutylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.
[0079] [0079] Nitrogen protecting groups such as sulfonamide groups (eg, -S(=O).R*) include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3 ,6,-trimethyl4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte )) 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxymethylbenzenesulfonamide" (iMds) 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), B-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.
[0080] [0080] Other nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)-acyl derivative, N*-p-toluenesulfonylaminoacyl derivative, N*phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine, 4,5-diphenyl-3-oxazolin-2-one, Nphthalimide, Ndithiasuccinimide (Dts), N-2,3-diphenylmaleimide, — N2,5-dimethylpyrrole, N1,1,44-tetramethyldisilylazacyclopentane (STABASE) adduct ), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 3, 5-dinitro-—4-—I-substituted pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxylmethylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl4-—nitro-2 -OxO-3-pyrolin-3— iN)amine, quaternary ammonium salts, N-benzylamine, Ndi(4-methoxyphenyl)methylamine, N—5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4—- methoxyphenyl)diphenylmethylJamine (MMTr), N-9-phenylfluorenylamine (PhF), N2,7-dichloro-9-fluorenylmethyleneamine, Nfer rocenylmethylamino (Fem), N-2-picolylamino Ni-oxide, N1,1-—dimethylthiomethyleneamine, N—benzylideneamine, N—p-
[0081] [0081] In certain embodiments, the substituent present on an oxygen atom is an oxygen protecting group (also referred to as a hydroxyl protecting group). Oxygen protecting groups include, but are not limited to, -Rº, —N(R”*), —C(=O)SR*, -C(=O)R*, -COR*º, -C (=O)N(R ),, -C(=NRº)R&E, — CENRP)OR*, -C(ENRPIN(R),, -S(=O)R*, -SOR”, -Si( R*); — P(R)a, —P(RO)3 —P(=OLR%Y, -P(=O(R*), -P(=O(OR”)), - P(=O )N(R"*)2, and -P(=O)(NR””), where Rº , Rº”º, and Rºº are as defined here. Oxygen protecting groups are well known in technique and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
[0082] [0082] Exemplary oxygen protecting groups include, but are not limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsily))methoxymethyl (SMOM), benzyl-
[0083] [0083] In certain embodiments, the substituent present on a sulfur atom is a sulfur protecting group (also referred to as a thiol protecting group). Sulfur protecting groups include, but are not limited to, —“Rº, —N(Rºº), —C(=O)SR%, —
[0084] [0084] As used herein, a "leaving group" is a term understood in the art referring to a molecular fragment that diverges from a heterolytic bond-cleaving electron pair, where the molecular fragment is an anion or neutral molecule. See, for example, Smith, March Advanced Organic Chemistry 6th ed. (501-502). Exemplary leaving groups include, but are not limited to, halo (e.g., chlorine, bromine, iodine) and sulfonyl-substituted hydroxyl groups (e.g., tosyl, mesyl, besyl).
[0085] [0085] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, Figures, and Claims. The invention is not intended to be limited in any way by the above exemplary listing of substituents. Other definitions
[0086] [0086] As used here, use of the phrase "at least one example" refers to an example, but also encompasses more than one example, e.g. 1, 2, 3, 4, 5, 6, 7 , 8, 9, or 10 examples, and up to 100 examples.
[0087] [0087] An "amino acid" refers to natural and unnatural alpha D/L amino acids, as well as natural and unnatural gamma and beta amino acids. A "peptide" refers to two amino acids joined by a peptide bond. A "polypeptide" refers to three or more amino acids joined by peptide bonds. An "amino acid side chain" refers to the group(s) attached to the alpha carbon (if an alpha amino acid), alpha and beta carbon (if a beta amino acid), or the alpha, beta, and gamma carbon ( if a gamma amino acid). Exemplary amino acid side chains are depicted here; see, for example, Table 1 of the Examples.
[0088] [0088] As used herein, a "polymer" refers to a compound comprised of at least 3 (e.g., at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, etc. ) covalently linked repeating structural units.
[0089] [0089] "Conjugated" and "linked" refer to the covalent bond of a group, and are used interchangeably herein.
[0090] [0090] As used herein, "lipophilic" refers to the ability of a group to dissolve in fats, oils, lipids, and non-polar lipophilic solvents such as hexane or toluene. In general, a lipophilic group refers to an unsubstituted n-alkyl or unsubstituted n-alkenyl group having 6 to 50 carbon atoms, e.g. 6 to 40, 6a30,6a20,8a20,8a19,8a18,8a17, 8 to 16, or 8 to 15 carbon atoms.
[0091] [0091] Use of the terms "structural isomer," "organic molecule," and "inorganic molecule" are intended to encompass the common meaning of each term as known in the art.
[0092] [0092] As used herein, a "small organic molecule" or "small molecule" refers to an organic molecule with a molecular weight of 800 g/mol or less (e.g., less than 700 g/mol, less than than 600 g/mol, less than 500 g/mol, less than 400 g/mol, less than 300 g/mol, less than 200 g/mol, less than 100 g/mol, between 50 to 800 g/mol, inclusive, between 100 to 800 g/mol, inclusive, or between 100 to 500 g/mol, inclusive). In certain embodiments, the small organic molecule is a therapeutically active agent such as a drug (e.g., an organic molecule).
[0093] [0093] As used herein, a "large organic molecule" or "large molecule" refers to an organic compound with a molecular weight of greater than 800 g/mol (e.g., greater than 800 g /mol, greater than 900 g/mol, greater than 1000 g/mol, greater than 2000 g/mol, between 801 to 2000 g/mol, inclusive, between 900 to 2000 g/mol, inclusive, between 1000 to 2000 g/mol, inclusive, or between 801 to 1000 g/mol, inclusive). In certain embodiments, the large organic molecule is a therapeutically active agent such as a drug (eg, a large organic molecule approved by the U.S. Food and Drug Administration as provided in the Code of Federal Regulations (CFR)). The large organic molecule may also be complexed with a metal. In this case, the large organic molecule is also referred to as a "large organometallic compound."
[0094] [0094] As used herein, a "small inorganic molecule" refers to an inorganic compound having a molecular weight of 800 g/mol or less (e.g., less than 700 g/mol, less than 600 g /mol, less than 500 g/mol, less than 400 g/mol, less than 300 g/mol, less than 200 g/mol, less than 100 g/mol, between 50 to 800 g/mol , inclusive, from 100 to 800 g/mol, inclusive, or from 100 to 500 g/mol, inclusive). In certain embodiments, the small inorganic molecule is a therapeutically active agent such as a drug (e.g., a small inorganic molecule approved by the U.S. Food and Drug Administration as provided in the Code of Federal Regulations (CFR)).
[0095] [0095] As used here, a "large inorganic molecule" referred to
[0096] [0096] As used herein, the term "salt" or "pharmaceutically acceptable salt" refers to those salts that fall within the scope of safe medical diagnosis, suitable for use in contact with the tissues of humans and animals. minors without undue toxicity, irritation, allergic response and the like, and are provided with a reasonable benefit/risk balance. Pharmaceutically acceptable salts are well known in the art. For example, S.M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable organic and inorganic bases and acids. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid , tartaric acid, citric acid, succinic acid or malonic acid or using other methods used in the art such as phon exchange. Other pharmaceutically acceptable salts include salts of adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumara-
[0097] [0097] Figure 1 depicts the structural design and optimization through in vivo evaluation in mice. Single amino acid based lipid derivatives were tested at a dose of 1 Img/kg in mice, which indicated that lysine was a favorable amino acid. Lysine-based peptide and polypeptide-lipid derivatives were then investigated at the same dose. The hit rate was improved from 1.7% to 23% (including those compounds not selected due to particle instability or no siRNA entrapment). Top hits and their analogues were explored at a lower dose of 0.1 mg/kg, which led to the selection of cKK-E12 as the inducing compound. K-E12; K: abbreviation for lysine, E: epoxide, A: aldehyde
[0098] [0098] Figure 2 depicts the biodistribution of free Cy5.5-labeled siRNA and Cy5.5-labeled siRNA-cKK-E12 formulation in mice at 1 hr and 24 hr.
[0099] [0099] Figure 3 depicts the silencing effects of apolipoproteins on cKK-E12 in HeLa cells. Apolipoproteins including ApoA-1 (recombinant human ApoA-| protein), ApoA-II (native human A-poA-II protein), ApoB (native Human ApoB protein), ApoC-1 (native Human ApoC-| protein), ApoC- ll (native Human ApoC-ll protein), ApoC-lll (native Human ApoC-lll protein), ApoE (native Human ApoE protein), ApoE2 (recombinant Human ApoE2 protein), ADoE3 (recombinant Human ApoE3 protein), ApoE4 ( recombinant Human ApoE4 protein), ApoH (native Human ApoH protein).
[00100] [00100] Figure 4 depicts the effects of ApoE on gene silencing and cell uptake. THE). ApoE silencing effects on cKK-E12, cKK-A12, and cKK-012 in vitro (SiRNA: 50 ng/well). With the addition of ApoE, the order of silencing effects was cKK-E12 > cKK-A12 > cKK-O012, correlating well with in vivo activity. B). Cell internalization of cKK-E12 with siRNA labeled by Alex-647 after 3 hr of incubation is demonstrated by automated confocal HT microscope. ApoE enhanced cellular uptake and endosomal escape of cKK-E12; graduation bar: 20 um. Detailed Description of Certain Modalities of the Invention
[00101] [00101] Described herein are inventive compositions and compounds, certain embodiments of which involve conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide. co, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as "APPLs". Such
[00102] [00102] Exemplary APPLs include, but are not limited to, compounds of formula (1), (11), (III), (IV), (V), and (VI), and salts thereof, as described herein: Ro Ww Eira SA RR Rº er n R (1) (11) ts js oxo O
[00103] [00103] in whom,n,p,R',R ,R , Ri, R,Rº,Z,W, Y, and Z are as defined herein.
[00104] [00104] Various R1 groups, e.g. lipophilic groups, can be linked to APPL through conjugation of a primary or secondary amino group or amide of the amino acid, peptide, or polypeptide precursor, or structural isomer thereof, with an epoxide, thiirane, or aziridine of formula (ix), Michael addition to an unsaturated ester o,B, thioester, or amide of formula (ii-x), or reductive amination to an aldehyde of formula (iii-x) ) (Scheme 1). Scheme 1.
[00105] [00105] Thus, in the broadest sense, the present invention provides APPLs, and in certain embodiments, compounds of formula (1), (11), (UI), (IV), (V), and (VI), comprising at least one case of a group linked thereto of the formula: Ava As Ú L RE o / () (ii) (iii) in which:
[00106] [00106] each case of R' is independently hydrogen or optionally substituted alkyl;
[00107] [00107] XéoO,S, NR“, wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00108] [00108] YéoO,S,NR", wherein R" is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00109] [00109] R hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and
[00110] [00110] R optionally substituted C1-50 alkyl, optionally substituted C2-59 alkenyl, optionally substituted C2-595 alkynyl, optionally substituted C1-509 heteroalkyl, optionally substituted C7-50 heteroalkenyl, optionally substituted C2-59 heteroalkynyl da, or a polymer.
[00111] [00111] Various forms of formula (i), (ii), and (ili), and the variables R!, R , X, and Y are described in more detail here. Formula compounds (/)
[00112] [00112] Compounds of formula (|) encompass amino acids, linear peptides, and linear polypeptides that comprise one or more conjugation sites, for example, at the terminal amino group, an amino substituent, and/or a nitrogen of imino, from a group of formula (i), (ii), or (iii). In PEA | L o Roso terminal Ns amino substituents Re—N Tv” Ro imino nitrogens
[00113] [00113] Thereby, in one aspect, there is provided a compound of formula (1): q R , (1)
[00114] [00114] a balance even;
[00115] [00115] where:
[00116] [00116] n0Oou is an integer between 1 and 100,000, inclusive;
[00117] [00117] each case of m is independently 1, 2, or 3;
[00118] [00118] each case of Z is independently O, S, or NR , where R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii);
[00119] [00119] each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR*, -N(R)>, or -SRº. wherein each occurrence of R** is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a protecting group of oxygen when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, a nitrogen protecting group when bonded to a nitrogen atom, or two R** groups are joined to form a ring optionally substituted heterocyclic or optionally substituted heteroaryl;
[00120] [00120] R' is a group of formula (i), (ii), or (iii);
[00121] [00121] Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii);
[00122] [00122] or Rº and an R1 group are joined to form an optionally substituted 5- to 6-membered heterocyclic ring;
[00123] [00123] Rºis-OR*, -N(R)s, or -SR*. wherein each occurrence of R* is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a group of oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R*º groups are united - formed to form an optionally substituted heterocyclic ring or optionally substituted heteroaryl;
[00124] [00124] R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; and
[00125] [00125] — Formulas (i), (ii), and (ii) are: . R RE Ro 2 RE x. FR or () (ii) (iii)
[00126] [00126] where:
[00127] [00127] each case of R' is independently hydrogen or optionally substituted alkyl;
[00128] [00128] X is O,S, NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00129] [00129] YéoO,S, NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00130] [00130] RP” is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and
[00131] [00131] R| is optionally substituted C 2-59 alkyl, optionally substituted C 2-59 alkenyl, optionally substituted C 2-595 alkynyl, optionally substituted heteroC 1-5 alkyl, optionally substituted heteroC 2-59 alkenyl, heteroC 1-5,5 alkynyl optionally substituted, or a polymer.
[00132] [00132] In certain embodiments, when n is greater than 10, then neither R not R is a group of formula (iii). In certain modalities,
[00133] [00133] In certain embodiments, where n is 0 and Z is O, one or more of the following compounds are excluded: o o ro Me O à 2 2-N et, So ; SO Os a q o nos s o SO2ORº or, et, o o Re, AD PO Ro: R , (Om , Uô oe ga ,
[00134] [00134] and the same ones; in which R is a group of formula (i), R and Rº are independently hydrogen or a group of formula (I), and Yéo.
[00135] [00135] “As generally defined above, n is 0 or is an integer between 1 and 100,000, inclusive. It is thus understood that formula (|) encompasses amino acids conjugated to a lipid group, as well as linear peptides and linear polypeptides conjugated to lipid groups.
[00136] [00136] In certain embodiments, either O or is an integer between 1 and 90,000, inclusive. In certain embodiments, n is 0 or is an integer between 1 and 80,000, inclusive. In certain embodiments, n is 0 or is an integer between 1 and 70,000, inclusive. In certain embodiments, n is 0 or is an integer between 1 and 50,000, inclusive. In certain embodiments, n is 0 or is an integer between 1 and 40,000, inclusive. In certain embodiments, n is 0 or is an integer between 1 and
[00137] [00137] For example, when n is O, the compound of formula (1) is a compound of formula (I-a): elle & (ta)
[00138] [00138] a ;balance even.
[00139] [00139] In certain embodiments, when n is 1, the compound of formula (1) is a compound of formula (I-b): PS Z in the Z es of the Rº R (I-b)
[00140] [00140] an even balance.
[00141] [00141] In certain embodiments, when n is 2, the compound of formula (1) is a compound of formula (I-c): ed id ih Ro R R (I-c)
[00142] [00142] an even balance.
[00143] [00143] In certain embodiments, when n is 3, the compound of formula (1) is a compound of formula (1-d): RU RO Ro Ro (Id)
[00144] [00144] an even balance.
[00145] [00145] In certain embodiments, when n is 4, the compound of formula (1) is a compound of formula (1-e): RR Ré Ré [13 RR zZ AI A A hos R Ro Ro Ro Ro (I-e)
[00146] [00146] an even balance.
[00147] [00147] As generally defined above, each case of m is independently 1, 2, or 3. In certain embodiments, at least one case of m is 1. In certain embodiments, each case of m is 1. In certain embodiments, at least one case of m is 1. In these embodiments, at least one case of m is 2. In certain embodiments, at least one case of m is 3.
[00148] [00148] “As generally defined above, each case of R' is independently hydrogen or optionally substituted alkyl. In certain embodiments, at least one case of R' is hydrogen. In certain embodiments, at least two cases of R' are hydrogen. In certain embodiments, each case of R' is hydrogen. In certain embodiments, at least one instance of R' is optionally substituted alkyl, for example, methyl. In certain embodiments, at least two instances of R' are optionally substituted alkyl, for example,
[00149] [00149] As generally defined above, each case of Z is independently O, S, or NR , where Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, he- optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (ili))--. In certain embodiments, at least one case of Z is O. In certain embodiments, each case of ZéO. In certain embodiments, at least one case of Zé S. In certain embodiments, each case of Zé S. In certain embodiments, at least one case of Z is NR. In certain embodiments, each case of Z is NR”. In certain embodiments, each case of Rº is independently hydrogen or a group of formula (i), (ii), or (iii).
[00150] [00150] As generally defined above, each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, heteroaryl optionally substituted, halogen, -OR“º, -N(Rº), or -SR“.
[00151] [00151] In certain embodiments, at least one instance of R' is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally heteroaryl replaced.
[00152] [00152] In certain embodiments, at least one case of R' is optionally substituted alkyl; for example, optionally substituted C1-4 alkyl, C7-; optionally substituted alkyl, optionally substituted C3-5 alkyl, optionally substituted C1-5 alkyl, C1-5 alkyl
[00153] [00153] In certain embodiments, at least one case of R' is optionally substituted alkenyl, for example, C>2-; optionally substituted alkenyl, C;3z-; optionally substituted alkenyl, optionally substituted C1-6 alkenyl, optionally substituted C1-;s alkenyl, or optionally substituted C3-alkenyl.
[00154] [00154] In certain embodiments, at least one case of R' is optionally substituted alkynyl, for example, C>-; optionally substituted alkynyl, C3-; optionally substituted alkynyl, optionally substituted C1-6 alkynyl, optionally substituted C1-5 alkynyl, or optionally substituted C3- alkynyl.
[00155] [00155] In certain embodiments, at least one case of R' is optionally substituted carbocyclyl, for example, optionally substituted C3-19 carbocyclyl, optionally substituted Cs-3g carbocyclyl, optionally substituted Cs-6 carbocyclyl, optionally substituted Cs carbocyclyl - mally substituted, or optionally substituted carbocyclyl Cs.
[00156] [00156] In certain embodiments, at least one instance of R' is optionally substituted heterocyclyl, e.g., optionally substituted 3 to 14 membered heterocyclyl, optionally substituted 3 to 10 membered heterocyclyl, optionally substituted 5 to 8 membered heterocyclyl optionally substituted, optionally substituted 5- to 6-membered heterocyclyl, optionally substituted 5-membered heterocyclyl, or optionally substituted 6-membered heterocyclyl.
[00157] [00157] In certain embodiments, at least one instance of R' is optionally substituted aryl, for example, optionally substituted phenyl.
[00158] [00158] In certain embodiments, at least one instance of R' is optionally substituted heteroaryl, for example, optionally substituted 5 to 14 membered heteroaryl, optionally substituted 5 to 10 membered heteroaryl, optionally substituted 5 to 6 membered heteroaryl substituted, optionally substituted 5-membered heteroaryl, or optionally substituted 6-membered heteroaryl.
[00159] [00159] In any of the above embodiments, the group R1 alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl may be substituted, for example, with an optionally substituted amino group (e.g., -NRºR"), a group optionally substituted hydroxyl group (e.g. -OR$), an optionally substituted thiol group (e.g. -SR$), or with a group of formula (i), (ii), or (iii), wherein each case of Rº and R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when bonded to an oxygen atom, and a sulfur protecting group when bonded to a sulfur atom, or a group of formula (i), (ii), or ( iii).
[00160] [00160] For example, in certain embodiments, at least one instance of R' is an alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl group substituted with an amino group of the formula — N(RºNR”). In that case, in certain embodiments, at least one case of R* is a group of formula: 6
[00161] [00161] L is an optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, carbon
[00162] [00162] Rº and R' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, and a nitrogen protecting group;
[00163] [00163] as long as at least one case of Rº and R be a group of the formula (i), (ii), or (iii): Ae DO | R! or / () (ii) (iii)
[00164] [00164] whereR' ,X,Y,R!,andRº are as defined here.
[00165] [00165] In certain embodiments, at least two cases of R1 are a group of formula (iv). In certain embodiments, at least three instances of R' are a group of formula (iv). In certain embodiments, at least four instances of R1 are a group of formula (iv). In certain embodiments, at least five cases of R* are a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv).
[00166] [00166] In certain embodiments, L is an optionally substituted alkylene; for example, optionally substituted C1-59 alkylene, optionally substituted C1-40 alkylene, optionally substituted C1-35 alkylene, optionally substituted C1-2 alkylene, optionally substituted C1-205 alkylene, optionally substituted C6-205 alkylene, C6- optionally substituted alkylene, optionally substituted C109-205 alkylene, optionally substituted C-; alkylene, optionally substituted C1-6 alkylene, C3-; optionally substituted alkylene
[00167] [00167] In certain embodiments, L is an optionally substituted alkenylene, for example, optionally substituted C>2-59 alkenylene, optionally substituted C>2-409 alkenylene, optionally substituted C2-35 alkenylene, optionally substituted C2-25 alkenylene , optionally substituted C1-20 alkenylene, optionally substituted C1-25 alkenylene, optionally substituted C1-205 alkenylene, optionally substituted C110-20 alkenylene, C>2-; optionally substituted alkenylene, C3-; optionally substituted alkenylene, optionally substituted C,α-,alkenylene, optionally substituted C1-5 alkenylene, or optionally substituted C3-, alkenylene.
[00168] [00168] In certain embodiments, L is an optionally substituted alkynylene, for example, optionally substituted Ca-595 alkynylene, optionally substituted C>2-409 alkynylene, optionally substituted C2-35 alkynylene, optionally substituted C2-25 alkynylene, Ca -20 optionally substituted alkynylene, optionally substituted C8-25 alkynylene, optionally substituted C6-25 alkynylene, optionally substituted C10-20 alkynylene, C₁-; optionally substituted alkynylene, optionally substituted C3-5 alkynylene, optionally substituted Ca-6s alkynylene, optionally substituted C1-5 alkynylene, or optionally substituted C3-1 alkynylene.
[00169] [00169] In certain embodiments, L is an optionally substituted heteroalkylene; for example optionally substituted heteroC1-20alkylene, optionally substituted heteroC1-20alkylene, optionally substituted heteroC1-30alkylene, optionally substituted heteroC1-20alkylene, optionally substituted heteroC4-20alkylene, optionally substituted heteroC1-25alkylene, optionally substituted heteroC1-20alkylene, heteroC10 -25 optionally substituted alkylene, optionally substituted heteroC 1 -alkylene, heteroC 1 -
[00170] [00170] In certain embodiments, L is an optionally substituted heteroalkenylene, for example, optionally substituted heteroC2-50alkenylene, optionally substituted heteroC2-40alkenylene, heteroC2-30alkenylene — optionally — substituted, — optionally substituted heteroC2-20alkenylene, heteroC4- 20alkenylene, optionally substituted heteroCs-20alkenylene, optionally substituted heteroC1-20alkenylene, optionally substituted heteroC1-20alkenylene, optionally substituted heteroC1-20-alkenylene, optionally substituted heteroC1-3-salkenylene, heteroC1- optionally substituted salkenylene, heteroC, optionally substituted salkenylene, or optionally substituted heteroC3z-,alkenylene.
[00171] [00171] In certain embodiments, L is an optionally substituted alkynylene, for example, optionally substituted heteroC₁-soalkynylene, — optionally substituted heteroC₁-,oalkynylene, optionally substituted heteroC₁-3oalkynylene, optionally substituted heteroC₁-2,alkynylene optionally substituted heteroC1-25alkynylene, optionally substituted heteroCs-20alkynylene, optionally substituted heteroC1-25alkynylene, optionally substituted heteroC11-25alkynylene, optionally substituted heteroC1-25alkynylene, optionally substituted C1-alkynylene, heteroC, -optionally substituted -salkynylene, optionally substituted heteroC 1 -salkynylene, or optionally substituted heteroC 3 -alkynylene.
[00172] [00172] In certain embodiments, L is an optionally substituted carbocyclylene, for example, optionally substituted C3-195 carbocyclylene, optionally substituted Cs-8 carbocyclylene, optionally substituted Cs-1 carbocyclylene, optionally substituted Cs carbocyclylene, or Optionally substituted carbocyclylene Cs.
[00173] [00173] In certain embodiments, L is an optionally substituted heterocyclylene, for example, optionally substituted 3 to 14 membered heterocyclylene, optionally substituted 3 to 10 membered heterocyclylene, optionally substituted 5 to 8 membered heterocyclylene, optionally substituted 5 to 6 membered, optionally substituted 5 membered heterocyclylene, or optionally substituted 6 membered heterocyclylene.
[00174] [00174] In certain embodiments, L is an optionally substituted arylene, for example, optionally substituted phenylene.
[00175] [00175] In certain embodiments, L is an optionally substituted heteroarylene, for example, optionally substituted 5 to 14 membered heteroarylene, optionally substituted 5 to 10 membered heteroarylene, optionally substituted 5 to 6 membered heteroarylene, optionally substituted 5-membered heteroarylene, or optionally substituted 6-membered heteroarylene.
[00176] [00176] For example, in certain embodiments, where L is an optionally substituted alkylene group, the group of formula (iv) is a group of the formula: # Age
[00177] [00177] whereq is an integer between 1 and 50, inclusive.
[00178] [00178] In certain embodiments, q is an integer between 1 and 40, inclusive. In certain embodiments, q is an integer between 1 and 30, inclusive. In certain embodiments, q is an integer between 1 and 20, inclusive. In certain embodiments, q is an integer between 4 and 20, inclusive. In certain embodiments, q is an integer between 6 and 20, inclusive. In certain embodiments, q is an integer between 8 and 20, inclusive. In certain embodiments, q is 1. In certain embodiments, q is
[00179] [00179] In certain embodiments, both Rº and R' are hydrogen. In certain embodiments, R° is hydrogen and R' is a group of formula (i), (ii), or (iii). In certain embodiments, R° is hydrogen and R' is a group of formula (i). In certain embodiments, Rº is hydrogen and R' is a group of formula (ii). In certain embodiments, R° is hydrogen and R is a group of formula (iii). In certain embodiments, both R6 and R' are independently a group of the formula (i), (ii), or (iii))) In certain embodiments, both Rº and R' are independently a group of the formula ( i). In certain embodiments, both R° and R' are independently a group of formula (ii). In certain embodiments, both R° and R' are independently a group of formula (iii). In certain embodiments, both Rº and R are the same group, selected from a group of formula (i), (ii), or (iii).
[00180] [00180] It is understood that R' encompasses amino acid side chains, as exemplified in Table 1 of the examples. In certain embodiments, R' is a group selected from any of the amino acid side chain groups listed here.
[00181] [00181] In certain embodiments, each case of R' is the same. In certain embodiments, at least one R' group is different. In certain modalities, each R' group is different.
[00182] [00182] “As generally defined above, R is a group of the formula (1), (ii), or (ii): R$ R|
[00183] [00183] whereR',X,Y,R!,andRº are as defined here.
[00184] [00184] In certain embodiments, Rº is a group of formula (i). In certain embodiments, R is a group of formula (ii). In certain modalities, R is a group of formula (iii).
[00185] [00185] As generally defined above, Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group , or a group of formula (i), (ii), or (iii); optionally wherein R6 and an R1 group are joined to form an optionally substituted 6-membered heterocyclic ring;
[00186] [00186] In certain embodiments, Rº is hydrogen. In certain embodiments, Rº is optionally substituted alkyl; for example C1-; optionally substituted alkyl, C>2-; optionally substituted alkyl, optionally substituted C1-5 alkyl, optionally substituted C,a-5 alkyl, optionally substituted C,4-5 alkyl, or optionally substituted C3- alkyl.
[00187] [00187] In certain embodiments, Rº is optionally substituted alkenyl, eg C>-; optionally substituted alkenyl, optionally substituted C3-1-alkenyl, optionally substituted C1-5 alkenyl, optionally substituted C,4-5 alkenyl, or optionally substituted C3-14 alkenyl.
[00188] [00188] In certain embodiments, Rº is optionally substituted alkynyl, eg C>-; optionally substituted alkynyl, optionally substituted C3-65 alkynyl, optionally substituted C,4-s alkynyl, optionally substituted C3-5 alkynyl, or optionally substituted C3- alkynyl.
[00189] [00189] In certain embodiments, Rº is optionally substituted carbocyclyl, for example, C3-19 optionally substituted carbocyclyl,
[00190] [00190] In certain embodiments, R° is optionally substituted heterocyclyl, for example, optionally substituted 3 to 14 membered heterocyclyl, optionally substituted 3 to 10 membered heterocyclyl, optionally substituted 5 to 8 membered heterocyclyl, 5 to 6 membered heterocyclyl optionally substituted member, optionally substituted 5 membered heterocyclyl, or optionally substituted 6 membered heterocyclyl.
[00191] [00191] In certain embodiments, R° is optionally substituted aryl, for example, optionally substituted phenyl.
[00192] [00192] In certain embodiments, R° is optionally substituted heteroaryl, for example, optionally substituted 5 to 14 membered heteroaryl, optionally substituted 5 to 10 membered heteroaryl, optionally substituted 5 to 6 membered heteroaryl, heteroaryl optionally substituted 5-membered heteroaryl, or optionally substituted 6-membered heteroaryl.
[00193] [00193] In certain embodiments, Rº is a nitrogen protecting group.
[00194] [00194] In certain embodiments, Rº is a group of formula (i), (ii), or (iii)).. In certain embodiments, Rº is a group of formula (i).. In certain embodiments, Rº is a group of formula (ii). In certain embodiments, R° is a group of formula (iii).
[00195] [00195] In certain embodiments, R° and an adjacent R1 group are joined to form an optionally substituted 5- to 6-membered heterocyclic ring, e.g., a 5-membered heterocyclic ring, e.g., an optionally substituted pyrrolidinyl ring.
[00196] [00196] In certain embodiments, Rº is hydrogen and Rº is a group of formula (i), (ii), or (iii). In certain embodiments, Rº is hydrogen and R
[00197] [00197] “As generally defined above, Rº is -OR*, -N(R*)>, or -SRº*. wherein each occurrence of R* is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a pro- oxygen when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, a nitrogen protecting group when bonded to a nitrogen atom, or two R*º groups are joined to form a optionally substituted heterocyclic ring or optionally substituted heteroaryl.
[00198] [00198] In certain embodiments, Rº is -OR**, where R** is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl substituted, optionally substituted heteroaryl, or an oxygen protecting group. In certain embodiments, R*° is hydrogen or optionally substituted alkyl. In certain embodiments, R* is hydrogen.
[00199] [00199] In certain modalities, Rº is -N(R), where each occurrence
[00200] [00200] In certain embodiments, Rº is -SR* where R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, heteroaryl optionally substituted, or sulfur protecting group. In certain embodiments, R** is hydrogen or optionally substituted alkyl. In certain embodiments, Rº is hydrogen.
[00201] [00201] As generally defined above, R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a protecting group of nitrogen. In certain embodiments, at least one case of Rº is hydrogen. In certain embodiments, each case of Rº is hydrogen.
[00202] [00202] Various combinations of the above embodiments of formula (1) are contemplated here.
[00203] [00203] For example, in certain embodiments, where each case of m is 1 and each case of Z is 0, the compound of formula (|) is a compound of formula (I-f):
[00204] [00204] —myself. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, R is a group of formula (i). In certain embodiments, R is a group of formula (ii). In certain embodiments, R is a group of formula (iii). In certain embodiments, Rº is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, Rº is a group of formula (iii)... In certain embodiments, Rº is -OR*. In certain embodiments, Rº is hydrogen. In certain modes, n is 0. In certain modes, n is 1. In certain modes, n is 2. In certain modes, n is 3. In certain modes, n is 4. In certain modes, right.
[00205] [00205] For example, in certain embodiments of formula (If), where each case of R' is a group of formula (iv), a compound of formula (1-f1) is provided: hoo R2—N- "
[00206] [00206] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, Rº is a group of formula (i). In certain embodiments, Rº is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii).
[00207] [00207] In certain forms of formula (I-f), where R is a group of formula (i), the compound is of formula (1I-f2):
[00208] [00208] an actual balance. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, Rº is -OR*. In certain embodiments, Rº is hydrogen. In certain modalities, n is 0. In certain modalities, n is 1. In certain modalities, n is 2. In certain modalities, n is 3. In certain modalities, nе 4. In certain modalities, nе 5.
[00209] [00209] For example, in certain embodiments of formula (1-f2), where each case of R' is a group of formula (iv), a compound of formula (1-f3): 2 PL is provided. pa tr ME RR (1)
[00210] [00210] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii).
[00211] [00211] In certain embodiments of formula (I-f), where R and R° are each independently a group of formula (i), the compound is of formula (1-f4): A o Is ”
[00212] [00212] or even balance. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, Rº is -OR*. In certain embodiments, Rº is hydrogen. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 5.
[00213] [00213] For example, in certain embodiments of formula (I-f4), where each case of R' is a group of formula (iv), a compound of formula (1-f5) is provided: in Re SE & OR (Lf5)
[00214] [00214] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, Rº is a group of formula (i). In certain embodiments, Rº is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii).
[00215] [00215] In certain embodiments of formula (I-f), wherein R º is a group of formula (ii), the compound is of formula (1-f6): TS í L Rx " (1-f6)
[00216] [00216] or even. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, Rº is a group of formula (i). In certain embodiments, Rº is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, Rº is -OR*. In certain embodiments, Rº is hydrogen. In certain modes, n is 0. In certain modes, n is 1. In certain modes, n is 2. In certain modes, n is 3. In certain modes, n is 4. In certain modes, n is 5.
[00217] [00217] For example, in certain embodiments of formula (1-f6), where each case of R' is a group of formula (iv), a compound of formula (1-f7) is provided: FS The AAA RX & .". (7)
[00218] [00218] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, Rº is a group of formula (i). In certain embodiments, Rº is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii).
[00219] [00219] In certain embodiments of formula (I-f), where R and R° are independently a group of formula (ii), the compound is of formula (1-f8): RX. the Al FS f Is Rx . (1-f8)
[00220] [00220] or even balance. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, Rº is -OR*. In certain embodiments, Rº is hydrogen. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 5.
[00221] [00221] For example, in certain embodiments of formula (1-f8), where each case of R* is a group of formula (iv), a compound of formula (1-f9) is provided:
[00222] [00222] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii).
[00223] [00223] In certain embodiments of formula (I-f), where R is a group of formula (ili), the compound is of formula (1-f10): o dh
[00224] [00224] —oralofthemselves. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, Rº is -OR*. In certain embodiments, Rº is hydrogen. In certain modalities, n is 0. In certain modalities, n is 1. In certain modalities, n is 2. In certain modalities, n is 3. In certain modalities, nе 4. In certain modalities, nе 5.
[00225] [00225] For example, in certain embodiments of formula (1-f10), where each case of R' is a group of formula (iv), a compound of formula (1-f11) is provided:
[00226] [00226] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii).
[00227] [00227] In certain embodiments of formula (I-f), where R and Rº are independently a group of formula (iii), the compound is of formula (1-f12): nO q Rº n (1-f12)
[00228] [00228] or even. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, Rº is -OR*. In certain embodiments, Rº is hydrogen. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 5.
[00229] [00229] For example, in certain embodiments of formula (1-f12), where each case of R' is a group of formula (iv), a compound of formula (1-f13) is provided: so Is the Re not Le Se & OR (3)
[00230] [00230] or even balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, Rº is a group of formula (i). In certain embodiments, Rº is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). Formula compounds (//)
[00231] [00231] Compounds of formula (II) can be prepared by internal cyclization of the addition product of a primary or secondary amine or amide of an amino acid, peptide, or polypeptide, and an epoxide, thiirane, or aziridine of formula (ix) ) (Scheme 2). Scheme 2. x R W W w PAX RR R1 Rº : À Rº , R e xt on: R (1)
[00232] [00232] Compounds of formula (II) may encompass additional conjugation sites, for example, the secondary amino group, attached to a group attached to the secondary amino group, an amino substituent, and/or an imino nitrogen, the a group of formula (i), (ii), or (iii): ww qi RA Ri A aà IRES R- Lee iR8O Nà Rº RE
[00233] [00233] Thus, in a second aspect, a compound of formula (II) is provided: w Da Y
[00234] [00234] —or the very sum; on what:
[00235] [00235] each case of R' is independently hydrogen or optionally substituted alkyl;
[00236] [00236] each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR*, -N(R!)>, or -SR*!. wherein each occurrence of R** is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a protecting group of oxygen when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, a nitrogen protecting group when bonded to a nitrogen atom, or two R** groups are joined to form a ring optionally substituted heterocyclic or optionally substituted heteroaryl;
[00237] [00237] Rº is hydrogen, a group of formula (i), (ii), or (ii), or a group of formula (v): Zz
[00238] [00238] whereZ2Z, RR R,m, and n are as defined for formula (1);
[00239] [00239] or R° and an R' group are joined to form an optionally substituted 5- to 6-membered heterocyclic ring;
[00240] [00240] each case of W is independently O, S, or NR", wherein R""' is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl of, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i),
[00241] [00241] each case of Y is independently O, S, or NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
[00242] [00242] Formulas (i), (ii), and (ii) are: RE)—YRP L R ! Pu / (i) (ii) (iii) in which:
[00243] [00243] XéoO,S, NR“, wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00244] [00244] YéoO,S, NR", wherein R" is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00245] [00245] —Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and
[00246] [00246] R optionally substituted C1-59 alkyl, optionally substituted Ca-595 alkenyl, optionally substituted C1-59 alkynyl, optionally substituted heteroC1-5,5 alkyl, optionally substituted heteroC1-55 alkenyl, optionally substituted heteroC2- 55 alkynyl, or a polymer.
[00247] [00247] In certain embodiments, where Yé O and Wé O, the following compounds are specifically excluded: o o o o o O, DO, TO, TO, MTO,
[00248] [00248] wherein Rº and R$ are independently hydrogen or a group of formula (i), and salts thereof.
[00249] [00249] In certain embodiments, at least one case of R”, Rº, R , Rº, Rº, or Rº is a group of formula (i), (ii), or (iii).
[00250] [00250] — As generally defined above, each case of R' is independently hydrogen or optionally substituted alkyl. In certain embodiments, at least one case of R' is hydrogen. In certain embodiments, at least two cases of R' are hydrogen. In certain embodiments, each case of R' is hydrogen. In certain embodiments, at least one instance of R' is optionally substituted alkyl, for example, methyl. In certain embodiments, at least two instances of R' are optionally substituted alkyl, for example, methyl. In certain embodiments, one case of R' is optionally substituted alkyl, and the rest is hydrogen.
[00251] [00251] — As generally defined above, each case of R' is independent.
[00252] [00252] In certain embodiments, at least one case of R' is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally heteroaryl replaced.
[00253] [00253] In certain embodiments, at least one case of R' is optionally substituted alkyl; for example C1-; optionally substituted alkyl, C7-; optionally substituted alkyl, C3z-; optionally substituted alkyl, C1-; optionally substituted alkyl, optionally substituted C1-5 alkyl, or optionally substituted C3- alkyl.
[00254] [00254] In certain embodiments, at least one case of R' is optionally substituted alkenyl, for example, C7-; optionally substituted alkenyl, C3z-; optionally substituted alkenyl, optionally substituted C1-6 alkenyl, C,4-; optionally substituted alkenyl, or optionally substituted C3-1 alkenyl.
[00255] [00255] In certain embodiments, at least one instance of R' is optionally substituted alkynyl, e.g., C 1 -s optionally substituted alkynyl, C 3 -; optionally substituted alkynyl, optionally substituted C1-6 alkynyl, optionally substituted C4-5 alkynyl, or optionally substituted C3- alkynyl.
[00256] [00256] In certain embodiments, at least one case of R' is optionally substituted carbocyclyl, for example, optionally substituted C3-19 carbocyclyl, optionally substituted Cs-g carbocyclyl, optionally substituted Cs-6 C carbocyclyl, optionally substituted C5 carbocyclyl -
[00257] [00257] In certain embodiments, at least one instance of R' is optionally substituted heterocyclyl, e.g., optionally substituted 3 to 14 membered heterocyclyl, optionally substituted 3 to 10 membered heterocyclyl, optionally substituted 5 to 8 membered heterocyclyl optionally substituted, optionally substituted 5- to 6-membered heterocyclyl, optionally substituted 5-membered heterocyclyl, or optionally substituted 6-membered heterocyclyl.
[00258] [00258] In certain embodiments, at least one case of R' is optionally substituted aryl, for example, optionally substituted phenyl.
[00259] [00259] In certain embodiments, at least one instance of R' is optionally substituted heteroaryl, for example, optionally substituted 5 to 14 membered heteroaryl, optionally substituted 5 to 10 membered heteroaryl, optionally substituted 5 to 6 membered heteroaryl substituted, optionally substituted 5-membered heteroaryl, or optionally substituted 6-membered heteroaryl.
[00260] [00260] In any of the above embodiments, the R1 alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl group may be substituted, for example, with an optionally substituted amino group (e.g., -NRºR"), a group optionally substituted hydroxyl group (e.g. -OR$), an optionally substituted thiol group (e.g. -SR$), or with a group of formula (i), (ii), or (iii), wherein each case of Rº and R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when bonded to an oxygen atom, and a sulfur protecting group when bonded to a sulfur atom, or a group of formula (i), (ii), or ( iii).
[00261] [00261] For example, in certain embodiments, at least one instance of R' is an alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl group substituted with an amino group of the formula - N(RôI(R'). In that case, in certain embodiments, at least one case of R* is a group of formula: 6
[00262] [00262] L is an optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or optionally subs - titrated heteroarylene, or a combination thereof, and
[00263] [00263] R° and R' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, and a nitrogen protecting group;
[00264] [00264] provided that at least one case of R6 and R7 is a group of formula (i), (ii), or (iii): RdvRe Da L HR nº ' or A () (ii) (iii)
[00265] [00265] whereR' ,X,Y,R!,andRº are as defined here.
[00266] [00266] In certain embodiments, at least two cases of R' are a group of formula (iv). In certain embodiments, at least three cases of R' are a group of formula (iv). In certain embodiments, at least four instances of R' are a group of formula (iv). In certain embodiments, at least five instances of R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv).
[00267] [00267] In certain embodiments, R' alpha to the group -C(=W)-Y- is a group of formula (iv).
[00268] [00268] In certain embodiments, at least one case of R' provided in the group Rº is a group of formula (iv). In certain embodiments, at least two instances of R' provided in the group R° are a group of formula (iv). In certain embodiments, at least three instances of R' given in the group R° are a group of formula (iv). In certain embodiments, at least four cases of R* given in the R8 group are a group of formula (iv). In certain embodiments, at least five instances of R' provided in the group R° are a group of formula (iv). In certain embodiments, each case of R' provided in the group R° is a group of formula (iv).
[00269] [00269] In certain embodiments, L is an optionally substituted alkylene; for example, optionally substituted C1-409 alkylene, optionally substituted C1-30 alkylene, optionally substituted C1-25 alkylene, optionally substituted C4-25 alkylene, optionally substituted C1-25 alkylene, optionally substituted Csg-x alkylene, optionally substituted C10-25 alkylene, optionally substituted C1-; alkylene, optionally substituted C7-; alkylene, optionally substituted C1-6 alkylene, optionally substituted C1-; alkylene, optionally substituted C3-alkylene, or optionally substituted C3-alkylene.
[00270] [00270] In certain embodiments, L is an optionally substituted alkenylene, e.g. optionally substituted C>2-55 alkenylene, optionally substituted C2-405 alkenylene, optionally substituted C>7-309 alkenylene, optionally substituted C2-25 alkenylene, optional - optionally substituted C4-25 alkenylene, optionally substituted C1-25 alkenylene, optionally substituted C6-25 alkenylene, optionally substituted C109-25 alkenylene, optionally substituted C₁-; alkenylene, optionally substituted C13-; alkenylene, optionally substituted C1-1 alkenylene, optionally substituted C1-5 alkenylene, or optionally substituted C3-alkenylene.
[00271] [00271] In certain embodiments, L is an optionally substituted alkynylene, e.g. optionally substituted C>2-55 alkynylene, optionally substituted C2-45 alkynylene, optionally substituted C>2-309 alkynylene, optionally substituted C>2-25 alkynylene , optionally substituted C6-25 alkynylene, optionally substituted C6-20 alkynylene, optionally substituted C6-2 alkynylene, optionally substituted C10-25 alkynylene, optionally substituted C6-; alkynylene, optionally substituted C3-; alkynylene, optionally substituted Ca-6 alkynylene, optionally substituted Ca-5 alkynylene, or optionally substituted C3-, alkynylene.
[00272] [00272] In certain embodiments, L is an optionally substituted heteroalkylene; for example optionally substituted heteroC1-50alkylene, optionally substituted heteroC1-40alkylene, optionally substituted heteroC1-30alkylene, optionally substituted heteroC1-20alkylene, optionally substituted heteroC4-20alkylene, optionally substituted heteroC1-20alkylene, heteroC1-20alkylene optionally substituted, optionally substituted heteroC 10 -25 alkylene, optionally substituted heteroC 1 -alkylene, optionally substituted heteroC 1 -alkylene, optionally substituted heteroC 1 3 -alkylene, optionally substituted heteroC 1 -alkylene, heteroC 1 -alkylene optionally substituted, or heteroC3-
[00273] [00273] In certain embodiments, L is an optionally substituted heteroalkenylene, for example, optionally substituted heteroC2-50alkenylene, optionally substituted heteroC2-40alkenylene, heteroC2-30alkenylene — optionally — substituted, — optionally substituted heteroC2-20alkenylene, heteroC4- 20alkenylene, optionally substituted heteroCs-20alkenylene, optionally substituted heteroC1-20alkenylene, optionally substituted heteroC1-20alkenylene, optionally substituted heteroC1-20-alkenylene, optionally substituted heteroC1-3-salkenylene, heteroC1- optionally substituted salkenylene, heteroC, optionally substituted salkenylene, or optionally substituted heteroC3-,alkenylene.
[00274] [00274] In certain embodiments, L is an optionally substituted alkynylene, e.g. optionally substituted heteroC 1 -soalkynylene, optionally substituted heteroC 7-4oalkynylene, optionally substituted heteroC 2-2 2-alkynylene, optionally substituted heteroC 2 -2,alkynylene, optionally substituted heteroC1-20alkynylene, optionally substituted heteroC6-25alkynylene, optionally substituted heteroC10-25alkynylene, optionally substituted heteroC10-20alkynylene, optionally substituted heteroC,-salkynylene, optionally substituted C3-salkynylene, optionally substituted heteroC,-salkynylene, optionally substituted heteroC, - salkynylene, or optionally substituted heteroC3-,alkynylene.
[00275] [00275] In certain embodiments, L is an optionally substituted carbocyclylene, for example, optionally substituted C3-195 carbocyclylene, optionally substituted Cs-8 carbocyclylene, optionally substituted Cs-1 carbocyclylene, optionally substituted C; carbocyclylene, or optionally substituted carbocyclylene Cs.
[00276] [00276] In certain embodiments, L is an optional heterocyclylene-
[00277] [00277] In certain embodiments, L is an optionally substituted arylene, for example, optionally substituted phenylene.
[00278] [00278] In certain embodiments, L is an optionally substituted heteroarylene, for example, optionally substituted 5 to 14 membered heteroarylene, optionally substituted 5 to 10 membered heteroarylene, optionally substituted 5 to 6 membered heteroarylene, optionally substituted 5-membered heteroarylene, or optionally substituted 6-membered heteroarylene.
[00279] [00279] — For example, in certain embodiments, where L is an optionally substituted alkylene group, the group of formula (iv) is a group of the formula: n Ágoe
[00280] [00280] where q is an integer between 1 and 50, inclusive.
[00281] [00281] In certain embodiments, q is an integer between 1 and 40, inclusive. In certain embodiments, q is an integer between 1 and 30, inclusive. In certain embodiments, q is an integer between 1 and 20, inclusive. In certain embodiments, q is an integer between 4 and 20, inclusive. In certain embodiments, q is an integer between 6 and 20, inclusive. In certain embodiments, q is an integer between 8 and 20, inclusive. In certain embodiments, q is 1. In certain embodiments, q is
[00282] [00282] In certain embodiments, both Rº and R' are hydrogen. In certain embodiments, R° is hydrogen and R' is a group of formula (i), (ii), or (iii). In certain embodiments, Rº is hydrogen and R' is a group of formula (i).. In certain embodiments, Rº is hydrogen and R is a group of formula (ii)).. In certain embodiments, Rº is hydrogen and R' is a group of formula (iii). In certain embodiments, both R' and R' are independently a group of formula (i), (ii), or (ili)). In certain embodiments, both Rº and R' are independently a group of the formula (). In certain embodiments, both R° and R are independently a group of formula (ii). In certain embodiments, both Rº and R' are independently a group of formula (iii)) In certain embodiments, both Rº and R' are the same group, selected from a group of formula (i), (ii), or (iii).
[00283] [00283] It is understood that R' encompasses amino acid side chains, as exemplified in Table 1 of the examples. In certain embodiments, R' is a group selected from any of the amino acid side chain groups listed here.
[00284] [00284] In certain embodiments, each case of R' is the same. In certain embodiments, at least one R1 group is different. In certain modalities, each R1 group is different.
[00285] [00285] "As generally defined above, each case of W is independently O, S, or NR", where R"' is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl , optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii). In certain embodiments, WéoO. In certain embodiments, W is S. In certain embodiments, W is NR." In certain embodiments, R" is hydrogen or a group of the formula.
[00286] [00286] As generally defined above, each case of Y is independently O, S, or NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, he - optionally substituted terocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group. In certain embodiments, Y is O. In certain embodiments, each case of Y is S. In certain embodiments, Y is NR." in certain embodiments, R* is hydrogen or a nitrogen protecting group.
[00287] [00287] In certain modalities, WéOeYéoO. In certain embodiments, W is O and Y is S. In certain embodiments, W is O and Y is NR. In certain embodiments, W is If Y and O. In certain embodiments, W is S and YéS. In certain embodiments, W is S and Y is NR”. In certain modalities, W is NRO and Y is O. In certain modalities, W is NR and Y is S. In certain modalities, W is NR" and Y is NR”.
[00288] [00288] “As generally defined above, Rº is hydrogen, a group of formula (i), (ii), or (iii), or a group of formula (v): s z Rº Rn , (v)
[00289] [00289] where R º, R , Ró, Z, m, and n are as defined in formula (1), provided that at least one case of R””, R º, R à, Rº, R $, R6, or R6 is a group of formula (i), (ii), or (iii).
[00290] [00290] In certain embodiments, Rº is hydrogen.
[00291] [00291] In certain embodiments, Rº is a group of the formula (i), (ii), or (iii). In certain embodiments, R° is a group of formula (i). In certain embodiments, Rº is a group of formula (ii).. In certain embodiments, Rº is a group of formula (iii).
[00292] [00292] In certain embodiments, Rº is a group of formula (v). In certain embodiments, R° is a group of formula (v) and R is a group of formula (i), (ii), or (ili)).. In certain embodiments, Rº is a group of formula (v) and Rº is a group of formula (i), (ii), or (iii).
[00293] [00293] In certain embodiments, at least one R' is a group of formula (iv) and R' is a group of formula (i), (ii), or (iii). In certain embodiments, at least one R* is a group of formula (iv) and R' is a group of formula (i), (ii), or (ili))). In certain embodiments, at least one R' is a group of formula (iv), and both R' and R' are independently groups of formula (i), (ii), or (iii).
[00294] [00294] —Alternatively, in certain embodiments, Rº and the adjacent R group are joined to form an optionally substituted 5- to 6-membered heterocyclic ring, e.g., a membered heterocyclic ring, e.g., an optionally substituted pyrrolidinyl ring - of.
[00295] [00295] Various combinations of the above embodiments of formula (II) are contemplated herein.
[00296] [00296] For example, in certain embodiments, where each case of R' is hydrogen, W is O and Y is O, the compound of formula (II) is a compound of formula (II-a): the Ri e. CNS (II-a)
[00297] [00297] or even the balance. In certain embodiments, R° is a group of formula (i), (ii), or (iii). In certain embodiments, R° is a group of formula (v) and R is a group of formula (i), (ii), or (iii).. In certain embodiments, Rº is a group of formula (v) and Rº is a group of formula (1), (ii), or (ii). In certain embodiments, at least one R'* is a group of formula (iv). In certain embodiments, R' is a group of formula (iv) and R' is a group of formula (i), (ii), or (ili)). In certain embodiments, R' is a group of formula (iv). and R° is a group of formula (i), (ii), or (iii).
[00298] [00298] In certain embodiments of formula (II-a), wherein R' alpha to the -C(=0)-O- group is a group of formula (iv), a compound of formula (II-b) is provided : nº oe À, Bs (lb)
[00299] [00299] or balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii)... In certain embodiments, both Rº and R' are independently groups of formula (i), (ii), or (iii).
[00300] [00300] In certain embodiments of formula (II-a), wherein R6 is a group of formula (v), a compound of formula (II-c) is provided: Rn R2—N-Is Ro. (II-c)
[00301] [00301] or even balance. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, R is a group of formula (i). In certain embodiments, R is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, Rº is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, Rº is a group of formula (iii)... In certain embodiments, Rº is hydrogen. In certain modes, Z is 0. In certain modes, n is 0. In certain modes, n is 1. In certain modes, n is 2. In certain modes, n is 3. In certain modes, n is 4 . In certain embodiments, n is 5. In certain embodiments, m is 1.
[00302] [00302] In certain embodiments of formula (II-c), wherein R' alpha to the -C(=0)-O- group is a group of formula (iv), a compound of formula (II-c1) is provided : she À dao Re—)N 7” Ro " (11-01)
[00303] [00303] or balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii)... In certain embodiments, both Rº and R' are independently groups of formula (i), (ii), or (iii).
[00304] [00304] In certain embodiments of formula (II-c), where each case of R1 provided in the group Rº is a group of formula (iv), a compound of formula (II-c2) is provided: o
[00305] [00305] or balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). In certain embodiments, both Rº and R” are independent.
[00306] [00306] In certain embodiments of formula (II-c), where each case of R' is a group of formula (iv), a compound of formula (11-03) is provided: sda A ty Rea 2 Nº m Re The RR ç (11-03)
[00307] [00307] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, Rº is a group of formula (i). In certain embodiments, Rº is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). In certain embodiments, both R° and R' are independently groups of formula (i), (ii), or (iii).
[00308] [00308] In certain embodiments of formula (II-a), wherein Rº is a group of formula (i), a compound of formula (11-d) is provided: o o
[00309] [00309] a salt thereof. In certain embodiments, R' is hydrogen. In certain embodiments, R* is a group of formula (iv). In certain embodiments, R' is a group of formula (iv) and R° is a group of formula (1), (ii), or (iii). In certain embodiments, R* is a group of formula (iv) and both R° and R' are independently groups of formula (i), (ii), or (iii).
[00310] [00310] In certain embodiments of formula (II-d), wherein R' alpha to the -C(=0)-O- group is a group of formula (iv), a compound of formula (11-d1) is provided :
[00311] [00311] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). In certain embodiments, both R° and R are independently groups of formula (i), (ii), or (iii).
[00312] [00312] In certain embodiments of formula (II-a), wherein R6 is a group of formula (ii), a compound of formula (II-e) is provided: sÃ. RX. N.L VT” — (Il-e)
[00313] [00313] or even. In certain embodiments, R' is hydrogen. In certain embodiments, R' is a group of formula (iv). In certain embodiments, R' is a group of formula (iv) and R° is a group of formula (1), (ii), or (iii). In certain embodiments, R* is a group of formula (iv) and both R° and R are independently groups of formula (i), (ii), or (iii).
[00314] [00314] In certain embodiments of formula (II-e), wherein R' alpha to the -C(=0)-O- group is a group of formula (iv), a compound of formula (II-e1) is provided : [already RUEX, N TT” — (Il-e1)
[00315] [00315] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii).
[00316] [00316] In certain embodiments of formula (Il-a), wherein Rº is a group of formula (iii), a compound of formula (I1-f) is provided: o THE ADA
[00317] [00317] or even. In certain embodiments, R' is hydrogen. In certain embodiments, R' is a group of formula (iv). In certain embodiments, R' is a group of formula (iv) and R° is a group of formula (1), (ii), or (iii). In certain embodiments, R* is a group of formula (iv) and both R6 and R are independently groups of formula (i), (ii), or (iii).
[00318] [00318] In certain embodiments of formula (II-f), wherein R' alpha to the -C(=0)-O- group is a group of formula (iv), a compound of formula (I1-f1) is provided : rá o et o SNS AR)
[00319] [00319] or even. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). In certain embodiments, both R° and R are independently groups of formula (i), (ii), or (iii).
[00320] [00320] In certain embodiments of formula (Il-a), wherein R' and Rº are joined to form an optional 5- to 6-membered heterocyclic ring
[00321] [00321] an even balance. In certain embodiments, L is an optionally substituted alkylene. Formula compounds (/!)
[00322] [00322] Compounds of formula (III) are the cyclic condensation product of the same or different two, three, four, five, six, seven, eight, nine, or ten amino acids, and which also comprise one or more sites of conjugation bonds attached thereto, for example, to an internal amide nitrogen, an amino substituent, and/or an imino nitrogen, of a group of formula (i), (iii), or (iii). Such groups may be conjugated before cyclization, i.e., to the amino acid precursors of the cyclization product, or after cyclization. Re
[00323] [00323] “Thus, in a third aspect, a compound of formula (Ill) is provided: ne [RR X OQ: Q
[00324] [00324] —or the very sum; on what:
[00325] [00325] is an integer between 1 and 9, inclusive;
[00326] [00326] each case of Q is independently O, S, or NRº, where Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally aryl substituted, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), Gi);
[00327] [00327] each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR“, -N(R“)>, or -SR*!. wherein each occurrence of R** is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a protecting group of oxygen when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, a nitrogen protecting group when bonded to a nitrogen atom, or two R** groups are joined to form a ring optionally substituted heterocyclic or optionally substituted heteroaryl; and
[00328] [00328] each case of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i) ), (ii), or (iii); and
[00329] [00329] Formulas (i), (ii), and (iii) are:
[00330] [00330] each case of R' is independently hydrogen or optionally substituted alkyl;
[00331] [00331] XéoO, S, NR“, wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00332] [00332] YéoO,S, NR", wherein R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
[00333] [00333] Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and
[00334] [00334] R! optionally substituted C1-55 alkyl, optionally substituted C2-59 alkenyl, optionally substituted C1-59 alkynyl, optionally substituted heteroC1-5,5 alkyl, optionally substituted heteroC2-55 alkenyl, optionally substituted heteroC2-5, alkyne-
[00335] [00335] as long as at least one case of Rº, R , Rô, or R is a group of formula (i), (ii), or (iii).
[00336] [00336] As generally defined above, p is an integer between 1 and 9, inclusive. In certain modalities, p is 1. In certain modalities, p is 2. In certain modalities, p is 3. In certain modalities, p4. In certain embodiments, p is 5. In certain embodiments, p is 6. In certain embodiments, p is 7. In certain embodiments, p is 8. In certain embodiments, p is 9.
[00337] [00337] For example, in certain embodiments, where p is 1, the compound of formula (III) is a compound of formula (lll-a): as A" Q RR (lll-a)
[00338] [00338] or even.
[00339] [00339] In certain embodiments, where p is 2, the compound of formula (III) is a compound of formula (III-b): ms o: o Q (III-b)
[00340] [00340] —I really mean it.
[00341] [00341] In certain embodiments, where p is 3, the compound of formula (III) is a compound of formula (lll-c):
[00342] [00342] —I dare you.
[00343] [00343] In certain embodiments, where p is 4, the compound of formula (Ill) is a compound of formula (I1I-d):
[00344] [00344] —I really dared.
[00345] [00345] In certain embodiments, where p is 5, the compound of formula (III) is a compound of formula (III-e): R1 1 ha Rº n and FA o
[00346] [00346] or even.
[00347] [00347] In certain embodiments, where p is 6, the compound of formula (III) is a compound of formula (III-f): IE, RA 'Roo" (111-f)
[00348] [00348] or even the balance.
[00349] [00349] In certain embodiments, where p is 7, the compound of formula (III) is a compound of formula (III-g): : Q a'
[00350] [00350] —I really mean it.
[00351] [00351] In certain embodiments, where p is 8, the compound of formula (III) is a compound of formula (III-h):
[00352] [00352] —I really dared.
[00353] [00353] In certain embodiments, where p is 9, the compound of formula (III) is a compound of formula (III-i): Q Rn * Q R& RA N. Q Rº No. RóQ ph
[00354] [00354] —I really mean it.
[00355] [00355] — As generally defined above, each case of R' is independently hydrogen or optionally substituted alkyl. In certain embodiments, at least one case of R' is hydrogen. In certain embodiments, at least two cases of R' are hydrogen. In certain embodiments, each case of R' is hydrogen. In certain embodiments, at least one instance of R' is optionally substituted alkyl, for example, methyl. In certain embodiments, at least two instances of R' are optionally substituted alkyl, for example, methyl. In certain embodiments, one case of R' is optionally substituted alkyl, and the rest is hydrogen.
[00356] [00356] “As generally defined above, each case of Q is independently O, S, or NRº, where Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, he- optionally substituted terocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitro-protecting group
[00357] [00357] “As generally defined above, each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR*, -N(R')>, or -SR“*
[00358] [00358] In certain embodiments, at least one instance of R' is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally heteroaryl replaced.
[00359] [00359] In certain embodiments, at least one case of R' is optionally substituted alkyl; for example C1-; optionally substituted alkyl, Cx; optionally substituted alkyl, C3-; optionally substituted alkyl, C1-; optionally substituted alkyl, optionally substituted C1-5 alkyl, or optionally substituted C3- alkyl.
[00360] [00360] In certain embodiments, at least one case of R' is optionally substituted alkenyl, for example, C>-; optionally substituted alkenyl, C3z-; optionally substituted alkenyl, optionally substituted C1-6 alkenyl, optionally substituted C1-;s alkenyl, or optionally substituted C3-alkenyl.
[00361] [00361] In certain embodiments, at least one case of R' is al-
[00362] [00362] In certain embodiments, at least one case of R' is optionally substituted carbocyclyl, for example, optionally substituted C3-195 carbocyclyl, optionally substituted Cs-g carbocyclyl, optionally substituted Cs-6 carbocyclyl, optionally substituted C5 carbocyclyl - mentally substituted, or optionally substituted C6 carbocyclyl.
[00363] [00363] In certain embodiments, at least one instance of R' is optionally substituted heterocyclyl, e.g., optionally substituted 3 to 14 membered heterocyclyl, optionally substituted 3 to 10 membered heterocyclyl, optionally substituted 5 to 8 membered heterocyclyl optionally substituted, optionally substituted 5- to 6-membered heterocyclyl, optionally substituted 5-membered heterocyclyl, or optionally substituted 6-membered heterocyclyl.
[00364] [00364] In certain embodiments, at least one instance of R' is optionally substituted aryl, for example, optionally substituted phenyl.
[00365] [00365] In certain embodiments, at least one instance of R' is optionally substituted heteroaryl, for example, optionally substituted 5 to 14 membered heteroaryl, optionally substituted 5 to 10 membered heteroaryl, optionally substituted 5 to 6 membered heteroaryl substituted, optionally substituted 5-membered heteroaryl, or optionally substituted 6-membered heteroaryl.
[00366] [00366] In any of the above embodiments, the R1 alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl group may be substituted, for example, with an optionally substituted amino group (e.g., -NRºR"), a group optionally substituted hydroxyl (e.g. -ORº), an optionally substituted thiol group
[00367] [00367] For example, in certain embodiments, at least one instance of R' is an alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl group substituted with an amino group of the formula — N(RÓR”). In that case, in certain embodiments, at least one case of R' is a group of formula: Rô
[00368] [00368] L is an optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or optionally subs - titrated heteroarylene, or a combination thereof, and
[00369] [00369] R6 and R" are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl
[00370] [00370] provided that at least one case of R6 and R7 is a group of formula (i), (ii), or (iii): ms and EM () (ii) (iii)
[00371] [00371] whereR' ,X,Y,R!,andRº are as defined here.
[00372] [00372] In certain embodiments, at least two cases of R1 are a group of formula (iv). In certain embodiments, at least three cases of R1 are a group of formula (iv). In certain embodiments, at least four instances of R1 are a group of formula (iv). In certain embodiments, at least five instances of R' is a group of formula (iv). In certain embodiments, at least six instances of R' is a group of formula (iv). In certain embodiments, at least seven instances of R' is a group of formula (iv). In certain embodiments, at least eight instances of R' is a group of formula (iv). In certain embodiments, at least nine instances of R* is a group of formula (iv). In certain modalities, each case of R'* is a group of formula (iv).
[00373] [00373] In certain embodiments, L is an optionally substituted alkylene; for example, optionally substituted C1-10alkylene, optionally substituted C1-10alkylene, optionally substituted C1-30alkylene, optionally substituted C1-20alkylene, optionally substituted C1-20alkylene, optionally substituted Cs-20alkylene, optionally substituted Cs-20alkylene, optionally substituted C 10 -20 alkylene, optionally substituted C 1 -alkylene, optionally substituted C 1 -alkylene, optionally substituted C 1 -alkylene, optionally substituted C 1 -alkylene, optionally substituted C 1 -alkylene, or optionally substituted C 3 -alkylene.
[00374] [00374] In certain embodiments, L is an optionally substituted alkenylene, e.g. optionally substituted C₁-soalkenylene,
[00375] [00375] In certain embodiments, L is an optionally substituted alkynylene, for example, optionally substituted Ca-5soalkynylene, optionally substituted C7-,oalkynylene, optionally substituted Ca-zoalkynylene, optionally substituted Ca-2palkynylene, optionally substituted Ca-2oalkynylene, optionally substituted C6-20alkynylene, optionally substituted C6-2oalkynylene, optionally substituted Cao-xoalkynylene, optionally substituted C7-salkynylene, optionally substituted C3-salkynylene, optionally substituted Ca-salkynylene, optionally substituted Ca-salkynylene, or optionally substituted C3-,alkynylene .
[00376] [00376] In certain embodiments, L is an optionally substituted heteroalkylene; for example, optionally substituted heteroC1-50alkylene, = optionally substituted heteroC1-40alkylene, optionally substituted heteroC1-30alkylene, optionally substituted heteroC1-20alkylene, optionally substituted heteroC4-20alkylene, optionally substituted heteroCs-2xalkylene, heteroC;- 20 optionally substituted alkylene, optionally substituted heteroC 19-25 alkylene, optionally substituted heteroC 1 -alkylene, optionally substituted heteroC 1 -alkylene, optionally substituted heteroC 1 -3 -alkylene, optionally substituted heteroC 1 -alkylene, heteroC 1 - optionally substituted alkylene, or optionally substituted heteroC3;-4 alkylene.
[00377] [00377] In certain embodiments, L is an optionally substituted heteroalkenylene, for example, optionally substituted heteroC2-50alkenylene, optionally substituted heteroC2-40alkenylene, heteroC2-30alkenylene — optionally — substituted, — optionally substituted heteroC2-20alkenylene, heteroC4- optionally substituted heteroCs-20alkenylene, optionally substituted heteroCs-20alkenylene, optionally substituted heteroC1-20alkenylene, optionally substituted heteroC1-20alkenylene, optionally substituted heteroC1-20alkenylene, optionally substituted heteroC1-3-salkenylene, heteroC1- optionally substituted salkenylene, heteroC, optionally substituted salkenylene, or optionally substituted heteroC3z-,alkenylene.
[00378] [00378] In certain embodiments, L is an optionally substituted heteroalkynylene, e.g. optionally substituted heteroC1-5soalkynylene, optionally substituted heteroC7-,oalkynylene, optionally substituted heteroC1-35alkynylene, optionally substituted heteroC1-35alkynylene 2,alkynylene, optionally substituted heteroC1-20alkynylene, optionally substituted heteroC6-205alkynylene, optionally substituted heteroC1-25alkynylene, optionally substituted heteroC1-20alkynylene, optionally substituted heteroC1-20-salkynylene, optionally substituted heteroC1-3-salkynylene, optionally substituted heteroC1-20-alkynylene optionally substituted heteroC 3 -alkynylene, optionally substituted heteroC 3 -alkynylene, or optionally substituted heteroC 3 -alkynylene.
[00379] [00379] In certain embodiments, L is an optionally substituted carbocyclylene, e.g. optionally substituted C3-109 carbocyclylene, optionally substituted Cs-g carbocyclylene, optionally substituted Cs-1 carbocyclylene, optionally substituted Cs carbocyclylene, or optionally substituted Cs carbocyclylene.
[00380] [00380] In certain embodiments, L is an optional heterocyclylene-
[00381] [00381] In certain embodiments, L is an optionally substituted arylene, for example, optionally substituted phenylene.
[00382] [00382] In certain embodiments, L is an optionally substituted heteroarylene, for example, optionally substituted 5 to 14 membered heteroarylene, optionally substituted 5 to 10 membered heteroarylene, optionally substituted 5 to 6 membered heteroarylene, optionally substituted 5-membered, or optionally substituted 6-membered heteroarylene.
[00383] [00383] For example, in certain embodiments, where L is an optionally substituted alkylene group, the group of formula (iv) is a group of the formula: # Age
[00384] [00384] where q is an integer between 1 and 50, inclusive.
[00385] [00385] In certain embodiments, q is an integer between 1 and 40, inclusive. In certain embodiments, q is an integer between 1 and 30, inclusive. In certain embodiments, q is an integer between 1 and 20, inclusive. In certain embodiments, q is an integer between 4 and 20, inclusive. In certain embodiments, q is an integer between 6 and 20, inclusive. In certain embodiments, q is an integer between 8 and 20, inclusive. In certain embodiments, q is 1. In certain embodiments, q is
[00386] [00386] In certain embodiments, both Rº and R' are hydrogen. In certain embodiments, R° is hydrogen and R' is a group of formula (i), (ii), or (iii). In certain embodiments, Rº is hydrogen and R' is a group of formula (i).. In certain embodiments, Rº is hydrogen and R is a group of formula (ii)).. In certain embodiments, Rº is hydrogen and R' is a group of formula (iii). In certain embodiments, both R' and R' are independently a group of formula (i), (ii), or (ili)). In certain embodiments, both Rº and R' are independently a group of the formula (). In certain embodiments, both R° and R are independently a group of formula (ii). In certain embodiments, both Rº and R' are independently a group of formula (iii)) In certain embodiments, both Rº and R' are the same group, selected from a group of formula (i), (ii), or (iii).
[00387] [00387] It is understood that R' encompasses amino acid side chains, as exemplified in Table 1 of the examples. In certain embodiments, R' is a group selected from any of the amino acid side chain groups listed here.
[00388] [00388] In certain embodiments, each case of R' is the same. In certain embodiments, at least one R' group is different. In certain modalities, each R1 group is different.
[00389] [00389] “As generally defined above, each case of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii):
[00390] [00390] whereR' ,X,Y,R!,andRº are as defined here.
[00391] [00391] In certain embodiments, at least one case of R is optionally substituted alkyl; for example, optionally substituted C1-5 alkyl, C>-; optionally substituted alkyl, optionally substituted C3-s alkyl, optionally substituted C4-6 alkyl, optionally substituted C1-5 alkyl, or optionally substituted C3- alkyl.
[00392] [00392] In certain embodiments, at least one case of R is optionally substituted alkenyl, for example, optionally substituted C>2-65 alkenyl, C3-; optionally substituted alkenyl, optionally substituted C1-6 alkenyl, optionally substituted C1-5s alkenyl, or optionally substituted C3-alkenyl.
[00393] [00393] In certain embodiments, at least one case of R is optionally substituted alkynyl, for example C₁-; optionally substituted alkynyl, C3-; optionally substituted alkynyl, optionally substituted C1-6 alkynyl, optionally substituted C1-5 alkynyl, or optionally substituted C3- alkynyl.
[00394] [00394] In certain embodiments, at least one case of R is optionally substituted carbocyclyl, for example optionally substituted C3-195 carbocyclyl, optionally substituted Cs-6 carbocyclyl, optionally substituted Cs-6 carbocyclyl, Cs; optionally substituted carbocyclyl, or optionally substituted carbocyclyl.
[00395] [00395] In certain embodiments, at least one case of R is optionally substituted heterocyclyl, e.g. optionally substituted 3 to 14 membered heterocyclyl, optionally substituted 3 to 10 membered heterocyclyl, optionally substituted 5 to 8 membered heterocyclyl
[00396] [00396] In certain embodiments, at least one case of R is optionally substituted aryl, for example optionally substituted phenyl.
[00397] [00397] In certain embodiments, at least one case of R is optionally substituted heteroaryl, for example, optionally substituted 5 to 14 membered heteroaryl, optionally substituted 5 to 10 membered heteroaryl, optionally substituted 5 to 6 membered heteroaryl, optionally substituted 5 membered heteroaryl, or 6 membered heteroaryl optionally substituted members.
[00398] [00398] In certain embodiments, at least one case of R is a nitrogen protecting group.
[00399] [00399] In certain embodiments, at least one case of R is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii).
[00400] [00400] In certain embodiments, each case of R is a group other than the formula (i), (ii), or (ili); in that case, it follows that at least one R° is a group of formula (i), (ii), or (iii), or at least one R' is a group of formula (iv), and at least one of R° or R 'encompassed by R' is a group of the formula (i), (ii), or (ili). For example, in certain embodiments, both cases of R are hydrogen, and thus at least one R° is a group of formula (i), (ii), or (iii), or at least one R' is a group of formula (iv), and at least one of R° or R' encompassed by R' is a group of formula (i), (ii), or (iii).
[00401] [00401] Various combinations of the above embodiments of formula (III) are contemplated herein.
[00402] [00402] For example, in certain modalities, where each case of
[00403] [00403] or even. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv). In certain embodiments, each case of R is hydrogen. In certain embodiments, at least one case of R° is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii). In certain embodiments, p is
[00404] [00404] In certain embodiments of formula (III-a), wherein at least one R' is a group the formula (iv), a compound of formula (III-b) is provided: | Oo: sv o o R (II-b)
[00405] [00405] — or salt thereof. In certain embodiments, each case of R' is a group of formula (iv). In certain embodiments, R is hydrogen. In certain embodiments, each case of R is hydrogen. In certain modalities, at least one case of R is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii). In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, Rº is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments,
[00406] [00406] In certain embodiments of formula (III-a), where each case of R' is a group the formula (iv), a compound of formula (III-c) is provided: RR KR :
[00407] [00407] or even balance. In certain embodiments, each case of R is hydrogen. In certain embodiments, at least one case of R is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii). In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain modalities, Rº is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R is a group of formula (iii). In certain modalities, both Rº and R are independently groups of formula (i), (ii), or (iii).
[00408] [00408] In certain embodiments of formula (IIIl-c), wherein p is 1, a compound of formula (IIIl-c1) is provided: Re 2R Y
[00409] [00409] or even balance. In certain embodiments, each case of R is hydrogen. In certain embodiments, at least one case of R is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii). In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R" is a group of formula (i). In certain embodiments, R is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). In certain embodiments, both R6 and R are independently groups of formula (i), (ii), or (iii).
[00410] [00410] In certain embodiments of formula (III-c1), where each case of R is hydrogen, a compound of formula (III-c2) is provided: RR IT'S
[00411] [00411] or even the balance. In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R° is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). In certain embodiments, both R° and R' are groups of formula (i), (ii), or (iii).
[00412] [00412] In certain embodiments of formula (III-c1), wherein L is an optionally substituted alkylene, a compound of formula (III-c3) is provided: RR
[00413] [00413] or even balance, where q is an integer between 1 and 10, inclusive. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, Rº is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). In certain embodiments, both R' and R' are independently groups of formula (i), (ii), or (iii).
[00414] [00414] In certain forms of formula (III-a), in which at least one case of R is a group of formula (i) and each case of R' is hydrogen, a compound of formula (I1l-d) is provided: Rex Rº NA 1 NO: O
[00415] [00415] or even. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv). In certain embodiments, each case of R is hydrogen. In certain embodiments, at least one case of R is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii). In certain embodiments, R is a group of formula (iii). In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3.
[00416] [00416] In certain forms of formula (III-a), in which at least one case of R is a group of formula (ii) and each case of R' is hydrogen, a compound of formula (III-e) is provided: a OM . 1 | Laugh at (Ile)
[00417] [00417] or even. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv). In certain embodiments, each case of R is hydrogen. In certain embodiments, at least one case of R° is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii). In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3.
[00418] [00418] In certain forms of formula (III-a), in which at least one case of R is a group of formula (iii), a compound of formula (III-f) is provided: E 1 O: o AND
[00419] [00419] —oralofthemselves. In certain embodiments, at least one R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv). In certain embodiments, each case of R is hydrogen. In certain embodiments, at least one case of R° is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii). In certain embodiments, p is
[00420] [00420] Compounds of formula (IV), (V), and (VI), while not constructed of amino acid starting materials, com-
[00421] [00421] “Thus, in yet another aspect, a compound of formula (IV), (V), or (VI) is provided: Ri E Re QSQ Da << RA + O is * is the dd RR ( IV) (V) (VI)
[00422] [00422] —or even the same; on what:
[00423] [00423] each case of Q is independently O, S, or NRº, where Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally aryl substituted, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), (ii);
[00424] [00424] "each case of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR*, - N(R)>, or -SR**. wherein each occurrence of R** is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a protecting group of oxygen when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, a nitrogen protecting group when bonded to a nitrogen atom, or two R** groups are joined to form a ring optionally substituted heterocyclic or optionally substituted heteroaryl;
[00425] [00425] “each case of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i) ), (ii), or (iii); and
[00426] [00426] "Formulas (i), (ii), and (ii) are: Rº R-qo Da L as E () (ii) (iii)
[00427] [00427] where:
[00428] [00428] each case of R' is independently hydrogen or optionally substituted alkyl;
[00429] [00429] XéoO, S, NR“, wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00430] [00430] YéoO,S,NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00431] [00431] R hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and
[00432] [00432] R| is optionally substituted C1-50alkyl, optionally substituted C1-59alkenyl, optionally substituted C1-55alkynyl, optionally substituted heteroC1-5soalkyl, optionally substituted heteroC1-5soalkenyl, optionally substituted heteroC1-5soalkynyl, or a polymer ;
[00433] [00433] as long as at least one case of Rº, R , Rô, or R is a group of formula (i), (ii), or (iii).
[00434] [00434] As generally defined above, each case of Q is independently O, S, or NRº, where Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, heterocyclyl optionally substituted, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii). In certain embodiments, at least one case of Q is O. In certain embodiments, each case of Q isoO. In certain embodiments, at least one case of Q is S. In certain embodiments, each case of Q is S. In certain embodiments, at least one case of Q is NR”. In certain embodiments, each case of Q is NR. In certain embodiments, each case of R is independently hydrogen or a group of formula (i), (ii), or (iii).
[00435] [00435] “As generally defined above, each case of R' is independently hydrogen or optionally substituted alkyl. In certain embodiments, at least one case of R' is hydrogen. In certain embodiments, at least two cases of R' are hydrogen. In certain embodiments, each case of R' is hydrogen. In certain embodiments, at least one instance of R' is optionally substituted alkyl, for example, methyl. In certain embodiments, at least two instances of R' are optionally substituted alkyl, for example, methyl. In certain embodiments, one case of R' is optionally substituted alkyl, and the rest is hydrogen.
[00436] [00436] “As generally defined above, each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR“º, -N(Rº), or -SR*.
[00437] [00437] In certain embodiments, at least one instance of R' is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally heteroaryl replaced.
[00438] [00438] In certain embodiments, at least one case of R' is optionally substituted alkyl; for example C1-; optionally substituted alkyl, Cx; optionally substituted alkyl, C3-; optionally substituted alkyl, C1-; optionally substituted alkyl, optionally substituted C1-5 alkyl, or optionally substituted C3- alkyl
[00439] [00439] In certain embodiments, at least one case of R' is optionally substituted alkenyl, for example, C7-; optionally substituted alkenyl, C3-; optionally substituted alkenyl, optionally substituted C1-6 alkenyl, C,4-; optionally substituted alkenyl, or C3-, optionally substituted alkenyl.
[00440] [00440] In certain embodiments, at least one case of R' is optionally substituted alkynyl, for example, C>-; optionally substituted alkynyl, C3-; optionally substituted alkynyl, optionally substituted C1-6 alkynyl, optionally substituted C4-5 alkynyl, or optionally substituted C3- alkynyl.
[00441] [00441] In certain embodiments, at least one case of R' is optionally substituted carbocyclyl, e.g. optionally substituted C3-195 carbocyclyl, optionally substituted Cs-g carbocyclyl, optionally substituted Cs-6 carbocyclyl, optionally substituted C5 carbocyclyl - mally substituted, or optionally substituted carbocyclyl Cs.
[00442] [00442] In certain embodiments, at least one instance of R' is optionally substituted heterocyclyl, e.g., optionally substituted 3- to 14-membered heterocyclyl, optionally substituted 3- to 10-membered heterocyclyl, optionally-substituted 5- to 8-membered heterocyclyl optionally substituted, optionally substituted 5- to 6-membered heterocyclyl, optionally substituted 5-membered heterocyclyl, or optionally substituted 6-membered heterocyclyl.
[00443] [00443] In certain embodiments, at least one instance of R' is optionally substituted aryl, for example, optionally substituted phenyl.
[00444] [00444] In certain embodiments, at least one instance of R' is optionally substituted heteroaryl, for example, optionally substituted 5 to 14 membered heteroaryl, optionally substituted 5 to 10 membered heteroaryl, optionally substituted 5 to 6 membered heteroaryl
[00445] [00445] In any of the above embodiments, the group R 1 alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl may be substituted, for example, with an optionally substituted amino group (e.g., -NRºR”), a group optionally substituted hydroxyl group (for example -OR$), an optionally substituted thiol group (for example -SR°), or with a group of formula (i), (ii), or (iii), in which case of R° and R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when bonded to an oxygen atom, and a sulfur protecting group when bonded to a sulfur atom, or a group of formula (i), (ii), or ( iii).
[00446] [00446] "For example, in certain embodiments, at least one instance of R' is an alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl group substituted by an amino group of the formula — N(RºNR”). In that case, in certain embodiments, at least one case of R' is a formula group: RF
[00447] [00447] L is an optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or optionally subs - titrated heteroarylene, or a combination thereof, and
[00448] [00448] R° and R' are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, and a nitrogen protecting group;
[00449] [00449] “as long as at least one case of R6 and R7 is a group of formula (i), (ii), or (iii): Rd Da x RO : PR RR or (i) (ii) (iii) )
[00450] [00450] whereR' ,X,Y,R!,andRº are as defined here.
[00451] [00451] In certain embodiments, both cases of R' are groups of formula (iv).
[00452] [00452] In certain embodiments, L is an optionally substituted alkylene; for example optionally substituted C1-25 alkylene, optionally substituted C1-105 alkylene, optionally substituted C1-20 alkylene, optionally substituted C1-25 alkylene, optionally substituted C1-25 alkylene, optionally substituted C1-20 alkylene, optionally substituted C6-x alkylene, optionally substituted C10-205 alkylene, optionally substituted C1-; alkylene, optionally substituted C7-6 alkylene, optionally substituted C1-6 alkylene, optionally substituted C1-5 alkylene, optionally substituted C1-5 alkylene, or optionally substituted C3- alkylene.
[00453] [00453] In certain embodiments, L is an optionally substituted alkenylene, e.g. optionally substituted C2-55 alkenylene, optionally substituted C2-49 alkenylene, optionally substituted
[00454] [00454] In certain embodiments, L is an optionally substituted alkynylene, e.g. optionally substituted Ca-soalkynylene, optionally substituted C7-,oalkynylene, optionally substituted Ca-3oalkynylene, optionally substituted Ca-2palkynylene, optionally substituted Ca-2oalkynylene, optionally substituted C6-20alkynylene, optionally substituted C6-25alkynylene, optionally substituted Cao-xoalkynylene, optionally substituted C7-salkynylene, optionally substituted C3-salkynylene, optionally substituted Ca-salkynylene, optionally substituted C1-salkynylene, or optionally substituted C3-, alkynylene.
[00455] [00455] In certain embodiments, L is an optionally substituted heteroalkylene; for example optionally substituted heteroC1-50alkylene, optionally substituted heteroC1-40alkylene, optionally substituted heteroC1-30alkylene, optionally substituted heteroC1-20alkylene, optionally substituted heteroC4-20alkylene, optionally substituted heteroCs-2xoalkylene, optionally substituted heteroCs-20alkylene substituted, optionally substituted heteroC 19-25 alkylene, optionally substituted heteroC 1 -alkylene, optionally substituted heteroC 1 -alkylene, optionally substituted heteroC 3 -alkylene, optionally substituted heteroC 1 -alkylene, optionally substituted heteroC 1 -alkylene substituted, or optionally substituted heteroC3;-to-4alkylene.
[00456] [00456] In certain embodiments, L is an optional heteroalkenylene
[00457] [00457] In certain embodiments, L is an optionally substituted heteroalkynylene, e.g. optionally substituted heteroC1-5soalkynylene, optionally substituted heteroC7-,oalkynylene, optionally substituted heteroC1-35alkynylene, optionally substituted heteroC1-2 ,alkynylene, optionally substituted heteroC1-20alkynylene, optionally substituted heteroC6-205alkynylene, optionally substituted heteroC1-25alkynylene, optionally substituted heteroC1-20alkynylene, optionally substituted heteroC1-20-salkynylene, optionally substituted heteroC1-20-salkynylene, optionally substituted heteroC,-salkynylene, optionally substituted heteroC,-salkynylene, or optionally substituted heteroC3-a4alkynylene.
[00458] [00458] In certain embodiments, L is an optionally substituted carbocyclylene, for example optionally substituted C3-19 carbocyclylene, optionally substituted Cs-g carbocyclylene, optionally substituted Cs-1 carbocyclylene, optionally substituted Cs carbocyclylene, or optionally substituted Cs carbocyclylene.
[00459] [00459] In certain embodiments, L is an optionally substituted heterocyclylene, for example, optionally substituted 3 to 14 membered heterocyclylene, optionally substituted 3 to 10 membered heterocyclylene, optionally substituted 5 to 8 membered heterocyclylene, optionally substituted 5 to 6 membered, optionally substituted 5 membered heterocyclylene, or optionally substituted 6 membered heterocyclylene.
[00460] [00460] In certain embodiments, L is an optionally substituted arylene, for example, optionally substituted phenylene.
[00461] [00461] In certain embodiments, L is an optionally substituted heteroarylene, for example, optionally substituted 5 to 14 membered heteroarylene, optionally substituted 5 to 10 membered heteroarylene, optionally substituted 5 to 6 membered heteroarylene, optionally substituted 5-membered, or optionally substituted 6-membered heteroarylene.
[00462] [00462] For example, in certain embodiments, where L is an optionally substituted alkylene group, the group of formula (iv) is a group of the formula: no.
[00463] [00463] where q is an integer between 1 and 50, inclusive.
[00464] [00464] In certain embodiments, q is an integer between 1 and 40, inclusive. In certain embodiments, q is an integer between 1 and 30, inclusive. In certain embodiments, q is an integer between 1 and 20, inclusive. In certain embodiments, q is an integer between 4 and 20, inclusive. In certain embodiments, q is an integer between 6 and 20, inclusive. In certain embodiments, q is an integer between 8 and 20, inclusive. In certain embodiments, q is 1. In certain embodiments, q is
[00465] [00465] In certain embodiments, both Rº and R' are hydrogen. In certain embodiments, R° is hydrogen and R' is a group of formula (i), (ii), or (iii). In certain embodiments, Rº is hydrogen and R' is a group of formula (i).. In certain embodiments, Rº is hydrogen and R is a group of formula (ii)).. In certain embodiments, Rº is hydrogen and R' is a group of formula (iii). In certain embodiments, both R' and R' are independently a group of formula (i), (ii), or (ili)). In certain embodiments, both Rº and R' are independently a group of the formula (). In certain embodiments, both R° and R are independently a group of formula (ii). In certain embodiments, both Rº and R' are independently a group of formula (iii)) In certain embodiments, both Rº and R' are the same group, selected from a group of formula (i), (ii), or (iii).
[00466] [00466] It is understood that R' encompasses amino acid side chains, as exemplified in Table 1 of the examples. In certain embodiments, R' is a group selected from any of the amino acid side chain groups listed here.
[00467] [00467] In certain embodiments, each case of R' is the same. In certain embodiments, at least one R' group is different. In certain modalities, each R1 group is different.
[00468] [00468] “As generally defined above, each case of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii):
[00469] [00469] whereR' ,X,Y,R!,andRº are as defined here.
[00470] [00470] In certain embodiments, at least one case of R is optionally substituted alkyl; for example C1-; optionally substituted alkyl, C>-; optionally substituted alkyl, optionally substituted C3-s alkyl, optionally substituted C,4-s alkyl, optionally substituted C3- alkyl, or optionally substituted C3- alkyl.
[00471] [00471] In certain embodiments, at least one case of R° is optionally substituted alkenyl, for example, C>2-5 optionally substituted alkenyl, C3z-; optionally substituted alkenyl, optionally substituted C1-6 alkenyl, optionally substituted C1-s alkenyl, or optionally substituted C3-alkenyl.
[00472] [00472] In certain embodiments, at least one case of R is optionally substituted alkynyl, for example C₁-; optionally substituted alkynyl, C3-; optionally substituted alkynyl, optionally substituted C1-6 alkynyl, optionally substituted C,a-5 alkynyl, or optionally substituted C3- alkynyl.
[00473] [00473] In certain embodiments, at least one case of R is optionally substituted carbocyclyl, for example, optionally substituted C3-19 carbocyclyl, optionally substituted Cs-6 carbocyclyl, optionally substituted Cs-6 carbocyclyl, optionally substituted C5 carbocyclyl, or optionally substituted C6 carbocyclyl.
[00474] [00474] In certain embodiments, at least one case of R is optionally substituted heterocyclyl, e.g. optionally substituted 3 to 14 membered heterocyclyl, optionally substituted 3 to 10 membered heterocyclyl, optionally substituted 5 to 8 membered heterocyclyl, optionally substituted 5 to 6 membered heterocyclyl
[00475] [00475] In certain embodiments, at least one case of R is optionally substituted aryl, for example optionally substituted phenyl.
[00476] [00476] In certain embodiments, at least one case of R is optionally substituted heteroaryl, for example, optionally substituted 5 to 14 membered heteroaryl, optionally substituted 5 to 10 membered heteroaryl, optionally substituted 5 to 6 membered heteroaryl, optionally substituted 5 membered heteroaryl, or 6 membered heteroaryl optionally substituted members.
[00477] [00477] In certain embodiments, at least one case of R is a nitrogen protecting group.
[00478] [00478] In certain embodiments, at least one case of R is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii).
[00479] [00479] In certain embodiments, each case of Rº is a different group of formula (i), (ii), or (ili); in that case, it follows that at least one R° is a group of formula (i), (ii), or (iii), or at least one R' is a group of formula (iv), and at least one of R° or R ' covered by R' is a group of the formula (i), (ii), or (ili).Y. For example, in certain embodiments, both cases of R are hydrogen, and thus at least one R° is a group of formula (i), (ii), or (iii), or at least one R' is a group of formula (iv), and at least one of R° or R' encompassed by R' is a group of formula (i), (ii), or (iii).
[00480] [00480] Various combinations of the above embodiments of formula (IV), (V), and (VI) are contemplated herein. For example, in certain embodiments, where each case of Q is O, the compound of formula (IV), (V), or (Vl) is a compound of formula (IV-a), (Va), or (Vl-a):
[00481] [00481] or even. In certain embodiments, at least one case of R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv). In certain embodiments, at least one case of R is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl. In certain embodiments, at least one case of R is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii).
[00482] [00482] In certain embodiments of formula (IV-a), (Va), or (Vl-a), wherein at least one R' is a group the formula (iv), a compound of formula (IV- b), (Vb), or (VI-b): R$ Ro o S, 7 We > w.
[00483] [00483] or even balance. In certain embodiments, at least one case of R is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl. In certain modalities, at least one case of R is a group of formula (i). In certain embodiments, at least one case of R is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (ili). In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain modalities, Rº is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). In certain embodiments, both R° and R' are independently groups of formula (i), (ii), or (iii).
[00484] [00484] In certain embodiments of formula (IV-b), (Vb), or (VI-b), where both R* groups are a group the formula (iv), a compound of formula (IV-c) is provided ), (Vc), or (Vl-c): Reg R Ro ss << Moo E (IV-c) (Vc) (Vl-c)
[00485] [00485] or even balance. In certain embodiments, at least one case of R is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl. In certain modalities, at least one case of R is a group of formula (i). In certain embodiments, at least one case of R° is a group of formula (ii). In certain embodiments, at least one case of R is a group of formula (iii)).) In certain embodiments, L is an optionally substituted alkylene. In certain embodiments, R° is a group of formula (i).K. In certain embodiments, R° is a group of formula (ii). In certain modalities, Rº is a group of formula (iii). In certain embodiments, R' is a group of formula (i). In certain embodiments, R' is a group of formula (ii). In certain embodiments, R' is a group of formula (iii). In certain embodiments, both R° and R” are independently groups of formula (i), (ii), or (iii).
[00486] [00486] In certain embodiments of formulas (IV-a), (V-a), and (Vl-a), in which at least one case of R is a group of formula (i) and each case of R' is hydrogen, provided it is a compound of formulas (IV-d), (V-d), and (VI-d):
[00487] [00487] or even balance. In certain embodiments, at least one case of R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv). In certain embodiments, R6 is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl. In certain embodiments, R is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R is a group of formula (iii).
[00488] [00488] In certain forms of formulas (IV-a), (V-a), and (Vl-a), in which both instances of R is a group of formula (i) and each case of R' is hydrogen, provided that it is a compound of formulas (IV-e), (V-e), and (Vl-e): Rx & E 5 as Da x Ao . S / RO) Y x) y SAX R- R Õ RR (IV-e) (V-e) (Vl-e)
[00489] [00489] —oralofthemselves. In certain embodiments, at least one case of R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv).
[00490] [00490] In certain embodiments of formulas (IV-a), (V-a), and (Vl-a), in which at least one case of R is a group of formula (ii) and each case of R' is hydrogen, provided it is a compound of formulas (IV-f), (V-f), and (VI-f):
[00491] [00491] or even balance. In certain embodiments, at least one case of R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv). In certain embodiments, R is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl. In certain embodiments, R is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R is a group of formula (iii).
[00492] [00492] In certain embodiments of formulas (IV-a), (V-a), and (Vl-a), in which both the cases of R are a group of formula (ii) when each case of R' is hydrogen, provided it is a compound of formulas (IV-g), (Vg), and (VI-g): Rº ooo Rx: RX R js SD P À o The " + RX o
[00493] [00493] or even. In certain embodiments, at least one case of R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv).
[00494] [00494] In certain embodiments of formulas (IV-a), (V-a), and (Vl-a), in which at least one case of R is a group of formula (iii), provided it is a compound of formulas (IV-h), (V-h), and (VI-h):
[00495] [00495] or balance. In certain embodiments, at least one case of R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv). In certain embodiments, R6 is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl. In certain embodiments, R is a group of formula (i). In certain embodiments, R° is a group of formula (ii). In certain embodiments, R is a group of formula (iii).
[00496] [00496] In certain embodiments of formulas (IV-a), (V-a), and (Vl-a), in which both cases of R are a group of formula (iii), provided it is a compound of formulas (IV-e), (Ve), and (Vl-e): so a, (7 RZ/ Rº o Ó RR (IV-i) ( Vi) (VI-i)
[00497] [00497] or even. In certain embodiments, at least one case of R' is a group of formula (iv). In certain embodiments, each case of R' is a group of formula (iv). Formula groups (1), (ii), and (iii)
[00498] [00498] “As understood from the aforementioned discussion, APPLs, and in particular, APPL compounds of formulas (1), (III), (IV), (V), and (VI), each include at least one case of a group of formula (i), (ii), or (iii):
[00499] [00499] each case of R' is independently hydrogen or optionally substituted alkyl;
[00500] [00500] XéoO,S, NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , or a nitrogen protecting group;
[00501] [00501] YéoO,S, NR", wherein R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
[00502] [00502] —R”º is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a protecting group of oxygen when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and
[00503] [00503] R optionally substituted C1-59 alkyl, optionally substituted C2-55 alkenyl, optionally substituted C1-55 alkynyl, optionally substituted heteroC1-50 alkyl, optionally substituted heteroC1-5,5 alkenyl, optionally substituted heteroC1-5 55 alkyne-
[00504] [00504] — In the case of formula (II), the at least one case of the group of formula (i) is incorporated as part of the scaffold, for example, by monoaddition of a compound (i-x), followed by internal cyclization. See, for example, Scheme 2.
[00505] [00505] In certain embodiments, an APPL, and in particular a compound of formulas (1), (11), (III), (IV), (V), or (VI), comprises at least one instance of a group of formula (i) attached to them: R HUH ().
[00506] [00506] In certain embodiments of formula (i), Y is O. In certain embodiments of formula (i), Y is S. In certain embodiments of formula (i), Y is NR", where R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group. In certain embodiments of formula (i), Y is NR”, where R* is hydrogen, optionally substituted alkyl, or a nitrogen protecting group. In certain embodiments of formula (i), each case of R' is hydrogen.
[00507] [00507] As used herein, when the group R" is represented as severing a carbon-carbon bond, for example, from the group of formula (i), it is understood that R1 may be substituted on any carbon. Nucleophilic attack of an amino or amide group at least on the sterically hindered carbon of the epoxide, thiirane, or aziridine of formula (ix) provides a group of formula (i-a1), (i-a2), or (i-a3) (routine a ), whereas nucleophilic attack at the most sterically hindered carbon of the epoxide, thiirane, or aziridine of formula (ix) provides a group of formula (i-b1), (i-b2), or (i-b3) (routine b ), wherein Rº is hydrogen (Scheme 6). It is understood that compounds of the present invention may comprise a mixture of products bound thereto arising from routine (a) and routine (b) depending on preference, or absence thereof, of the addition mode. The sectioning group R" represented in the formulas seeks to cover all contemplated modes of addition.
[00508] [00508] The resulting hydroxyl, thiol, or amino group -YRº , where Rº is hydrogen, can optionally be converted to a substituted group, where Rº is a group other than hydrogen, that is, where Rº is independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom , a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; using conventional methods. Alkylation, acylation, and/or protection of a hydroxyl, thiol, or amino moiety are methods well known in the art; see, for example, Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3a. edition, John Wiley & Sons, 1999; Smith and March, March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformation
[00509] [00509] In certain embodiments of formula (i), Rº is hydrogen. In certain embodiments of formula (i), R° is optionally substituted alkyl. In certain embodiments of formula (i), R° is optionally substituted for alkenyl. In certain embodiments of formula (i), R° is optionally substituted alkynyl. In certain embodiments of formula (i), R6 is optionally substituted by carbocyclyl. In certain embodiments of formula (i), R6 is optionally substituted heterocyclyl. In certain embodiments of formula (i), R6 is optionally substituted aryl. In certain embodiments of formula (i), R6 is optionally substituted heteroaryl. In certain embodiments of formula (i), R° is an oxygen protecting group when bonded to an oxygen atom. In certain embodiments of formula (i), Rº is a sulfur protecting group when attached to a sulfur atom. In certain embodiments of formula (i), R° is a nitrogen protecting group when bonded to a nitrogen atom.
[00510] [00510] It is understood from the present description that the group of formula (i) represents a group of formula (i-a) or a group of formula (i-b):
[00511] [00511] In certain embodiments, the reaction mixture provides a mixture of APPLs comprising more APPLs conjugated to a group of formula (ia) than formula (ib), for example, the reaction mixture comprises more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, more than 95%, more than 99%, between about 60% to about 100%, between about 70% to about 100%, between about 80% to about 100%, between about 90% to about 100%, between about 95% to about 100%, or between about 99% to about 100%, of an APPL linked to formula (ia).
[00512] [00512] In certain embodiments, the epoxide, thiirane, or aziridine of formula (i-x) is chiral, i.e., having (R) or (S) stereochemistry. Chiral epoxides, tyrannes, and aziridines can be obtained from a variety of sources that are familiar to those skilled in the art of organic synthesis. In some embodiments, the chiral epoxide, thiirane, or aziridine is obtained commercially. In some embodiments, the chiral epoxide, thiirane, or aziridine is synthesized according to methods known to those skilled in the art, such as, but not limited to, the Sharpless Epoxidation of primary and secondary allylic alcohols to 2,3-epoxyalcohols (see , for example, Katsuki et al., J. Am. Chem. Soc. 1980, 102, 5974; Hill et al., Org. Syn., Coll. Vol. 7, p.461 (1990); Vol. 63, p. 66 (1985); Katsuki et al., Org. React. 1996, 48, 1-300). In some embodiments, the chiral epoxide, thiirane, or aziridine is obtained by resolving a mixture (eg, racemic mixture) of epoxides, thiranes, or aziridines. In some embodiments, the chiral epoxide, thiirane, or aziridine is obtained by separating enantiomers or diastereoisomers using chiral chromatography. Chirality can be characterized in a variety of ways, for example, obtaining a crystal structure of the compound containing a heavy atom attached to them, obtaining optical rotation of the compound, and/or NMR analysis after chemical modification of the compound optically. active, with a chiral derivatization agent are some useful methods in assessing chirality.
[00513] [00513] In certain embodiments, where the epoxide, thiirane, or aziridine of formula (i-x1) is chiral, the conjugation reaction is regioselective, and the reaction yields a chiral mixture of APPLSs comprising more conjugated APPLs to a group of formula (i-a1) than formula (i-b1), for example, the reaction mixture comprises more than 50%, more than 60%, more than 70%, more than 80% , more than 90%, more than 95%, more than 99%, between about 60% to about 100%, between about 70% to about 100%, between about 80% to about 100 %, from about 90% to about 100%, from about 95% to about 100%, or from about 99% to about 100%, of an APPL linked to formula (i-a1).
[00514] [00514] In other embodiments, where the epoxide, thiirane, or aziridine of formula (i-x2) is chiral, the conjugation reaction is regioselective, and the reaction yields a chiral mixture of APPLs comprising more conjugated APPLs to a group of formula (i-a2) than formula (i-b2), for example, the reaction mixture comprises more than 50%, more than 60%, more than 70%, more than 80% , more than 90%, more than 95%, more than 99%, between about 60% to about 100%, between about 70% to about 100%, between about 80% to about 100 %, from about 90% to about 100%, from about 95% to about 100%, or from about 99% to about 100%, of an APPL bound to formula (i-a2).
[00515] [00515] In certain embodiments, an APPL, and in particular a compound of formulas (1), (II), (III), (IV), (V), or (VI), comprises at least one instance of a group of formula (ii) attached thereto: RY R| R(ii).
[00516] [00516] In certain embodiments of formula (ii), X is O. In certain embodiments of formula (ii), X is S. In certain embodiments of formula (ii), X is NR, where R* is hydrogen, optionally alkyl substituted, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group. In certain embodiments of formula (ii), X is NR*, where R* is hydrogen, optionally substituted alkyl, or a nitrogen protecting group. In certain embodiments of formula (i), each case of R' is hydrogen.
[00517] [00517] In certain embodiments, an APPL, and in particular a compound of formulas (1), (11), (III), (IV), (V), or (VI), comprises at least one instance of a group of formula (ii) attached to them:
[00518] [00518] “As generally defined above, R| is optionally substituted C1-59 alkyl, optionally substituted C1-595 alkenyl, optionally substituted C1-50 alkynyl, optionally substituted C1-55 heteroalkyl, optionally substituted C2-509 heteroalkenyl, optionally substituted C2-5,9 heteroalkynyl , or a polymer. The Rº group seeks to encompass lipophilic, hydrophobic, and/or non-polar groups, but such terms should not limit the scope of R".
[00519] [00519] In certain embodiments, at least one case of R| is
[00520] [00520] In certain embodiments, at least one case of R| is an unsubstituted alkyl. Exemplary unsubstituted alkyl groups include, but are not limited to, -CH3, -CaHs, -CaH7, -CaHa, -C5H11, -CeH13, -C7H15, -CaH17, -CoH19, -CioHat, -C11H23, -C1iaH25 , -C13H27, -CiaHao, “Ci5H31, “CieH33, “C17H35, “Ci8H37, -Ci9H3o9, “CaoHa, -Ca1Ha3, 7 Ca2Has, “CaaHar, “CaaH49, and “CasHs1.
[00521] [00521] In certain embodiments, at least one case of R| is a substituted alkyl. For example, in certain embodiments, at least one case of R! is an alkyl substituted with one or more fluorine substituents. Exemplary fluorinated alkyl groups include, but are not limited to: NS RFFRFREF - FE RF NV FFFF A O Ê E PC RF RFERFRARARS
[00522] [00522] In certain embodiments, at least one case of R| is an optionally substituted C>α-50 alkenyl. In certain embodiments, R- is an optionally substituted Cc-595 alkenyl. In certain embodiments, R° is an optionally substituted Cg-40 alkenyl. In certain embodiments, R6 is an optionally substituted C6-30 alkenyl. In certain embodiments, R° is an optionally substituted Cc-25 alkenyl. In certain embodiments, R" is an optionally substituted Cg-25 alkenyl. In certain embodiments, R° is an optionally substituted C; alkenyl. In certain embodiments, R°* is an optionally substituted C, alkenyl. In certain embodiments, R1 is an optionally substituted C1, alkenyl. In certain embodiments, R1 is an optionally substituted C1, alkenyl. In certain embodiments, R1 is an optionally substituted C,2 alkenyl. In certain embodiments, R1 is a C,2 alkenyl. ;3 optionally substituted alkenyl. In certain embodiments, R1 is an optionally substituted C1, alkenyl. In certain embodiments, R1 is an optionally substituted Cisalkenyl. In certain embodiments, R1 is an optionally substituted C,6 alkenyl. In certain embodiments, R| is a C1; optionally substituted alkenyl. In certain embodiments, R" is an optionally substituted C1;6 alkenyl. In certain embodiments, R1 is an optionally substituted C1;6 alkenyl. In certain embodiments, R1 is an optionally substituted C>2 alkenyl. In either of the above embodiments, the R1 group is an unsubstituted alkenyl group.
[00523] [00523] Exemplary unsubstituted alkenyl groups include, but are not limited to: Ea Rs OO A, DDD Fs— OC
[00524] [00524] In modalities, where R| is defined as a C6-50 alkyl or C6-59 alkenyl groups, such groups are understood to encompass lipophilic groups (also referred to as a "lipid tail"). Lipophilic groups comprise a group of molecules that include fats, waxes, oils, fatty acids, and the like. Pre-
[00525] [00525] In certain embodiments, Rº is an optionally substituted Co-59 alkynyl. In certain embodiments, R6 is an optionally substituted C6-50 alkynyl. In certain embodiments, R6* is an optionally substituted C6-40 alkynyl. In certain embodiments, R6* is an optionally substituted C6-30 alkynyl. In certain embodiments, R- is an optionally substituted Cs-2alkynyl. In certain modalities, R| is an optionally substituted Cg-25 alkynyl. In certain embodiments, R" is an optionally substituted C; alkynyl. In certain embodiments, Rº* is an optionally substituted C,1 alkynyl. In certain embodiments, Rº is an optionally substituted C1, alkynyl. In certain embodiments, Rº is an optionally substituted C,1 alkynyl. In certain embodiments, R|" is an optionally substituted C12 alkynyl. In certain embodiments, R° is an optionally substituted C13 alkynyl. In certain embodiments, R| is an optionally substituted Ca4alkynyl. In certain embodiments, R| is an optionally substituted C15 alkynyl. In certain embodiments, R!| is an optionally substituted C16 alkynyl. In certain embodiments, R| is an optionally substituted C1 alkynyl. In certain embodiments, Ré uma Cai; optionally substituted alkynyl. In certain embodiments, R| is an optionally substituted C19 alkynyl. In certain embodiments, R1" is an optionally substituted Ca, alkynyl. In any of the above embodiments, the group Rh is an unsubstituted alkynyl group.
[00526] [00526] In certain embodiments, at least one case of R| is an optionally substituted heteroC1-595 alkyl. In certain embodiments, R!| is an optionally substituted heteroC 6 -50 alkyl. In certain embodiments, R! is an optionally substituted heteroC 6 -40 alkyl. In certain embodiments, R6 is an optionally substituted hetero-C 5 -35 alkyl. In certain embodiments, R6 is an optionally substituted heteroC6-20alkyl. In certain embodiments, R6 is an optionally substituted heteroC,o-20alkyl. In certain embodiments, R!| is an optionally substituted heteroalkyl. In certain embodiments, R| is an optionally substituted heteroalkyl. In certain modalities, R| is an optionally substituted heteroC 1 alkyl. In certain modalities, R!| is an optionally substituted heteroC 1 alkyl. In certain embodiments, R" is an optionally substituted heteroC 2 alkyl. In certain embodiments, R º is an optionally substituted heteroC 3 alkyl. In certain embodiments, R º is an optionally substituted heteroC 1 alkyl. In certain embodiments, Rh is an optionally substituted heteroC₁₋alkyl. In certain embodiments, R₂ is an optionally substituted heteroC₄alkyl. In certain embodiments, R* is an optionally substituted heteroC₁₋alkyl. optionally replaced. In certain embodiments, R| is an optionally substituted heteroC 1 alkyl. In certain embodiments, R6 is an optionally substituted heteroC2 alkyl. In any of the above modalities, the group R| is an unsubstituted heteroalkyl group.
[00527] [00527] Exemplary unsubstituted heteroalkyl groups include, but are not limited to,
[00528] [00528] In certain embodiments, at least one case of R| is an optionally substituted heteroC₁-soalkenyl. In certain modalities, R| is an optionally substituted heteroC 6 -soalkenyl. In certain embodiments, R6 is an optionally substituted hetero-C5s-409alkenyl. In certain embodiments, R6 is an optionally substituted heteroC6-3.alkenyl. In certain embodiments, R6 is an optionally substituted heteroC6s-2,alkenyl. In certain embodiments, R- is an optionally substituted heteroC6-2xalkenyl. In certain modes, R| is an optionally substituted heteroCgalkenyl. In certain embodiments, R° is an optionally substituted heteroCsalkenyl. In certain embodiments, R| is an optionally substituted heteroC,oalkenyl. In certain embodiments, R!| is an optionally substituted heteroC1,alkenyl. In certain embodiments, Rh is an optionally substituted heteroC1,alkenyl. In certain modalities, R| is an optionally substituted heteroC 1 3 alkenyl. In certain embodiments, R6 is an optionally substituted heteroC1,alkenyl. In certain embodiments, R° is an optionally substituted heteroC,salkenyl. In certain embodiments, R* is an optionally substituted heteroC,salkenyl. In certain embodiments, R₂ is an optionally substituted heteroC₄ alkenyl. In certain embodiments, R₂ is an optionally substituted heteroC,galkenyl. is an optionally substituted heteroCa,alkenyl In any of the above embodiments, the group Rh is an unsubstituted heteroalkenyl group.
[00529] [00529] In certain embodiments, Rº is an optionally substituted heteroC>-soalkynyl. In certain embodiments, R6 is an optionally substituted heteroC6 -soalkynyl. In certain embodiments, R6 is an optionally substituted hetero-C6s-20alkynyl. In certain modalities, R| is an optionally substituted heteroC 6 -zoalkynyl. In certain embodiments, R6 is an optionally substituted heteroC;s-2oalkynyl. In certain embodiments, R| is an optionally substituted heteroC s -xalkynyl. In certain embodiments, R° is an optionally substituted heteroCsalkynyl. In certain embodiments, R1" is an optionally substituted heteroC,alkynyl. In certain embodiments, R1 is an optionally substituted heteroC,oalkynyl. In certain embodiments, R* is an optionally substituted heteroC,alkynyl. substituted heteroC, palkynyl. In certain embodiments, R1 is an optionally substituted heteroC,z3 alkynyl. In certain embodiments, R1 is an optionally substituted heteroC1,alkynyl. In certain embodiments, R6 is an optionally substituted heteroC,2,alkynyl. salkynyl In certain embodiments, R1 is an optionally substituted heteroC,7alkynyl. In certain embodiments, R6 is an optionally substituted heteroC,7alkynyl. In certain embodiments, R1 is an optionally substituted heteroC,7alkynyl. In certain embodiments, R1 is an optionally substituted heteroC1 -alkynyl In certain embodiments, R6 is an optionally substituted heteroCa,alkynyl In any of the above embodiments, the group R1 is is an unsubstituted heteroalkynyl group.
[00530] [00530] In certain embodiments, at least one case of R| it's a polymer. As used herein, a "polymer" refers to a compound comprised of at least 3 (e.g., at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, etc.) structural units covalently linked repeats. The polymer is in certain embodiments biocompatible (ie, non-toxic). Exemplary polymers include, but are not limited to, cellulose polymers (e.g., hydroxyethyl cellulose, ethyl cellulose, carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose (HPMC)), dextran polymers, polymaleic acid polymers, poly( acrylic), poly(vinylalcohol) polymers, polyvinylpyrrolidone (PVP) polymers, and polyethylene glycol (PEG) polymers, and combinations thereof. Additional Preparation Methods
[00531] [00531] As described herein, in order to provide compounds of the present invention, an APPL precursor is treated with one or more conjugation reagents, for example selected from an epoxide, thirian, or aziridine of formula (ix), an o,B-unsaturated ester, thioester, or amide of formula (ii-x), or an aldehyde of formula (ili-x), to provide the APPL. AX, ROUND of (ix) (ii-x) (iii-x)
[00532] [00532] For example, in one aspect, there is provided a method of preparing a functionalized APPL with a group of formula (i) comprising heating the precursor in an organic solvent (e.g., EtOH) with one or more reactants. of formula (ix) conjugation to provide the desired APPL. In certain embodiments, the mixture is heated to between about 100 to about 200%, including, for example, about 150%.
[00533] [00533] In another aspect, there is provided a method of preparing an APPL functionalized with a group of formula (ii) comprising heating the precursor in an organic solvent (e.g. EtoOH) with one or more conjugating reagents of formula (ii- x) to provide the desired APPL. In certain embodiments, the mixture is heated to between about 50 to about 100°, inclusive, for example, about 90%.
[00534] [00534] In another aspect, there is provided a method of preparing an APPL functionalized with a group of formula (iii) comprising mixing the precursor in an organic solvent (e.g. THF) with one or more conjugating reagents of formula (iii- x) and a reducing agent (e.g. NaBH(OAc)3) to provide the desired APPL. In certain embodiments, the temperature of the reaction mixture is room temperature mixture.
[00535] [00535] In certain embodiments, where only one conjugation reagent is used, each case of R" is equal in APPL. For example, in certain embodiments, each case of R* is equal where R!| is an al- optionally substituted alkyl. In certain embodiments, each case of Rº is equal in which R| is an unsubstituted alkyl. In certain embodiments, each case of R1 is equal in which R* is selected from the group consisting of -CH3 , -CaHs, -CaH7, -CaHo, -CsH11, -CoH13, -C7H15, -CaH17, -CoHi19, -CioH2a1, -C11H23, -Ci2aHas, -C13H27, -CriaHao, -CisHa1, -C16H33, -C17H35, - Ci8H37, -CioH39, E -CooH41. In certain embodiments, each case of R! is equal where R| is an n-alkyl group selected from -CaH17, -CoH1o, “CioH2a1, “C11H>3, “C12H>25 , -C13H27, "CyaH>9, -C15H31, and -C16H33.
[00536] [00536] —Alternatively, in certain embodiments, where more than one conjugation reagent is used in the conjugation reaction (e.g., two, three, four, five, six, seven, eight, nine, or ten different agents conjugation), the APPL may comprise two or more (e.g., two, three, four, five, six, seven, eight, nine, or ten) different groups of formula (i), (ii), and/or ( ili) attached to it.
[00537] [00537] For example, in certain embodiments, two different epoxides are used in the conjugation reaction. In this case, in certain embodiments, the APPL comprises two different Rj groups. by e-
[00538] [00538] As would be appreciated by one skilled in the art, the degree of conjugation can be controlled by a reaction condition (eg, temperature, starting materials, concentration, solvent, etc.) used in the synthesis. The synthesized APPL can be purified by any technique known in the art including, but not limited to, precipitation, crystallization, chromatography, distillation, etc.
[00539] [00539] In certain embodiments, APPL is isolated as a salt. For example, in certain embodiments, APPL is reacted with an acid (e.g., an organic acid or an inorganic acid) to form the corresponding salt. In other embodiments, tertiary amines are alkylated to form a quaternary ammonium salt of APPL. Tertiary amines can be alkylated with any alkylating agent, for example, alkyl halides such as methyl iodide can be used to form the quaternary amino groups. The anion associated with the quaternary amine can be any organic or inorganic anion. In certain embodiments, the anion is a pharmaceutically acceptable anion.
[00540] [00540] The invention also provides libraries of APPLs prepared by the inventive methods. For example, in certain embodiments, a method of evaluating a compound library is provided, the method comprising providing a plurality of different APPLs, or salts thereof; and performing at least one assay with the compound library to determine the presence or absence of a desired property. These APPLs can be prepared and/or evaluated using high-throughput techniques involving liquid handlers, robots, microtiter plates, computers, etc. In certain embodiments, APPLs are evaluated for their ability to transfect polynucleotides or other agents (eg, proteins, peptides, small molecules) into the cell. For example, in one embodiment, a method of evaluating a compound library is provided, the method comprising providing a plurality of two or more different APPLs and evaluating the compound library for a desired property.
[00541] [00541] In one embodiment, a library of different APPLs is prepared in parallel. A different precursor and/or conjugation reagent is added to each vial in a group of vials Or to each well of a multi-well plate used to prepare the library. The array of reaction mixtures is incubated at a temperature and time period sufficient to allow the formation of the APPL. APPL can then be isolated and purified using techniques known in the art. The APPL can then be evaluated using high throughput techniques to identify APPLs with a desired property, e.g. where the desired property is water solubility, solubility at different pH, ability to bind a polynucleotide, ability to bind binding to heparin, ability to bind small molecules, ability to bind protein, ability to form microparticles, ability to increase transfection efficiency, ability to support cell growth, ability to support cell attachment, ability to support tissue growth, and/or intracellular release of APPL and/or an agent complexed or linked thereto to aid in bioprocessing, for example, for the purpose of manufacturing proteins. In certain embodiments, APPLs may be evaluated for properties or useful characteristics as coatings, additives, materials, and excipients in biotechnology and biomedical applications, such as coating medical devices or implants with multilayer films or films as agents. not bioincrust-
[00542] [00542] Certain compounds of the present invention are specifically contemplated herein. For example, compounds comprising unsubstituted n-alkyl R* groups containing 8, 9, 10, 11, 12, 13, and 14 carbon atoms are specifically contemplated. In certain embodiments R'* of such compounds is an amino acid side chain as defined in Table 1 of the examples.
[00543] [00543] “Exemplary amino acid, peptide, and polypeptide compounds of formula (1) include, but are not limited to: REAL RELA EL AL, dd dE, Rº o 1 1
[00544] [00544] and the same ones.
[00545] [00545] — Exemplary cyclized compounds of formula (II) include, but are not limited to: o o o R1 1 ss à Ao Na RO CaHiz est ; 1oHos is ; o o 8 Rt j Ri Rº o NS " 7 NA
[00546] [00546] and the same ones.
[00547] [00547] Exemplary cyclic dipeptide and cyclic polypeptide compounds of formula (Ill) include, but are not limited to: HO Cat Ho o routes ; CH; HO CraHos; " NANDA Wo " AR AE º VA Oo: à Oo: Oo: o: o: o né [e ,. R"e,,RÉ Ne,R"e,,RAe,aq; R, AO] emrol moh, enol io Nao Hs Rº 2 p Rl* |, Rlw |, Fm... " le |, 2 sk 3 SO | o H Pp el nt ica q sil | 3 | ; le | ; 3 | ; KR lx | ; tl ç e sr Short ; cm [xo: oo: o: le), ; Ri le), ; Re |, ; RIR Sd, Ae est Ç | 3 | o | “3 o: Oo :o: od Ní h Rd Re ,, RR ,, R | ”, RR ”, nie, and CR
[00548] [00548] and, in particular, cyclic KK and polycyclic lysine APPLs of the formula:
[00549] [00549] and the same ones. compositions
[00550] [00550] The present invention contemplates an APPL as a component of a composition. For example, in certain embodiments, a composition is provided which comprises an APPL, or salt thereof, and an excipient, wherein the APPL is an amino acid, a linear or cyclic peptide, or a linear or cyclic polypeptide, or isomer. structure thereof, and wherein an amino or amide group of the APPL is conjugated to a group of formula (i), (ii), or (ili)). In certain embodiments, the group of formula (i), (ii), or (iii) is attached to an amino group present on the APPL scaffold.
[00551] [00551] Compositions, as described herein, comprising an APPL and an excipient of some kind may be useful in a variety of medical and non-medical applications. For example, pharmaceutical compositions comprising an APPL and an excipient may be useful in delivering an effective amount of an agent to a subject in need thereof. Nutraceutical compositions comprising an APPL and an excipient may be useful in delivering an effective amount of a nutraceutical, eg, a dietary supplement, to an individual in need thereof. cosmetic compositions comprising an APPL and an excipient may be formulated as a cream, ointment, balm, paste, film, or liquid, etc., and may be useful in applying makeup, hair care products, and materials useful for personal hygiene, etc. Compositions comprising an APPL and an excipient may be useful for non-medical applications, for example, as an emulsion or emulsifier, useful, for example, as a food component, for quenching sting, for disinfecting surfaces, for removing oil, etc.
[00552] [00552] —Peptides play significant roles in endogenous cellular signaling and tracheal reaction series, and offer tremendous potential in potentiating such interactions to enhance the delivery efficiency of systems that incorporate peptide moieties. Thus, compositions comprising an APPL and an excipient may also be useful in bioprocessing, such as cellular bioprocessing of a commercially useful chemistry or fuel. For example, intracellular release of APPL or an agent complexed to it, can be useful in bioprocessing for the maintenance of health and/or cell growth, for example, in the manufacture of proteins.
[00553] [00553] The composition may comprise one type of APPL, but may also comprise any number of different types of APPLs, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different ti - types of APPLs.
[00554] [00554] In certain embodiments, the composition also comprises an agent, as described herein. For example, in certain embodiments, the agent is a small molecule, organometallic compound, nucleic acid, protein, peptide, polynucleotide, metal, targeting agent, an isotopically labeled chemical compound, drug, vaccine, immunological agent, or an isotopically labeled chemical agent. useful in bioprocessing. In certain embodiments, the agent is a polynucleotide. In certain embodiments, the polynucleotide is DNA or RNA. In certain embodiments, the RNA is RNA, dsRNA, siRNA, shRNA, miRNA, or antisense RNA. In certain embodiments, the polynucleotide and one or more APPLs are non-covalently linked. In certain embodiments, one or more APPLs are in the form of a particle. In certain embodiments, the particle is a nanoparticle or microparticle. In certain embodiments, one or more APPLs are in the form of liposomes or micelles. It is understood that, in certain embodiments, these APPLs assemble to provide a particle, micelle, or liposome. In certain embodiments, the particle, micelle, or liposome encapsulates an agent. The agent to be released by the particle, micelle, or liposome may be in the form of a gas, liquid, or solid. APPLs can be combined with polymers (synthetic or natural), surfactants, cholesterol, carbohydrates, proteins, lipids, etc. to form the particles. These particles can also be combined with an excipient to form the composition.
[00555] [00555] ""Excipients" include any and all solvents, diluents or other liquid carriers, dispersing or suspending aids, surfactants, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like. res, as appropriate for the particular dosage form desired. General formulation and/or manufacturing considerations can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, EW Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st. Edition (Lippincott Williams & Wilkins, 2005).
[00556] [00556] Exemplary excipients include, but are not limited to, any non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material, or formulation aid of any kind.
[00557] [00557] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol , sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, etc., and combinations thereof.
[00558] [00558] Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycollate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood, natural sponge, cation exchange resins, calcium carbonate, silicates, sodium carbonate, polyvinyl pyrrolidone) cross-linked (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, carboxymethyl cross-linked sodium cellulose (croscarmellose), methyl cellulose, pregelatinized starch (starch 1500), microcrystalline starch, water-insoluble starch, carboxymethyl calcium cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds , etc., and combinations thereof.
[00559] [00559] — Exemplary surfactants and/or emulsifiers include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, lanolin , cholesterol, wax, and lecithin), colloidal clays (e.g., bentonite [aluminium silicate] and Veegum [magnesium aluminum silicate]), long-chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., polymethylene carboxy, polyacrylic acid, acid polymer acrylic, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g.
[00560] [00560] Exemplary binding agents include starch (eg, corn starch and starch paste), gelatin, sugars (eg, sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc. .), natural and synthetic gums (e.g. acacia, sodium alginate, Irish moss extract, panwar gum, ghatti gum, isapol husk mucilage, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose , hydroxypropyl methyl cellulose, microcrystalline cellulose, cellulose acetate, poly(vinylpyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts , silicic acid, polymethacrylates, waxes, water, alcohol, etc., and/or combinations thereof.
[00561] [00561] Exemplary condoms include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
[00562] [00562] Exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
[00563] [00563] Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g. citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, alcohol! ethyl, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
[00564] [00564] —Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
[00565] [00565] —Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
[00566] [00566] — Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
[00567] [00567] — Other preservatives include tocopherol, tocopheryl acetate, detheroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES) ), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Fenonip, methylparaben, Germall 115, Germabene II, Neolona, Kathon, and Euxyl. In certain embodiments, the preservative is an antioxidant. In other embodiments, the condom is a chelating agent.
[00568] [00568] Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, gluceptate calcium, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate , potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, citrate sodium, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline ca, Ringer's solution, ethyl alcohol, etc., and combinations thereof.
[00569] [00569] Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride , leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.
[00570] [00570] Exemplary natural oils include almond, apricot, avocado, babassu, bergamot, black chain seed, borage, cade, chamomile, canola, cumin, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, linseed, geraniol, gourd, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender , lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, rough orange, palm, palm seed, peach seed, peanut, poppy seed, pumpkin, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savory, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and germ wheat. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicon oil, and combinations thereof.
[00571] [00571] - Additionally, the composition may comprise a phospholipid. Exemplary phospholipids include, but are not limited to, dysteroylphosphatidylcholine (DSPC), dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), and dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-Dilauroyl-sn-Glycer-3 -Phosphocholine (dilauroylphosphatidylcholine, DLPC), 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (dimyristoylphosphatidylcholine, DMPC), 1,2-Dipentadecanoyl-sn-Glycer-3-Phosphocholine (dipentadecanoylphosphatidylcholine, DPDPC), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (Dipalmitoylphosphatidylcholine, DPPC), 1-Myristoyl-2-Palmitoyl-sn-Glycero-3-Phosphocholine (1I-myristoyl-2-palmitoylphosphatidylcholine, MPPC), 1,2- Dimyristoyl-sn-Glycero-3-[Phosphorac-(1-glycerol)] (DMPG), and 1,2 Dimyristoyl-3-Trimethylammonium-propane.
[00572] [00572] - Additionally, the composition may also comprise a polymer.
[00573] [00573] Additionally, the composition may also comprise an emulsifying agent.
[00574] [00574] - Additionally, the composition may also comprise an apolipoprotein. Previous studies reported that Apolipoprotein E (ApoE) was able to enhance cell uptake and gene silencing for certain types of materials. See, for example, Akinc, A., et al., Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 18(7): pp. 1357-64. In certain embodiments, the apolipoprotein is ApoA, ApoB, ApoC, ApoE, or ApoH, or an isoform thereof.
[00575] [00575] Solid compositions include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to APPL, the liquid composition may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing and emulsifying agents, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, peanut, corn, germ, olive, castor, and sesame oils ), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. In addition to inert diluents, oral compositions may also include adjuvants, such as wetting, emulsifying and suspending agents, sweetening, flavoring and smoking agents.
[00576] [00576] Injectable compositions, for example, injectable aqueous or oleaginous suspensions can be formulated according to known technique, using dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be an injectable solution, suspension or emulsion, in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents for pharmaceutical or cosmetic compositions that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Any bland fixed oil can be used including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. In certain embodiments, the particles are suspended in a carrier fluid comprising 1% (w/v) sodium carboxymethyl cellulose and 0.1% (v/v) Tween 80. The injectable composition may be sterilized, for example, by filtration through by means of a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions, which can be dissolved or dispersed in sterile water or other sterile injectable medium before use.
[00577] [00577] Compositions for rectal or vaginal administration may be in the form of suppositories which may be prepared by mixing the particles with suitable non-irritating excipients or carriers, such as cocoa butter, polyethylene glycol, or a suppository wax, which they are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the particles.
[00578] [00578] Solid compositions include capsules, tablets, pills, powders, and granules. In such solid compositions, the particles are mixed with at least one excipient and/or a) fillers or extenders
[00579] [00579] “Tablets, pills, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They may optionally contain opacifying agents and may also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[00580] [00580] “Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatine capsules, using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like.
[00581] [00581] “Compositions for topical or transdermal administration include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. APPL is mixed with an excipient and any necessary condoms or tampons, as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as included within the scope of this invention.
[00582] [00582] Ointments, pastes, creams, and gels may contain, in addition to APPL, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, acid silica, talc, and zinc oxide, or mixtures thereof.
[00583] [00583] Powders and sprays may contain, in addition to APPL, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays may additionally contain customary propellants, such as chlorofluorohydrocarbons.
[00584] [00584] “Transdermal patches have the added advantage of providing controlled release of a compound into the body. Such dosage forms can be made by dissolving or dispersing the microparticles or nanoparticles in an appropriate medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or dispersing the particles in a polymer matrix or gel. agents
[00585] [00585] Agents to be released for the systems described herein may be therapeutic, diagnostic, or prophylactic agents. Any chemical compound to be administered to an individual can be delivered using the complexes, picoparticles, nanoparticles, micro-
[00586] [00586] In certain embodiments, the agents are organic molecules with pharmaceutical activity, for example, a drug. In certain embodiments, the drug is an antibiotic, antiviral agent, anesthetic, steroidal agent, anti-inflammatory agent, antineoplastic agent, anticancer agent, antigen, vaccine, antibody, decongestant, antihypertensive, sedative, birth control agent , progestational agent, anticholinergic, analgesic, antidepressant, antipsychotic, B-adrenergic blocking agent, diuretic, cardiovascular active agent, vasoactive agent, non-steroidal anti-inflammatory agent, nutritional agent, etc.
[00587] [00587] In certain embodiments of the present invention, the agent to be delivered may be a mixture of agents.
[00588] [00588] Diagnostic agents include gases; metals; commercially available imaging agents used in positron emission tomography (PET), computer-assisted tomography (CAT), single-photon emission computed tomography, x-ray, fluoroscopy, and magnetic resonance imaging (MRI); and contrast agents. Examples of materials suitable for use as MRI contrast agents include gadolinium chelates, as well as iron, magnesium, manganese, copper, and chromium. Examples of materials useful for CAT and x-ray imaging include iodine-based materials.
[00589] [00589] Therapeutic and prophylactic agents include, but are not limited to, antibiotics, nutritional supplements, and vaccines. Vaccines may comprise isolated proteins or peptides, inactivated organisms and viruses, killed organisms and viruses, genetically altered organisms or viruses, and cell extracts.
[00590] [00590] Since it is often desirable to target a particular cell, collection of cells, or tissue, an APPL, and the complexes, liposomes, micelles, microparticles, picoparticles and nanoparticles prepared therefrom can be modified to include targeting agents or airing regions. For example, APPL scaffolding may include a targeting region. A variety of agents or regions that target particular cells are known in the art. See, for example, Cotten and another, Methods Enzym. 217:618, 1993. The bleaching agents may be included in every particle or may be only on the surface. The targeting agent can be protein, peptide, carbohydrate, glycoprotein, lipid, small molecule, nucleic acid, etc. The targeting agent can be used to target specific cells or tissues or can be used to promote endocytosis or phagocytosis of the particle. Examples of targeting agents include, but are not limited to, antibodies, antibody fragments, low-density lipoproteins (L-DLs), transferrin, asialicoproteins, human immunodeficiency virus (HIV) gp120 envelope protein, carbohydrates , receptor ligands, sialic acid, aptamers, etc. If the bleaching agent is included in the entire particle, the bleaching agent can be included in the mixture that is used to form the particles. If the bleaching agent is only on the surface, the bleaching agent may be associated with (ie, covalent hydrogen bonding, hydrophobic, van der Waals, or other interactions) particles formed using standard chemical techniques. Polynucleotide Complexes
[00591] [00591] The present invention contemplates APPLs that are particularly useful in the administration of polynucleotides. For example, AP
[00592] [00592] In one aspect, there is provided a method of delivering a polynucleotide to a biological cell, comprising providing a composition comprising an APPL, or salt thereof, and a polynucleotide; and exposing a composition to the biological cell under conditions sufficient to facilitate release of the polynucleotide into the interior of the biological cell; wherein the APPL is an amino acid, a linear or cyclic peptide, or a linear or cyclic polypeptide, or structural isomer thereof, wherein an amino or amide group of the APPL is conjugated to a group of formula (i), (ii) , or (iii))). In certain embodiments, the method is an in vivo method. In certain embodiments, the method is an in vitro method.
[00593] [00593] “An APPL can be at least partially supplied as a salt (eg, it is protonated) in order to form a complex with the negatively charged polynucleotide. In certain modes
[00594] [00594] Increasing nitrogen:phosphate ratios have been shown to positively influence the release of genetic material by increasing nucleic acid binding and negatively influence the release by increasing toxicity. See, for example, Incani et al, Soft Matter (2010) 6:2124-2138. In certain embodiments, the nitrogen:phosphate ratio (i.e., the ratio between the amino groups present on the APPL, and the phosphate groups present on the polynucleotide) is between about 10:1 to about 50:1, including. In certain embodiments, the nitrogen:phosphate ratio is from about 10:1 to about 45:1, from about 15:1 to about 45:1, or from about 20:1 to about 40:1 , including. In certain embodiments, the APPL:polynucleotide mass ratio is between about 10:1 to about 20:1, inclusive. In certain embodiments, the APPL:polynucleotide mass ratio is about 15:1. In certain embodiments, the molar ratio of APPL:polynucleotide is between about 10:1 to about 400:1, inclusive. In certain embodiments, the molar ratio of APPL:polynucleotide is from about 10:1 to about 350:1, from about 15:1 to about 300:1, or from about 20:1 to about 300:1. 250:1 inclusive.
[00595] [00595] In certain embodiments, the complex may form a particle. In certain embodiments, the diameter of the particles ranges from 10 to 500 micrometers. In certain embodiments, the diameter of the particles ranges from 10 to 1200 micrometers. In certain embodiments, the diameter of the particles ranges from 50 to 150 micrometers. In certain embodiments, the diameter of the particles ranges from 10 to 500 nm, in certain embodiments
[00596] [00596] The polynucleotide may be complexed, encapsulated by an APPL, or included in a composition comprising an APPL. The polynucleotide can be any nucleic acid including, but not limited to, RNA and DNA. In certain embodiments, the polynucleotide is DNA. In certain embodiments, the polynucleotide is RNA. In certain embodiments, in the release of RNA into a cell, the RNA is able to interfere with the expression of a specific gene in the biological cell.
[00597] [00597] In certain embodiments, the polynucleotide is an RNA that performs RNA interference (RNA/). The RNAi phenomenon is described in greater detail, for example, in the following references: Elbashir et al., 2001, Genes Dev., 15:188; Fire et al., 1998, Nature, 391:806; Tabara et al., 1999, Cell, 99:123; Hammond et al., Nature, 2000, 404:293; Zamore et al., 2000, Cell, 101:25; Chakraborty, 2007, Curr. Drug Targets, 8:469; and Morris and Rossi, 2006, Gene Ther., 13:553. In certain embodiments, the polynucleotide is a dsRNA (double-stranded RNA). In certain embodiments, the polynucleotide is an SIiRNA (short interference RNA). In certain embodiments, the polynucleotide is an sShRNA (short hairpin RNA). In certain embodiments, the polynucleotide is an mIRNA (micro RNA). micro RNAs
[00598] [00598] In certain embodiments, the polynucleotide may be provided as an antisense or RNA interference agent (RNAi). See, for example, Fire et al., Nature 391:806-811, 1998. Antisense therapy is understood to include, for example, in situ administration or provision of single- or double-stranded oligonucleotides, or derivatives thereof that specifically hybridize, for example, bind, under cellular conditions, with cellular mMRNA and/or genomic DNA, or mutants thereof, in order to inhibit the expression of the encoded protein, for example, by inhibiting transcription and/or translation. See, for example, Crooke "Molecular mechanisms of action of antisense drugs" Biochim. Biophys. Acta 1489(1):31-44, 1999; Crooke "Evaluating the mechanism of action of antiproliferative antisense drugs" Antisense Nucleic Acid Drug Dev. 10(2):123-126, discussion 127, 2000; Methods in Enzymology volumes 313-314, 1999. Binding may be by conventional base-pair complementarity, or, for example, in the case of binding to DNA doubles, via specific interactions at the highest rate. - double helix gap (ie triple helix formation). See, for example, Chan et al., J. Mol. Med. 75(4):267-282, 1997.
[00599] [00599] In some embodiments, dsRNA, siRNA, shRNA, miRNA, antisense RNA, and/or RNAi can be assigned and/or predicted using one or more of a large number of available algorithms. To provide, however, some examples, the following resources can be used to design and/or predict polynucleotides: algorithms found in Alnylum Online, Dharmacon Online, OligoEngine Online, Molecula Online, Ambion Online, BioPredsi Online, RNAi Web Online, Chang Bioscience Online, Invitrogen Online, LentiWeb Online GenScript Online, Protocol Online; Reynolds et al., 2004, Nat. Biotechnol., 22:326; Naito et al., 2006, Nucleic Acids Res., 34:W448; Li et al., 2007, RNA, 13:1765; Yiu et al., 2005, Bioinformatics, 21:144; and Jia et al., 2006, BMC Bioinformatics, 7: 271.
[00600] [00600] Polynucleotides can be of any size or sequence, and they can be single-stranded or double-stranded. In certain embodiments, the polynucleotide is more than 100 base pairs in length. In certain embodiments, the polynucleotide is greater than 1000 base pairs in length and may be greater than 10,000 base pairs in length. The polynucleotide is optionally purified and substantially pure. In certain embodiments, the polynucleotide is greater than 50% pure, in certain embodiments more than 75% pure, and in certain embodiments greater than 95% pure. The polynucleotide can be provided by any methods known in the art. In certain embodiments, the polynucleotide has been constructed using recombinant techniques. See, for example, Ausubel et al., Current Protocols in Molecular Biology (John Wiley & Sons, Inc., New York, 1999); Molecular Cloning: A Laboratory Manual, 2a. Ed., ed. by Sambrook, Fritsch, and Maniatis (Cold Spring Harbor Laboratory Press: 1989). The polynucleotide can also be obtained from natural sources and purified from contaminating components normally found in nature. The polynucleotide can also be chemically synthesized in a laboratory. In certain embodiments, the polynucleotide is synthesized using standard solid phase chemistry.
[00601] [00601] The polynucleotide can be modified by chemical or biological methods. In certain embodiments, these modifications lead to increased stability of the polynucleotide. Modifications include methylation, phosphorylation, end capping, etc.
[00602] [00602] Polynucleotide derivatives may also be used in the present invention. These derivatives include modifications to the bases, sugars, and/or phosphate bonds of the polynucleotide. Modified bases include, but are not limited to, those found in the following nucleoside analogs: 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 7-deazaadenosine, T-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine. Modified sugars include, but are not limited to, 2-fluororibose, ribose, 2'-deoxyribose, 3-azido-2,3-dideoxyribose, 2,3-dideoxyribose, arabinose (the 2'-epimer of ribose), sugars acyclics, and hexoses. Nucleosides can be linked together by bonds other than the phosphodiester bond found in naturally occurring DNA and RNA. Modified bonds include, but are not limited to, phosphorothioate and 5-N-phosphoramidite bonds. Combinations of the various modifications can be used in a single polynucleotide. These modified polynucleotides can be provided by any methods known in the art; however, as will be appreciated by those skilled in the art, the modified polynucleotides can be prepared using synthetic chemistry in vitro.
[00603] [00603] The polynucleotides to be released can be in any form. For example, the polynucleotide can be a circular plasmid, a linearized plasmid, a cosmid, a viral genome, a modified viral genome, an artificial chromosome, and so on.
[00604] [00604] The polynucleotide can be of any sequence. In certain embodiments, the polynucleotide encodes a protein or peptide.
[00605] [00605] In certain embodiments, the polynucleotide to be released comprises a sequence encoding an antigenic peptide or protein. Nanoparticles containing these polynucleotides can be delivered to an individual to induce an immune response sufficient to decrease the chance of a subsequent infection and/or reduce the symptoms associated with such an infection. The polynucleotide of these vaccines can be combined with interleukins, interferon, cytokines, and adjuvants, such as cholera toxin, alum, Freund's adjuvant, etc. A large number of adjuvant compounds are known; a useful compendium of many such compounds is prepared by the National Institutes of Health. See, for example, Allison Dev. Biol. Stand. 92:3-11, 1998; Unkeless and another, Annu. Rev. Immunol. 6:251-281, 1998; and Phillips et al., Vaccine 10:151-158, 1992.
[00606] [00606] The antigenic protein or peptides encoded by the polynucleotide may be derived from such bacterial organisms as Streptococcceus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyrogenes, Corynebacterium diphtheriae,
[00607] [00607] The present invention also contemplates APPLs useful as a delivery device. APPLs have several properties that make them particularly suitable for delivery, including: 1) the ability of an APPL to complex and "protect" labile agents; 2) the ability to buffer the pH in the endosome; 3) the ability to act as a "proton sponge" and cause endosomolysis; and 4) the ability to neutralize the charge on negatively charged agents.
[00608] [00608] In certain embodiments, an APPL is used to form part-
[00609] [00609] In certain embodiments, the diameter of the particles varies between 1 micrometer to 1,000 micrometers. In certain embodiments, the diameter of the particles ranges from 1 micrometer to 100 micrometers. In certain embodiments, the diameter of the particles ranges from 1 micrometer to 10 micrometers. In certain embodiments, the diameter of the particles ranges from 10 micrometers to 100 micrometers. In certain embodiments, the diameter of the particles ranges from 100 micrometers to
[00610] [00610] The particles can be prepared using any method known in the art. These include, but are not limited to, spray drying, single and double emulsion solvent evaporation, solvent extraction, phase separation, simple and complex coacervation, and other methods well known to those skilled in the art. technique. In certain embodiments, methods of preparing the particles are the double emulsion and spray drying process. The conditions used in preparing the particles can be altered to produce particles of a desired size or property (eg, hydrophobicity, hydrophilicity, external morphology, "stickiness", shape, etc.). The method and conditions of particle preparation (e.g., solvent, temperature, concentration, air flow rate, etc.) used may also depend on the agent being encapsulated and/or the composition of the matrix.
[00611] [00611] The methods developed for the preparation of particles for release of encapsulated agents are described in the literature. See, for example, Doubrow, M., Ed., "Microcapsules and Nanoparticles in Medicine and Pharmacy," CRC Press, Boca Raton, 1992; Matiowitz and Langer, J. Controlled Release 5:13-22, 1987; Matiowitz et al., Reactive Polymers 6:275-283, 1987; Matiowitz et al., J. Appl. Polymer Sci. 35:755-774, 1988.
[00612] [00612] If particles prepared by any of the above methods have a size variation outside the desired range, the particles can be delimited, for example, using a sieve. The particle may also be coated. In certain embodiments, the particles are coated with a bleaching agent. In other modalities
[00613] [00613] The present invention also contemplates the use of APPLs in the preparation of micelles or liposomes. Any agent can be included in a micelle or liposome. Micelles and liposomes are particularly useful in delivering hydrophobic agents, such as small hydrophobic molecules. When the micelle or liposome is complexed with (e.g., encapsulates or encompasses) a polynucleotide it is also referred to as a "lipoplex." Many techniques for preparing micelles and liposomes are known in the art, and any such method can be used with an APPL to prepare micelles and liposomes.
[00614] [00614] In certain embodiments, liposomes are formed through spontaneous assembly. In other embodiments, liposomes are formed when thin lipid films or lipid masses are hydrated and stacks of lipid crystalline bilayers become fluid and swell. The hydrated lipid sheets separate during shaking and close to form large multilamellar vesicles (LMV). This prevents water from interacting with the hydrocarbon core of the bilayers at the edges. Once these particles form, the particle size reduction can be modified through input of sonic energy (sonication) or mechanical energy (extrusion). See, for example, Walde, P. "Preparation of Vesicles (Liposomes)" In Encyclopedia of Nanoscience and Nanotechnology; Nalwa, H.S.Ed. American Scientific Publishers: Los Angeles, 2004; Vol. 9, pp. 43-79; Szoka et al., "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)" Ann. Rev. Biophys. Bioeng. 9:467-508, 1980; each of which is incorporated here. Liposome preparation involves preparing the APPL for hydration,
[00615] [00615] The following scientific papers described other methods for preparing liposomes and micelles: Narang et al., "Cationic Lipids with Increased DNA Binding Affinity for Nonviral Gene Transfer in Dividing and Nondividing Cells" Bioconjugate Chem. 16:156-68, 2005; Hofland et al., "Formation of stable cationic lipid/DNA complexes for gene transfer" Proc. natl. academy Sci. USA 93:7305-7309, July 1996; Byk and another, "Synthesis, Activity, and Structu-
[00616] [00616] It is estimated that over 10,000 human diseases are caused by genetic disorders, which are abnormalities in genes or chromosomes. See, for example, McClellan, J. and M.C. King, Genetic heterogeneity in human disease. Cell. 141(2): p. 210-7; Leachman, S.A., et al., Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci, 2008. 51(3): p. 151-
[00617] [00617] Thus, in another aspect, methods of using APPLs are provided, for example, for the treatment of a disease, disorder or condition from which an individual suffers. It is contemplated that APPLs will be useful in the treatment of a variety of diseases, disorders or conditions, especially a system for delivering agents useful in the treatment of that particular disease, disorder, or condition. "Disease," "disorder," and "condition" are used interchangeably here. In certain embodiments, the disease, disorder, or condition from which an individual suffers is caused by an abnormality in an individual's gene or chromosome.
[00618] [00618] For example, in one embodiment, there is provided a method of treating the disease, disorder, or condition from which an individual suffers, comprising administering to an individual in need thereof an effective amount of a composition comprising an APPL, or salt of the same. Exemplary diseases, disorders, or conditions contemplated include, but are not limited to, proliferative disorders, inflammatory disorders, autoimmune disorders, painful conditions, liver diseases, and amyloid neuropathies.
[00619] [00619] “As used here, an "active ingredient" is any agent that elicits the desired biological response. For example, APPL may be the active ingredient in the composition. Other agents, for example therapeutic agents, as described herein, may also be classified as an active ingredient. In certain embodiments, the composition also comprises, in addition to APPL, a therapeutic agent useful in treating a disease, disorder, or condition. In certain embodiments, APPL encapsulates the other (therapeutic) agent of the particle (eg, nanoparticle, microparticle, micelle, liposome, lipoplex).
[00620] [00620] In certain embodiments, the condition is a proliferative disorder and, in certain embodiments, the composition also includes an anticancer agent. Exemplary proliferative diseases include, but are not limited to, tumors, benign neoplasms, pre-malignant neoplasms (carcinoma in situ), and malignant neoplasms (cancers).
[00621] [00621] Exemplary cancers include, but are not limited to, acoustic neuroma, adenocarcinoma, adrenal gland cancer,
[00622] [00622] Anticancer agents encompass biotherapeutic anticancer agents as well as chemotherapeutic agents.
[00623] [00623] Exemplary biotherapeutic anticancer agents include, but are not limited to, interferons, cytokines (eg, tumor necrosis factor, interferon a, interferon y), vaccines, hematopoietic growth factors, monoclonal serum therapy, immunostimulating agents, and /or immunomodulators (eg, IL-1, 2, 4, 6, or 12), immune cell growth factors (eg, GM-CSF), and antibodies (eg, HERCEPTIN (trastuzumab), T- DM1, AVASTIN (bevacizumab), ERBITUX (cetuximab), VECTIBIX (panitumumab), RITUXAN (rituximab), BEXXAR (tositumomab)).
[00624] [00624] Exemplary chemotherapeutic agents include, but are not limited to, antiestrogens (eg, tamoxifen, raloxifene, and megestrol), LHRH agonists (eg, goscrelin and leuprolide), antiandrogens (eg, flutamide and bicalutamide) , photodynamic therapies (eg, vertoporfin (BPD-MA), phthalocyanine, Pc4 photosensitizer, and demethoxyhypocrelin A (2BA-2-DMHA)), nitrogen mustards (eg, cyclophosphamide, ifosfamide, trophos- famide, chlorambucil, estramustine, and melphalan), nitrosoureas (eg, carmustine (BCNU) and lomustine (CCNU)), alkylsulfonates (eg, busulfan and treosulfan), triazenes (eg, dacarbazine, temozolomide), platinum-containing compounds (eg, cisplatin, carboplatin, oxaliplatin), vinca alkaloids (eg, vincristine, vinblastine, vindesine, and vinorelbine), taxoids (eg, paclitaxel or a paclitaxel equivalent such as paclitaxel bound to nanop albumin article (ABRAXANE), docosahexaenoic acid-linked paclitaxel (DHA-paclitaxel, Taxoprexin), polyglutamate-linked paclitaxel (PG-paclitaxel, paclitaxel polygiumex, CT-2103, XYOTAX), the tumor-activated prodrug (TAP) ANG1005 (Angiopep-2 bound to three paclitaxel molecules), paclitaxel-EC-1 (paclitaxel bound to erbB2 recognition peptide EC-1), and glucose-conjugated paclitaxel, e.g. 2-glucopyranosyl succinate from 2'-paclitaxel methyl; docetaxel, taxol), epipodophyllins (e.g. etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mitomycin C), antimetabolite
[00625] [00625] In certain embodiments, the condition is an inflammatory disorder and, in certain embodiments, the composition also includes an anti-inflammatory agent. The term "inflammatory disorder" refers to those diseases, disorders, or conditions that are characterized by signs of pain (pain, from the generation of noxious substances and the stimulation of nerves), heat (heat, from vasodilation), redness (flushing), , of vasodilation and increased blood flow), swelling (tumor, of excessive inflow or restricted flow of fluid), and/or loss of function (functio laesa), which may be partial or complete, temporary or permanent. Inflammation occurs in many forms and includes, but is not limited to, acute, adhesive, atrophic, catarrhal, chronic, cirrhotic, diffuse, disseminated, exudative, fibrinous, fibrosing, focal, granulomatous, hyperplastic, hypertrophic, interstitial , metastatic, necrotic, obliterated
[00626] [00626] Exemplary inflammatory disorders include, but are not limited to, inflammation associated with acne, anemia (eg, anaplastic anemia, autoimmune hemolytic anemia), asthma, arteritis (eg, polyarteritis, temporal arteritis, periarteritis nodosa, arteritis Takayasu's), arthritis (eg, crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis, and Reiter's arthritis), ankylosing spondylitis, amylosis, amyotrophic lateral sclerosis, autoimmune diseases, allergies or allergic reactions, atherosclerosis, bronchitis, bursitis, chronic prostatitis, conjunctivitis, Chagas disease, chronic obstructive pulmonary disease, kermatomyositis, diverticulitis, diabetes (eg, type 1 diabetes mellitus, type 2 diabetes mellitus), a skin condition (eg, psoriasis, eczema, burns, dermatitis, pruritus (itching), endometriosis, Guillain-Barre syndrome, infection, ischemic heart disease, Kawasaki disease, glomerulonephritis, gingivitis, hypersensitivity, headaches (eg, hemicrania headaches, tension headaches), ileus (eg, postoperative phleus and ileus during sepsis), idiopathic thrombocytopenic purpura, interstitial cystitis (painful bladder syndrome), gastrointestinal disorder ( for example, selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (eg, eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic colitis), gastritis, diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory bowel disease (IBD) (eg, Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischemic colitis, diversion colitis, Behcet syndrome, indeterminate colitis) and inflammatory bowel syndrome (IBS), lupus, multiple sclerosis, morphea, myasthenia gravis, myocardial ischemia, nephrotic syndrome, pemphigus vulgaris, pernicious anemia, peptic ulcers, polymyositis, primary biliary cirrhosis, neuroinflammation associated with brain disorders (eg, Parkinson's disease, Huntington's disease, and Alzheimer's disease), prostatitis, chronic inflammation associated with brain damage cranial radiation, pelvic inflammatory disease, reperfusion damage, regional enteritis, rheumatic fever, systemic lupus erythematosus, scleroderma, scirodoma, sarcoidosis, spondyloarthopathy, Sjogren's syndrome, thyroid, transplant rejection, tendonitis, trauma or damage (eg (eg, frostbite, chemical irritants, toxins, scarring, burns, physical damage), vasculitis, vitiligo, and Wegener's granulomatosis.
[00627] [00627] In certain embodiments, the inflammatory disorder is inflammation associated with a proliferative disorder, eg, inflammation associated with cancer.
[00628] [00628] In certain embodiments, the condition is an autoimmune disorder and, in certain embodiments, the composition also includes an immunomodulatory agent. Exemplary autoimmune disorders include, but are not limited to, arthritis (including rheumatoid arthritis, spondyloarthropathies, gouty arthritis, degenerative joint diseases such as osteoarthritis, systemic lupus erythematosus, Sjogren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, autoimmune hemolytic anemias, multiple sclerosis, amyotrophic lateral sclerosis, amylosis, acute painful shoulder, psoriatic and juvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin condition (e.g. , psoriasis, eczema, burns, dermatitis, pruritus (itching)), enuresis, eosinophilic disease, gastrointestinal disorder (e.g. selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis, gas-
[00629] [00629] In certain embodiments, the condition is a painful condition and, in certain embodiments, the composition also includes an analgesic agent. A "painful condition" includes, but is not limited to, neuropathic pain (eg, peripheral neuropathic pain), core pain, deafferentation pain, chronic color (eg, chronic nociceptive pain, and other forms of chronic pain, such as postoperative pain, for example, pain arising after hip, knee, or other replacement surgery, preoperative pain, stimulation of nociceptive receptors (nociceptive pain), acute pain (for example, phantom and acute transient pain) , non-inflammatory pain, inflammatory pain, pain associated with cancer, wound pain, burning pain, postoperative pain, pain associated with medical procedures, pain resulting from itching, painful bladder syndrome, pain associated with premenstrual dysphoric disorder and/or premenstrual syndrome, pain associated with chronic fatigue syndrome, pain associated with preterm birth, pain associated with drug addiction withdrawal symptoms, joint pain, arthritic pain (e.g. ociated with crystalline arthritis, os-
[00630] [00630] In certain embodiments, the painful condition is inflammatory pain. In certain embodiments, the painful condition (eg, inflammatory pain) is associated with an inflammatory disorder and/or an autoimmune disorder.
[00631] [00631] In certain embodiments, the condition is liver disease, and in certain embodiments, the composition also includes an agent useful in treating liver disease. Exemplary liver diseases include, but are not limited to, drug-induced liver damage (eg, acetaminophen-induced liver damage), hepatitis (eg, chronic hepatitis, viral hepatitis, alcohol-induced hepatitis, autoimmune hepatitis, steatohepatitis), non-alcoholic fatty liver disease, alcohol-induced liver disease (eg, alcoholic fatty liver, alcoholic hepatitis, alcohol-related cirrhosis), hypercholesterolemia (eg, severe hypercholesterolemia), hereditary transthyretin-related amyloidosis, cirrhosis of the liver, liver cancer, primary biliary cirrhosis, cholestat, cystic liver disease, and primary sclerosing cholangitis. In certain embodiments, liver disease is associated with inflammation.
[00632] [00632] In certain embodiments, the condition is a familial amyloid neuropathy and, in certain embodiments, the composition also includes an agent useful in a familial amyloid neuropathy.
[00633] [00633] A "patient" to which administration is contemplated includes, but is not limited to, human beings (i.e. a male or female of any age group, e.g. a pediatric patient (e.g. , infant, child, adolescent) or adult patient (e.g. young adult, middle-aged adult or older adult)) and/or other non-human animals, e.g. mammals [e.g. primates (e.g. cynomolgus monkeys, rhesus monkeys); and commercially relevant mammals, such as mice, rats, hamsters, cattle, pigs, horses, sheep, cats, and/or dogs] and birds (e.g., commercially relevant birds, such as francs, ducks, geese, and /or turkeys). In certain embodiments, the patient is a non-human animal. The non-human animal can be a male or female and at any stage of development. A non-human animal can be a transgenic animal.
[00634] [00634] As used herein, and unless otherwise specified, the terms "treat," "treating," and "treatment" contemplate an action that occurs while the individual is suffering from the specified disease, disorder, or condition, that reduces the severity of the disease, disorder or condition, or delays or slows down the progression of the disease, disorder or condition ("therapeutic treatment"), and also contemplates an action that occurs before an individual begins suffering from the specified disease, disorder or condition ("prophylactic treatment").
[00635] [00635] In general, the "effective amount" of an active ingredient refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those skilled in the art, the effective amount of a compound of the invention can vary depending on
[00636] [00636] As used herein, and unless otherwise specified, a "therapeutically effective amount" of an active ingredient is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of an active ingredient means an amount of the active ingredient, alone or in combination with other agents or therapies, that provides a therapeutic benefit in the treatment of the disease, disorder or condition. The term "therapeutically effective amount" can encompass an amount that improves general therapy, reduces or prevents symptoms or causes of disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
[00637] [00637] "As used herein, and unless otherwise specified, a "prophylactically effective amount" of an active ingredient is an amount sufficient to prevent a disease, disorder, or condition, or one or more symptoms associated with an active ingredient. disease, disorder or condition, or prevents its recurrence. A prophylactically effective amount of an active ingredient means an amount of the active ingredient, alone or in combination with other agents or therapies, that provides a prophylactic benefit in preventing a disease, disorder or condition. The term "prophylactically effective amount" may encompass an amount that improves the overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
[00638] [00638] The active ingredient may be administered in such amounts
[00639] [00639] The active ingredient may be administered by any routine. In some embodiments, the active ingredient is administered via a variety of routines, including oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, buccal, enteral, sublingual; by intratracheal installation, bronchial installation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. In general, the most appropriate administration routine will depend on a variety of factors including the nature of the active ingredient (eg, its stability in the gastrointestinal tract environment), the individual's condition (eg, whether the individual is able to tolerate oral administration), etc.
[00640] [00640] The exact amount of an active ingredient required to obtain a therapeutically or prophylactically effective amount will vary from individual to individual, depending on the species, age, and general condition of the individual, severity of side effects or disorder, identity of the individual. particular compound(s), mode of administration, and the like. The amount to be administered to, for example, a child or adolescent may be determined by a medical practitioner or person skilled in the art and may be less than or equal to that administered to an adult. EXAMPLES
[00641] [00641] In order that the invention described herein may be more fully understood, the following examples are mentioned. It is to be understood that these examples are for illustrative purposes only and are not construed as limiting this invention in any way. Amino acid-, peptide-, and polypeptide-lipids (APPL) for drug delivery
[00642] [00642] To address the challenges associated with delivery efficiency, specificity, and toxicity of biological agents, we have developed a potent and selective siRNA delivery system with a broad therapeutic window through rational planning and optimization of biological agents. new amino acid-based lipid derivatives.
[00643] [00643] Previously, the group pursued a combinatorial synthetic method to develop new cationic lipids (lipidoids) for siRNA release. See, for example, Akinc, A., et al., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol, 2008. 26(5): p. 561-9; Love Kevin, T., et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci US A. 107(5): p. 1864-9; Siegwart, D.J., et al. Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery. Proc Natl Acad Sci U S A. 108(32): p. 12996-3001. Several of these compounds showed significant silencing effects in vivo. See, for example, Leuschner, F., et al., Therapeutic siRNA silencing in infltammatory monocytes in mice. Nat Biotechnol. 29(11): p. 1005-10. Previous studies have identified key chemical and structural aspects and formulation methods for the development of new materials. See, for example, Akinc, A., et al. Development of lipid-siRNA formulations for systemic delivery to the liver. Mol Ther, 2009. 17(5): p. 872-9; Akinc, A., et al., Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 18(7): p. 1357-64; Semple, S.C., et al., Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 28(2): p. 177x5. For example, active compounds have 12 or more carbons in tail length and multiple tails. See, for example, Love Kevin, T., et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 107(5): p. 1864-9. In order to improve efficacy, tissue and cell type selectivity, and tolerability, new chemical scaffolds needed to be designed and investigated.
[00644] [00644] — Amino acids are naturally occurring building blocks of peptides and proteins. Amino acid derivatives can be metabolized by the human body; therefore, these materials are likely to be well tolerated and safe as therapeutic products. Additionally, peptides play significant roles in membrane transport, endogenous cell signaling and trafficking reaction series, and offer tremendous potential in influencing such interactions to enhance the delivery efficiency of systems that incorporate peptide portions. Because of their significant physiological functions and safety in humans, amino acid-based materials such as insulin and trastuzumab have been widely applied as supplements and therapeutic drugs in the clinic for various diseases. Studies have shown that it is feasible to apply amino acid derivatives for gene release or siRNA release. See, for example, Prata, C.A., and another, Lipophilic peptides for gene delivery. Bioconjug Chem, 2008. 19(2): p. 4183-209; Adami, R.C., et al., an amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Mol Ther. 19(6): p. 1141-51; Margus, H., K. Padari, and M. Pooga, Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther. 20(3): pp. 525-33. Combining the advantages of both natural amino acid properties and lipid structural features, we applied a structural optimization strategy through an iterative evaluation process and rationally designated a series of amino acid-based lipid derivatives. The design, synthesis, and biological evaluation of this new series of amino acid-based lipid derivatives were reported. This efficient and rational strategy produced a cKK-E12 inducing material. Systemically, we investigated its release efficiency, tissue and cell type selectivity, tolerability, and mechanism of action. Current results demonstrate that this delivery system is a new platform for efficient, selective, and safe delivery of SIRNA, which shows great potential for the treatment of various diseases. General Methods Method 1. Preparation of Compounds of formula (I)-(III) . Conjugation for formula (i).
[00645] [00645] A mixture of amino acids, peptides or polypeptides and the conjugation reagent (an epoxide, thiran, or aziridine) (a 1.5:1 to 3:1 ratio of conjugation reagent to amine) in EtoH was irradiated in a microwave oven at 150 °C for 5 hours. The reaction mixture was purified by flash column chromatography. If amino acids, peptides or polypeptides are in salt form, triethylamine was added to the solution and stirred for 30 minutes at room temperature before irradiation. Scheme A. [) oox 150º RA ow rn Aga Ex CC EAN x mA RY=O,S,NR' R Scheme B. o ' Da o YH 'NH K + Á —C, uh Nor Ss EtoH - NR o RY= 0,S.NR' Ô Scheme C. o R + ÁÃ 2% LX HaN ORM A. EOH ah 9 Y=0,S NR” oa Ng
[00646] [00646] A mixture of amino acids, peptides or polypeptides and conjugation reagent (acrylate or acrylamide) (a 1.5:1 to 3:1 ratio of acrylates or conjugation reagent to amine) in ethanol (EtoH), isopropanol ( iPrOH), or acetonitrile was heated to 90°C and stirred for 2 hours to 2 days. The reaction solution was concentrated with silica gel and purified with flash column chromatography. Scheme F. oo Ar oa O HoN Oras AY Ron TAN Xoot nuX N. Xe KYA RE OR Y* ARX=O,S, NRX Scheme G. " RA AA, " ' H + so o R ii Aus PAR Teca" " XL o or xº0.8 NR* oo x xo Scheme H. HH . No A N NA ORM v RENO O NS Fa X=O,S NRX ” Rh o Schema |. and one * a TA, x-os Nº AI A x
[00647] [00647] To the solution of amino acids, peptides or polypeptides and conjugation reagent (aldehyde) (a 1.5:1 to 3:1 ratio of aldehydes to amine) in THF was added sodium triacetoxyborohydride (NaBH(OAc) 3) in rt. The reaction mixture was stirred for 3 d at rt. The reaction solution was concentrated with silica gel and purified with flash column chromatography. K scheme | o sda À o o O oRM qd THE HNÇOR! ROANCE! q Scheme L.Rg 7 fd AFA, . x NaHB(OAC); o R HoN' ORt Ro THE R un 9 o R ANNA e o R Schema M. "a, O —NaHe(cAck X ro ut RE e . ” o
[00648] [00648] “Compounds of formula (IV) can be prepared by condensation of a 1,2-diamine with an activated oxalic acid, where X' is a leaving group, e.g. bromine, chlorine, or iodine, to supply the cyclized product. Groups of formula (i), (ii), or (iii) may be installed after cyclization, for example, by means of addition to an amino side chain substituent of R', or to imino nitrogen groups No. Other groups on the scaffold, eg R groups, can be installed before cycling. For example, R may be a group of formula (i), (ii), or (iii) installed prior to cyclization. Scheme P. Rº R R R NH x x + Q el Q NH xi ) N R2 O 2HXº R Q 1,2-diamine — derivative of (IV) oxalic acid Method 5. Preparation of Compounds of Formula (V)
[00649] [00649] “Compounds of formula (V), and (VI) can be prepared by condensation of a 1,1-diamine with an activated malonic acid, where X' is a leaving group, e.g. bromo, chlorine, or iodine, to provide the cyclized product. Groups of formula (i), (ii), or (iii) may be installed after cyclization, for example, by means of addition to an amino side chain substituent of R', or to imino nitrogen groups of R6. Other groups on the scaffold, eg groups R , can be installed before cycling. For example, R may be a group of formula (i), (ii), or (iii) installed before cyclization. Q scheme.
[00650] [00650] — Compounds of formula (VI) can be prepared by condensing a hydrazine with an activated succinic acid, where X' is a leaving group, e.g. bromine, chlorine, or iodine, to provide the cyclized product . Groups of formula (i), (ii), or (iii) may be installed after cyclization, for example, by means of addition to an amino side chain substituent of R', or to imino nitrogen groups No. Other groups on the scaffold, eg R groups, can be installed before cycling. For example, R it may be a group of formula (i), (ii), or (iii) installed before cycling. R scheme.
[00651] [00651] Rº and R' are hydrogen in the precursor, and, in conjunction, are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, aryl optionally substituted, optionally substituted heteroaryl, a nitrogen protecting group when bonded to a nitrogen atom, an oxygen protecting group when bonded to an oxygen atom, and a sulfur protecting group when bonded to a sulfur atom, or a group of formula (i), (ii), or (iii).
[00652] [00652] "Schemes A-R show the general synthetic retinas for APPLs of formulas (1) to (VI) of the present invention. The application of these methods generated a variety of APPLs, represented in Tables 4 eos.
[00653] [00653] “Compounds were named by combining the abbreviation of amino acids, aldehydes (A), acrylates (O), amides (N), or epoxides (E), and the size of carbon chains. For example, K-E12 represents the reaction of lysine with 1,2-epoxidodecane. ec; CroHa x O. NA, HOR cont EL o es Ki L À a 1 1 Fr R ' sà , "o E, oh Domo craccamonnts, RU = HED RER
[00654] [00654] Synthesis of compound B. Compound A (487 mg, 1.02 mmol) was charged to a 10 ml flask and trifluoroacetic acid (TFA, 1.3 ml) was added dropwise at 0°C. The reaction mixture was warmed to room temperature and stirred for 30 min. The solvents were evaporated under reduced pressure and the TFA salts in DMF (3.5 ml) were added dropwise to pyridine (100 ml) at 0°C. The reaction mixture was slowly warmed to room temperature and stirred overnight. The solvents were evaporated under reduced pressure and the white solid was washed with EtOAc to give pure B in 69% yield. MS: m/z 525 (M+H*); * H NMR (500 MHz, DMSO, ppm): δ 1.29-1.40 (m, 8H, CH 2 .CH 2 ), 1.61-1.68 (m, 4H, CH), 2.97 ( dd, J = 6.0, 12.5 Hz, 4H, NCH₂), 3.79 (br, 2H, COCH), 7.22 (t, J = 5.5 Hz, 2H, aromatic), 7, 33-7.37 (m, 8H, aromatic), 8.10 (s, 2H, NH).
[00655] [00655] Synthesis of compound C. To a cloudy solution of compound B (95 mg, 0.18 mmol) in 50% acetic acid/CH2Cl2 (6 mL) was added Pd on charcoal (10% wt, 36, 5 mg). The black suspension was degassed for 5 min and hydrogen gas was introduced. The reaction mixture was stirred at RT overnight and was then filtered through a pad of celite, which was washed several times with MeOH. The combined filtrates were concentrated to obtain a viscous yellow oil, which was solidified by the addition of EtOAc. The solid was washed with ethyl acetate to yield compound C at 90% yield. MS: m/z 257 (M+H*); *H NMR (500 MHz, D 2 O, ppm): δ 1.39-1.52 (m, 4H, CH 2 ), 1.67-1.71 (m, 4H, CH), 1.84-1.88 (m, 4H, CH), 2.99 (t, J = 7.5 Hz, 4H, NCH), 4.14 (t, J = 5.0 Hz, 2H, COCH).
[00656] [00656] Synthesis of compound 23 (cCKK-E12). To a mixture of compound C (169.2 mg, 0.45 mmol) and 1,2-epoxidodecane (523 mg, 2.7 mmol) in EtOH was added triethylamine (182 mg, 1.8 mmol), which was stirred 30 min on rt. The reaction mixture was then irradiated in a microwave oven at 150°C for 5 hours. The mixture was purified by flash column chromatography to obtain compound 23 (in 52% yield) as a pale yellow oil. MS: m/z 993 (M+H*); *' H NMR (500 MHz, DMSO, ppm): 5 0.87 (t, J = 7.0 Hz, 12H, CH 3 ), 1.21-1.39 (m, 80H, CH), 1 .64-1.67 (m, 4H, CH), 2.25-2.44 (m, 12H, NCH₂), 3.44 (br, 4H, CHOH), 3.79 (br, 2H, COCH ), 4.21 (d, J = 3.0 Hz, 2H, CHOH), 4.27 (d, J = 3.0 Hz, 2H, CHOH), 8.11 (br, 2H, CONH). Example 3. Synthesis of compound D
[00657] [00657] It is considered that compound D can be synthesized by reacting 23 with Lawesson's reagent in dry toluene. A Le Nao Lu &% Voe Voe to os 2 p Example 4. Synthesis of compound E
[00658] [00658] It is considered that compound E can be synthesized by reacting 23 with hydroxylamine hydrochloride or other amines substituted in methanol.
[00659] [00659] APPL, distearoyl phosphatidylcholine (DSPC), cholesterol and mMPEG2000-DMG were solubilized in 90% ethanol at a molar ratio of 50:10:38.5:1.5. The siRNA (against firefly luciferase or fVII) was solubilized in 10 mM citrate, pH 3 buffer at a concentration of 0.4 mg/mL. The ethanolic lipid solution and the aqueous siRNA solution were pumped by means of a syringe pump through a microfluidic mixing chamber to spontaneously form lipid nanoparticles containing siRNA. Lipids were combined with siRNA into a total lipid to siRNA ratio of 7:1 (weight:weight). These formulations were dialyzed against PBS to remove ethanol and exchange buffer. Formulation B
[00660] [00660] APPLs were formulated with cholesterol (Sigma-Aldrich), DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine, Avanti), mPEG2000-DMG (synthesized by Alnylam), and siRNA via an microfluidic base mixture. See, for example, Chen, D., et al., Rapid Discovery of Potent siRNA-Containing Lipid Nanoparticles Enabled by Controlled Microfluidic Formulation. J Am Chem Soc. Formulations were then dialyzed against PBS in 3,500 MWCO dialysis cassettes (Pierce) overnight. Particles were characterized with a modified Ribogreen assay (Invitrogen) for SIRNA trapping and dynamic light scattering (ZetaPALS, Brookhaven Instruments) for mean particle diameter. cKK-E12 formulations were made from cholesterol, DSPC, and mMPEG2000-DMG using a similar method in a molar ratio of 50:10:38.5:1.5. This formulation provided a particle diameter of 60 to 70 nm with approximately 65% siRNA entrapment. Luciferase Gene Silencing /n Vitro
[00661] [00661] HeLa cells, stably expressing firefly luciferase and Renilla luciferase, were seeded (14,000 cells/well) into each well of an opaque white 96-well plate (Corning-Costar) and allowed to attach for the night in the midst of growth. The growth medium was composed of 90% phenol red free DMEM, 10% FBS, 100 units/ml penicillin, 100 mg/ml streptomycin (Invitrogen). Cells were transfected with LNPs formulated with anti-luciferase siRNA by the addition of formulated particles to growth medium. Transfections were performed in quadruplicate. Cells were allowed to grow for 1 day at 37.5% CO 2 and were then analyzed for luciferase expression. Control experiments were performed with Lipofectamine 2000 as described by the vendor (In-vitrogen). The expression of Firefly and Renilla luciferase was analyzed using Dual-Glo Assay Kits (Promega). Luminescence was measured using a Victor3 luminometer (Perkin Elmer). In Vivo Factor VII Gene Silence in Mice
[00662] [00662] “C57BL/6 mice (Charles River Labs) were used for siRNA silencing experiments. Prior to injection, formulations were diluted in PBS at siRNA concentrations (SEQ ID NO 1 (sense siFVII): 9-GGAucAucucAAGucuuAcT*T-3'; SEQ ID NO 2 (antisense): 5-GuUAAGAcuuGAGAUGAuUceT*T-3' ) so that each mouse was given a dose of 0.01 mL/g of body weight. The formulations were administered intravenously by injection into the tail vein. After 48 or 72 hours,
[00663] [00663] The mice mentioned above were systemically injected with Cy5,5-labeled sIiRNA formulated at a dose of 1 mg/kg of total siRNA. Mice were sacrificed 1 hour or 24 hours after injection; the pancreas, spleen, liver, kidneys, ovaries, uterus, heart, lungs, and thymus as well as a section of adipose tissue and muscle tissue were then removed and imaged. The organs were examined with a Caliper lvis imaging system, using an excitation wavelength of 675nm and an emission wavelength of 720nm. Data were processed using Caliper's Living Image software. The signal strength of the individual organs was normalized compared to the total signal strength of all the organs. In Vitro siRNA Transfection Assay and Microscopy.
[00664] [00664] Effects of apolipoproteins were evaluated using an in vitro siRNA transfection assay in HeLa cells as previously reported. HeLa cells, stably expressing firefly luciferase and Renilla luciferase were seeded in an off-white 96-well plate (Corning-Costar) overnight. Cells were transfected by cKK-E12 formulated with 50 ng of firefly-specific siLuc in quadruplicate. Apolipoproteins (Fitzgerald Industries) were incubated with cKK-E12 formulations for minutes before addition to cells. After 24 hours incubation at 37°C, 5% CO2 , cells were analyzed for luciferase expression using Dual-Glo assay kits (Promega). For visualization of cell uptake, cKK-E12 was formulated with an Alexa-Fluor 647-labeled siRNA and incubated with Hela cells for 3 hours. Cells were then fixed in 4% paraformaldehyde, permeabilized with 0.1% saponin and stained with Hoescht. All images were acquired using an Opera spinning disk confocal system (Perkin Elmer), and data were analyzed using Acapella Software (Perkin Elmer).
[00665] [00665] — Single amino acids were reacted with aldehydes, acrylates, and epoxides to produce APPLs. Recently synthesized single amino acid-based lipid derivatives were evaluated for their ability to silence liver genes in mice. A validated genetic target, Factor VII (a blood clotting factor), was selected as a silencing marker. See, for example, Akinc, A., et al., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol, 2008. 26(5): pp. 561-9. Novel lipid derivatives were formulated with cholesterol, DSPC, PEG-lipid, and siRNA through a microfluidic-based mixing technology. See, for example, Chen, D., et al., Rapid Discovery of Potent siRNA-Containing Lipid Nanoparticles Enabled by Controlled Microfluidic Formulation. J Am Chem Soc. Formulations that were unstable in solution and had no siRNA entrapment were not evaluated. Stable formulations were injected into mice by systemic administration at a dose of 1 mg/kg (Figure 1). From this initial assessment, we identified
[00666] [00666] The enhanced potency of K-E12 led to our design of a second group of lysine-based peptide and polypeptide-lipid derivatives. Lysine-based dipeptides were reacted with epoxides to provide diketopiperizine APPLs. Microwave irradiation was used to produce these scaffolds, which dramatically reduced reaction time from 3 days to 5 hours. Furthermore, to also confirm the chemical structure and improve the chemical availability for large-scale synthesis, an alternative synthetic routine was developed for the synthesis of cKK-E12 (Example 2). Diamine 5 was synthesized according to the previously reported method (Bergeron, RJ, et al., Macromolecular Self-Assembly of Diketopiperazine Tetrapeptides. J. Am. Chem. Soc., 1994. 116(19): pp. 8479-84; Kaur, N., et al., A Delineation of Diketopiperazine SelF-Assembly Processes: Understanding the Molecular Events Involved in N-(Fumaroil)diketopiperazine of L-Lys (FDKP) Interactions. Mol. Pharmaceutics, 2008 5(2): pp. 294-315), which was reacted with 1,2-epoxidodecane to provide CcKK-E12. Compound (C) underwent reductive amination or Michael addition reactions with dodecanal or dodecyl acrylate to produce cKK-A12 and cKK-012. Reactions between lysine-lysine and poly-L-lysine (molecular weight 500-70000 g/mol) and aldehydes and acrylates were similar to those of single amino acids.
[00667] [00667] The silencing effects were then evaluated. Ten of the 43 compounds showed around 50% silencing at a dose of 1 mg/kg. The success rate of the second group of compounds was 23%, which was over 10 times more efficient compared to the first group of materials. The results suggested that our iterative evaluation process is an efficient strategy to identify inducing compounds. Results from the second group also showed that epoxide derivatives were more potent than aldehyde and acrylate derivatives (such as cKK-E12 vs cKK-A12 & cKK-012). Hit materials were also tested at a lower dose of 0.1 mg/kg. Tail size significantly affects silencing and tail lengths of 12-14 carbons appeared favorable (cKK-E10, -E12, -E14, & -E16). cKK-E12 was the most potent material and was selected for further exploration. Biodistribution Study
[00668] [00668] A biodistribution study was performed with siRNA labeled by Cy5,5 nu and formulated cKK-E12. Subtracting the contribution of free SIRNA in the cKK-E12 formulation, more than 80% of particles were located in the liver within 1 hour and most residual siRNA was cleared within 24 hours via the kidneys (Figure 2). Effects of Apolipoproteins on Cell Uptake and Gene Silence
[00669] [00669] Previous studies reported that Apolipoprotein E (A-poE) was able to enhance cellular uptake and gene silencing for a certain type of materials. Akinc, A., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 18(7): p. 1357-64. In order to test the effects of various apoliproteins on cellular uptake and gene silencing, and to explore the mechanisms of action, experiments were performed with cKK-E12 and 11 isoforms of ApoA, ApoB, ApoC, ApoE, and ApoH. Results in Hela cells showed that most apolipoproteins did not affect cell viability, with the exception of ApoB. ApoA, ApoC, and ApoH showed no significant effects on silencing compared to cKK-E12 (Figure 3). However, four different ApoE isoforms significantly improved silence.
[00670] [00670] The activity of cCKK-E12, cKK-A12, and cKK-012 was compared with and without the addition of apoE3 (apoE3 is the dominant isoform in humans. Figure 4A). Without the addition of ApoE3, cKK-A12 was more potent than cKK-E12 and cKK-012. However, with the addition of ApoE3, the order of silencing effects was CKK-E12 > cKK-A12 > cKK-012, which correlated well with in vivo activity. The results suggested that a cellular assay with the addition of ApoE may be a practical and effective model for a preliminary assessment of liver hepatocyte silencing. In addition, cellular uptake of cKK-E12 formulated with an Alexa-Fluor 647-labeled siRNA was visualized using automated confocal microscopy (Figure 4B). Other Modalities
[00671] [00671] In the claims articles such as "a, an (a)," "a, an (an)," and "the, a" may mean one or more of one, unless stated to the contrary or otherwise evident way from the context. Claims or descriptions that include "or" between one or more members of a group are considered satisfied if one, more than one, or all members of the group are present at, employed in, or otherwise relevant to a particular product or process. , unless stated to the contrary, or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a particular product or process. The invention includes embodiments in which more than one, or all members of the group are present in, employed in, or otherwise relevant to a particular product or process.
[00672] [00672] Further, the invention encompasses all variations, combinations, and exchanges in which one or more limitations, elements, clauses, and descriptive terms of one or more of the listed claims is introduced in another claim. For example, any claim that is dependent on another claim may be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, for example in Markush group format, each subgroup of the elements is also described, and any element(s) can be removed from the group. It is to be understood that, in general, where the invention, or aspects of the invention, is/are said to comprise particular elements and/or aspects, certain embodiments of the invention or aspects of the invention consist, or essentially consist of, such elements and/or aspects. For the purposes of simplicity, those modalities are not specifically mentioned in haec verba here. It is also noted that the terms "comprising" and "containing" are intended to be open-ended and allow for the inclusion of additional elements or steps. Where fees are administered, purposes are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one skilled in the art, values that are expressed as ranges may assume any specific value or subrange within the ranges set forth in different embodiments of the invention, up to one-tenth of a unit from the lower limit of the range, unless the context clearly dictates otherwise.
[00673] [00673] This application refers to various issued patents, published patent applications, journal articles, books, manuals, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the built-in references and the present specification, the specification shall control. Furthermore, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such modalities are considered to be known to one skilled in the art, they may be excluded even if the exclusion is not explicitly mentioned here. Any particular embodiment of the invention may be excluded from any claim, for any reason, whether or not related to the existence of prior art.
[00674] [00674] Those skilled in the art will recognize or be able to verify the use of no more than routine experimentation of many equivalents for the specific modalities described herein. The scope of the present embodiments described herein is not intended to be limited by the above description, but preferably is as mentioned in the appended claims. Those skilled in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.

权利要求:
Claims (30)
[1]
1. Compound, characterized by the fact that it has the formula (III): “. Q: Q
N RU LR Dea a salt thereof; where: p is an integer between 1 and 9, inclusive; each case of Q is independently O, S, or NRº, where Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl , a nitrogen protecting group, or a group of formula (i), (ii), (iii); each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR“, - NR), -SR!. wherein each occurrence of R** is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, a nitrogen protecting group when bonded to a nitrogen atom, or two R** groups are joined to form a hetero- ring
Optionally substituted cyclic or optionally substituted heteroaryl; or at least one case of R* is a group of formula: 6 o Rº (iv) wherein L is an optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene , optionally substituted heteroalkynylene, optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, or optionally substituted heteroarylene, and R6 and R are each independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group or a group of formula (i), (ii) or (iii); each case of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of the formula (i), (ii), or (iii); and Formulas (i), (ii), and (iii) are:
RX L R. k P RR" From A GO () FP” (ii) in which:
each case of R' is independently hydrogen or optionally substituted alkyl; X is O, S, NR, wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; Yéo,S, NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; R° is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to a oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and R6 is optionally substituted C2-59 alkyl, optionally substituted C2-59 alkenyl, optionally substituted C2-59 alkynyl, optionally substituted heteroC1-5,5 alkyl, optionally substituted heteroC2-59 alkenyl, heteroC2-55 alkynyl optionally substituted, or a polymer; provided that at least one case of R°, R', R6, or R' is a group of formula (i), (ii), or (iii).
[2]
2. Compound according to claim 1, characterized by
from the fact that each case of Q is O, e.in which at least one case of D is H.
[3]
3. Compound according to claim 1, characterized in that the compound is selected from the group consisting of: o es in ; With ; the H Net Sento is 4 Es - Es ) XY o: and Ace Ho Ho and PR n 3 in CruaHos- Ho K 2: or . R O: Re ), and ), 53 o o À. They are acts; &1H; no p cs + en % at N pc R E E q A ” | . * | P > ES md . Tom E, H; “this,
ie YEAR
The & “E | The in & | It is not.
are ess
EO ES & MR in 4 are at ; SN ; ao so E " o Q " ms , oro , a " > FO ES AOS ms R& N Rd, mt A » “. ; em) ; Hio 1oHos
Ç Ç CoHio Chaos S, K 1 Re |), R ),
AN AN est), in):
( FP a R CuHos s CraHos » R | Re | en to and b > CuHas , ms , and salts thereof.
[4]
4. Compound according to claim 1, characterized in that the compound is selected from the group consisting of:
T <= From
WS Y " or MH P motor oH tdi <Q DN o o o " TD o Hs UA, Croar MW NO no as a !
And "SHE, Ex
AA a.
Y Has vos no A. essõ nm PD eme 1 a et. ' : 2Hos Qu no TA" CnaHa Tx NA & Po , Ra Crato " H Pá co aa & no , no , Quo Rr N." HOT no TA, TA Cahn TA x ÃOL HN, Ho , " , Q Que N." no TZ ro Tx TU Ts SMA .o õ ON e SI Catas, 1aHos Y* FT Catas cm & S
THIGH and BA o os Y o EAN AC A got o Cd ei Ceú ,
in N. rf or HN.
Õ q | X Catas, oH O
Í AA Pa NH nm HN o om o OE
N N CH routes, cKG-E12 cKT-E12 oH ; oh oh oh
HN Ho HN Õ o o Po
N N Cyo Stump OYK-E12 and LK-E12 OH; oH ; the o o
s
NAAS TO NA
O HN HN o Prun or em
N N CaoHor CioHo cDK-E12 eMK-E12 OH , OH ,
[and]
THE
HN HN. o from 9 o'clock
N N CioHa, CroHa, cKV-E12 cAK-F12 OH; OH; o 8H o HN o Sa"
HN HN o E o Pot
N N Neither Net cCK-E12 coK-E12 OH , oH , o o
CO NH
N HN o om o Po
N N Cio Cota cPK-E12 cFK-E12 OH , OH , o o o Qy xr ANO NH S is an HN. 8 o'clock heat or o
DAN N Nes Nos cWK-EI2 cEK-E12 OH; OH;
the 1 ss Ho NH Au Y HN. the oc the OS . N Neat Naa cIK-E12 cSK-E12 OH; oH ; and salts thereof.
[5]
5. Compound according to claim 4, characterized in that the compound is: . "EEN
NS co E is or salt thereof.
[6]
6. Compound, characterized by the fact that it presents the formula (1): Ro Í id Í Rº RN A 1
R R' (1) or salt thereof; where: n is 0 or is an integer between 1 and 100,000, inclusive; each case of m is independently 1, 2, or 3; each case of Z is independently O, S, or NRZ, where R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i) , (ii), or
(iii); each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR, -N (R*)>, or -SR*!. wherein each occurrence of R* is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a protecting group of oxygen when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, a nitrogen protecting group when bonded to a nitrogen atom, or two R** groups are joined to form a optionally substituted heterocyclic ring or optionally substituted heteroaryl; or at least one case of R' is a group of formula: Rô
AN R° (iv) wherein L is an optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene or optionally substituted heteroarylene; R° and R' are independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, he-
optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group or a group of formula (i), (ii) or (iii), provided that at least one case of R° and R' is a group of formula (i), (ii) or (iii);
R is a group of formula (i), (ii), or (iii);
R° is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii);
or R' and an R' group are joined to form an optionally substituted 5- to 6-membered heterocyclic ring;
Rº is -OR*, -N(R*), or -SR*. wherein each occurrence of R* is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a group of oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, a nitrogen protecting group when attached to a nitrogen atom, or two R*º groups are united. - formed to form an optionally substituted heterocyclic ring or optionally substituted heteroaryl;
R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; and
Formulas (i), (ii), and (iii) are:
R! RR ' or / () (ii) (iii)
on what:
each case of R' is independently hydrogen or optionally substituted alkyl;
X is O, S, NR, wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
Yéo,S, NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
R° is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to a oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and
R| is optionally substituted C1-59 alkyl, optionally substituted C1-59 alkenyl, optionally substituted C1-59 alkynyl, optionally substituted heteroC2-59 alkyl, optionally substituted heteroC2-55 alkenyl, optionally substituted heteroC2-59 alkynyl
da, or a polymer.
[7]
7. Compound according to claim 6, characterized by the fact that it has the formula: e R2—N Rº m R , where n is O; and R2—N N Rº m m Rº Rº , where n is 1; i Z ” Z ij Z R2—N N N Rº m m m R R R , where n is 2; mg Rg Rm z mw z PA da m m m R R R R , where n is 3; or og Rm gg Rm zo Rm z Rm z R2—N k AA LA ( a o m m m m m R R R R R , where n is 4 or salt thereof.
[8]
8. Compound according to claim 6, characterized by the fact that each case of Z is 0, each case of m is 1, and each case of R$ is hydrogen.
[9]
9. Compound according to claim 6, characterized by the fact that R is a group of formula (i), (ii), or (iii), and R° is hydrogen; or in what R and Rº are the same group selected from the group consisting of formulas (i), (ii) and (ii).
[10]
10. Compound according to claim 6, characterized in that the compound is selected from the group consisting of:
oH es o N. HOT « Te Ç or NH OH: ote: YEAR eo o
oh
N a Ne Ho TA Nor Ca Cora, Coto ; oH H co H CroHor o no Tr" ORº N 1021 .s in TX, or
No
HOT ORM OH CroHas ; HoSo Quotas, in
N ro TX, ORM OH H && in the CioHoí no. N A N Y HOT ORM oRM Crotas CroHas , ' ,
OH H es E Co À N. e. mo Te" ORM ro Tx, logs Cronos À 9 10Hos motos HOT! o Cro or , OH , ,
H A C, o H or” and o mo TA" ORA: Cio: N, 1oHos Ho Tn ORM OH O 1oHar oÊÉN = NON O DI Ne N=e/ Quoting, HO CioHos, Cortar =,
OH OH es o est o oH
N N
CH ro Tx, 'oRº Tx, Rº es o Ho TN or $S CioHas , D , ,
CuHos exnmaá ou En ct ess o su a : CH N. Ca : ro Tx, ORº o Cro aà et A — CuHas, Guta Croriar à e. fem a a o »* er en in the DX de.
H H Boc” OEt Boo oo oH
H AE nd CuoHar Dor Cro ; Ho, E o bel Sos cn o
O R is Cro; < oz CH ON H Geo x» Ao ” N. Cro es es dos, ea, qd oo cs ! 4 4 ' o 2 Cx Choirs NS echoes Ss. with Ho E x o ; The ,
est o DO oH PH CroHor Ms CiaoHos o Ql À N Aul | À “os CA A oH A, A oa es Ares CioHo ot OH sH
FS VS, AE2 cER
OH oH PR CH CioH: 10121 o o o o! < the o
N N Pa " oH A OH Coto, CioHar Crotor or oH EEt2 oH DEI2 OH nor So ; F-E12 ; oH
H oH cos o o o o with N o N oH A ema coma A or “Pr or Cotar oH N=e/ Neta, GEZ HEIZ Ho ; -E12 ; or oH CroHor OH CioHor Ss o o N CioH: OH N. CH oH oH CroHar CioHor OH HN. H NE12 dk S.LE2; MEI2Z DO, HOT YSCioHa,, oH PH with Ho CioHor o N ” A oH CioHos o N or Tor x Ho N. CroHos CioHas REI2 Sor PEIZ qe É No Coto, ;
OoH CioH Pp 10H24 oH ACE o oo esto o N o . Ps OH N Ps oH CSiob H coma % co; oH Hr or or Ss-E12; T-E2; vEI2;
oh oh
PH HAN CroHor OH o oH N CoHor Co A OH i o K-E12 10527 N oH 7 oH HO. NH es v on WS All Ww-EIZ ; veI2 OH CroHos , Ci1Hos CuH or CH ad o 7 x o
N OH N CÃO ol Cos C1iHos vos sH C11Hoa o AAt2o o, cA2 D-AI2 OH Ts o
CH N 7 IS OH N nos o c [f OH C 1 Hog dd Has oH E-M 2 and Ç 11 Hos Ho" So , F-A12 ; GAR, Fis o and the Prism
N N IS oH IS OH r n oH CH. 1 PAN Ca1Has Chaos N=a/H-A12; 1A12; L-A12;
fis o CH: 11 * o N N oH IS OH Was f Cr 1H O N CxiHaz oH Ss NH, MAI2 > O, N-A12 ; PAIZ E tas o CiiHoa N E D oH ” E oH N e Cr1Hos No E OH 113 A Cc.HA 11H23 NINTH en " o-nt2 NO R-A12 ; S-A12 ; C11Has, Ci1Haa Ci1Haz D o va Mao Ad NN IS oH IS OH IS oH C11Hoz Au CylHoz OH C11Haz T-A12 ; V-A12 ; W-A12 ; CS12Has CH.l1.o is op
N ts o c Ç Y IN i 1193
N mA a K-A12 CiiHas OH is en As YAt2 OH Cut ao , Praias Cias OO Graros Ô fe)
N OH HN VS OH o OH o. Í SH OH E-012 Color, D-O12 , Ho So ;
CH SS o GraHas Grabos Graas Oo Oo o o N o o
HN N o HN OH a oH oH H o. P O NES " Fo12 ; com — CH nor ; rot2 ; CioH: Gras 12 Pias O O o. o Oo o HN. HN,
HN OH OH oH or S. NH. Loi2 ; Mo2 > o, No12 À, Grahos GFaaros OO CaaHos Poç “ o 9 HAN 9 OH o HN or vw o
N Color A A and nt
H HE Ppoiz, chorus No, R-o12; CiaH Caos CiaHos 1122 lia Oo O o de o NS , CÚ . :
HN HN HN O x oH oH H so12 ; T-012; v.o12;
CiaHos Tratos o Oo come GL, mm 9 o Cc, XY H HN o
OH NH FZ A, o O w-o12 ; voi2 oH Yet and salts thereof.
[11]
11. Compound, characterized by the fact that it has the formula (II): Ww
FROG
Y
R and R (11) or salt thereof; wherein: each case of R' is independently hydrogen or optionally substituted alkyl; each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR“, - NR), or -SR*. wherein each occurrence of R** is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a protecting group of oxygen when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, a nitrogen protecting group when bonded to a nitrogen atom, or two R** groups are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring; or R' is a group of formula: Rô
AN R' (iv) wherein L is an optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted carbocyclylene, optionally substituted heterocyclylene , optionally substituted arylene or optionally substituted heteroarylene; R° and R' are independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group or a group of formula (i), (ii) or (ili), provided that at least one case of R° and R' is a group of formula (i), (ii) or (iii); W is oO, S, or NR", wherein R" * hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii); each case of Y is independently O, S, or NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, aryl-
optionally substituted la, optionally substituted heteroaryl, or a nitrogen protecting group;
R' and R' are joined to form an optionally substituted 5-6 membered heterocyclic ring; or
Rº is hydrogen, a group of formula (i), (ii), or (iii), or a group of formula (v):
The
R2—N Tv” Re o (v)
on what:
n is 0 or is an integer between 1 and 100,000, inclusive;
each case of m is independently 1, 2, or 3;
each case of Z is independently O, S, or NR , where R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i) , (ii), or (ii);
R is a group of formula (i), (ii), or (iii);
R is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (1), (ii), or (iii);
or R6 and an R1 group are joined to form an optionally substituted 5- to 6-membered heterocyclic ring;
R$ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, car-
optionally substituted bocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
Formulas (i), (ii), and (iii) are:
at the . R Rº- RO From SS R R or (i) (ii) (iii)
on what:
each case of R' is independently hydrogen or optionally substituted alkyl;
X is oO, S, NR, where R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
Yéo,S, NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
R° is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to a oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and
R!| optionally substituted C 1-505 alkyl, optionally substituted C 2-55 alkenyl, optionally substituted C 2-59 alkynyl, optionally substituted heteroC 55 alkyl, optionally substituted heteroC 2-55 alkenyl, optionally substituted heteroC 2-55 alkynyl, or a polymer.
[12]
12. Compound according to claim 11, characterized by the fact that W is O and Y is O.
[13]
13. Compound according to claim 11, characterized by the fact that the compound has the formula:
TR e A, o ag (1b), o o no [SÍNA RE ns " ” q
R o (Il-c), o
of the
NDA Rº (11-d), the
OF
TO RUX. N. Re VT” (Il-e), or the Ri o RR —N NE À (111), or salt thereof.
[14]
14. Compound according to claim 11, characterized in that the compound is selected from the group consisting of:
Crete CroHas C CroHas no À HP H EX a Crotai Su NH NA Car Ta NH NA AJ Sa. Ao A NA "Ss HOT 'CioHos ota CroHas ooo NA mo HOT Cro, CroHas and HOOC routes. Ho o oHor N. Ho TA e, DA Ho CroHor Too, oa Fo os o CioHa o Eta A, NA Da Ho TA Coto CroHos CroHos
OH o o ID, Bu SA NA, in Tx, 10H2s in Tx, oo: o o Ps CO
NA HN HOT CioH: A H. NC CioHos 1021 1021 CaoHao fe] o o o
NA BN Ho TT Quotas Crotias 107
CioHa, rocoo The HooC UV, O. MU. Ho TA Ho TA H: CroHor CroHas CioHos 10H21
H CroHar o Ho o
Ô NA HOT CioHas q Crotla Ho TA CaoHar CroHos HO. CroH2, E TA à o à o o o N. N. HoTA Ae o, HOT Ao oo, Cut CroHas os H oH H
AA XN CroH2i CA CroHaí Ts ERA. N. HoTA Cut Croter ro Ta, Cronos Quota, or Quota, om Ç Cú N o N o Ho, n oH Ho Tx votes co ota CroHas POSI mo Ciotos 1oHas 1oHos
Í Í fe] o o
NA BN Ho TA CioHas CioHa 1021 o o As As ro PAA, a, mM, CioHa OH Coto and PS N. N. stamp Q stamp o o o to Doi NA eos
P Ce: And Salts thereof.
[15]
15. Compound, characterized by the fact that it has the formula (IV), (V), or (VI):
R R RA RR Q
N N N = RA x fo
N N Rº Q R Ao Q R (IV) (V) (VI) or salt thereof; wherein: each case of Q is independently O, S, or NRº, wherein Rº is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), (iii); each case of R' is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, al-
optionally substituted quinyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -OR, -N(R*)>, or -SR*!. wherein each occurrence of R* is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a protecting group of oxygen when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, a nitrogen protecting group when bonded to a nitrogen atom, or two R** groups are joined to form a optionally substituted heterocyclic ring or optionally substituted heteroaryl; or R' is independently a group of formula: Rô
AN R' (iv) wherein L is an optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, optionally substituted carbocyclylene, optionally substituted heterocyclylene , optionally substituted arylene or optionally substituted heteroarylene; and R° and R' are independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii) or (ili), provided that at least one case of R° and R' is a group of formula (i), (ii) or (iii); each case of R is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or a group of formula (i), (ii), or (iii); and Formulas (i), (ii), and (iii) are:
RR A L R ! dou / () (ii) (iii) wherein: each case of R' is independently hydrogen or optionally substituted alkyl; X is O, S, NR, wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; Yéo,S, NR", wherein R* is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group; R° is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl
tited, an oxygen protecting group when bonded to an oxygen atom, a sulfur protecting group when bonded to a sulfur atom, or a nitrogen protecting group when bonded to a nitrogen atom; and R1 is optionally substituted C1-50 alkyl, optionally substituted C7-505 alkenyl, optionally substituted C2-55 alkynyl, optionally substituted heteroC1-50 alkynyl, optionally substituted heteroC1-55 alkenyl, optionally substituted heteroC1-5 alkynyl la, or a polymer; provided that at least one case of R°, R'°, R°, or R' is a group of formula (i), (ii), or (iii).
[16]
A compound according to any one of claims 1, 2, 6-9, 11-13 and 15, characterized in that Rº is optionally substituted Cg.5o alkyl, optionally substituted Cg.5o alkenyl, Ce .50 optionally substituted alkynyl, optionally substituted C1-50 heteroalkyl, optionally substituted C8-50 heteroalkenyl, optionally substituted C8-50 heteroalkynyl or a polymer.
[17]
17. Compound according to any one of claims 1, 6, 11 and 15, characterized in that R' is a group of formula
Á à where q is an integer between 1 and 50, inclusive.
[18]
18. Composition, characterized in that it comprises a compound as defined in any one of claims 1 to 17, or a salt thereof and an excipient.
[19]
19. Composition according to claim 18, characterized in that the composition is a pharmaceutical composition, a cosmetic composition, a nutraceutical composition, or a composition with non-medical application.
[20]
20. Composition according to claim 18, characterized in that the composition also comprises cholesterol, PEGylated lipid, a phospholipid or an apolipoprotein.
[21]
21. Composition according to claim 18, characterized in that the composition also comprises an agent, wherein the agent is an organic molecule, an inorganic molecule, nucleic acid, protein, peptide, polynucleotide, targeting agent, an isotopically labeled chemical compound, vaccine, an immunological agent, or an agent useful in bioprocessing.
[22]
22. Composition according to claim 21, characterized by the fact that the agent is a polynucleotide, and the polynucleotide is DNA or RNA.
[23]
23. Composition according to claim 22, characterized by the fact that the RNA is RNA/, dsRNA, siRNA, shRNA, miRNA, or antisense RNA.
[24]
24. Composition according to claim 22, characterized by the fact that the polynucleotide encodes a protein or peptide.
[25]
25. Method of evaluating a compound library, characterized in that it comprises: providing a plurality of different compounds as defined in any one of claims 1 to 17, or salts thereof; and performing at least one assay with the compound library to determine the presence or absence of a desired property; where the desired property is water solubility, solubility at different pH, ability to bind polynucleotides, ability to bind heparin, ability to bind small molecules, ability to bind if to protein, ability to form microparticles, ability to increase transfection efficiency, ability to support cell growth, ability to support cell attachment, ability to support tissue growth, and/or intracellular release of the compound and/or or an agent complexed or linked thereto to aid in bioprocessing.
[26]
26. Use of a compound as defined in any one of claims 1 to 17, or a salt thereof or use of a composition as defined in any one of claims 18 to 24, characterized in that it is in the preparation of a medicament to treat a disease, disorder or condition that an individual suffers from.
[27]
27. Use according to claim 26, characterized in that the disease, disorder, or condition is selected from the group consisting of proliferative disorders, inflammatory disorders, autoimmune disorders, painful conditions, liver diseases, and amyloid neuropathies relatives.
[28]
28. Use of a composition as defined in any one of claims 18 to 24, characterized in that it is for delivery of polynucleotide to a cell.
[29]
29. Use according to claim 28, characterized in that the polynucleotide is DNA or RNA, or in which the polynucleotide is RNA and in the release of the RNA into the cell, the RNA is capable of interfering with the expression of a specific gene in the cell, or where the polynucleotide encodes a protein or peptide
[30]
30. Invention, characterized by the fact that it is in any form of its embodiments or in any applicable category of claim, for example, of product or process or use encompassed by the matter initially described, disclosed or illustrated in the application for patent.
2 Go esmas Cl IOIDE ê z sms 2 LD = s. that O ET Read) o To ARENA Di ZL3DOSXA 8 2nd prncen tiemeneeeeeA 7 LIONE 8 sã some 2 FIGHT S E 1a E LNOOEDIO | E ss seems O L oO É a E Tem e br STADIO | 2 Ô qm UCL LISDAO Í 8 ss scene OL SADO ! & AND& ! = E 8 those 2 É 2 1 MO Z 5 1 Seen T LITOMVO o rms 7 CLEAN > this SS 7 LO DIO ss 1 ssssscssssvvéfl 2 & 21-S41AIO S nap 2 Lo-MIO 2 SS— CEA Ss 1 p—s c- oiCio - NS eee o LIDAS : PP = SERASA ESTsree CHOX Pia oO és So t—— p— 2 LOGOS ad [TM ; o ssa 2 Lo ADA A Í Z 7 a O LIA Í s Z ELVIS ! <Z É ET ITHDO i o EC LIDOPDIS Í E ACLiANIAS a ZLAHDSO : CLEO : E fuera aeee 2 | 1 : E x PSBRSSSSONSSRSNISNSSASAECRALAE YES 8 Ss step 2 OA : 4X - x ps 2 LT i s + 1st taste 7 1 Nfi os ses ES 2 LOCO | P SUPPER | + —m—m—p—D——S IOIIILOO | o o o o o : hey o. - the OANEJa! |AA BUjSJo1d Sp [JN am % Po fot &, ÉS 9 8 À EN 11 z % S 8 .O : MN A “o, SS : > . a ss ENS O o, %ç SS &, & 8 ê $ AIN FE ap jaal 8 Es Docs, = enpuo ! engejo: % a IS “SO
NA & F E “e, o do z 12%) | and heaven . Ss — SNS % ” E qn If do, Ss E | SNS Bs E | SN &% E VW | and. NR | 4 if | “o ss “& É : ê É = SAIN a x = ê JOnI4 Sp | ) 8 Elougose. z EANEJOU E!
the Yeah! = ! "AND AR cr + e LL F AML i | TD) ! Bu o o E A) | QN e
=|&
AND SAN Bar
Px PMNNNO | : RE mm ! es ET e ra
—an O o O Tan O ve -—o7 ooo ! BAIJE|S1 asBJa9N| ap JaNIN : | i
| | | | o So Ro Ro 2 << < RE RO o 5 E eso Ra
AE EEE EL ud O) ESSA RIOS
FS ARROW º o 2 sº z sa s SEA fly 6 8 3 o ZA | << EANES Joselajon| ap OBSSaldxa mm ESA i
Í i | |
I

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2017265103B2|2019-11-28|Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof

---

US10933139B2|2021-03-02|Conjugated lipomers and uses thereof

---

US9872911B2|2018-01-23|Alpha-aminoamidine polymers and uses thereof

---

NZ719941B2|2018-02-27|Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres

---

NZ733610B2|2020-03-03|Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres

同族专利:

---

公开号 | 公开日

---

SG11201401885TA|2014-09-26|

---

US20190076462A1|2019-03-14|

---

BR112014010050A8|2017-06-20|

---

IL268756D0|2019-10-31|

---

AU2012328570A1|2014-05-22|

---

US10682374B2|2020-06-16|

---

AU2020201387B2|2021-07-29|

---

CA2853522C|2021-07-13|

---

IL259414A|2019-09-26|

---

NZ733610A|2019-11-29|

---

MX363734B|2019-03-29|

---

PE20181541A1|2018-09-26|

---

CA2853522A1|2013-05-02|

---

AU2012328570B2|2017-08-31|

---

JP2017222642A|2017-12-21|

---

JP6973805B2|2021-12-01|

---

EA201490847A1|2014-12-30|

---

MX2014005072A|2014-07-28|

---

CN113149869A|2021-07-23|

---

US10086013B2|2018-10-02|

---

IL232158A|2017-02-28|

---

JP6522690B2|2019-05-29|

---

US20130158021A1|2013-06-20|

---

NZ719941A|2017-11-24|

---

NZ747501A|2020-05-29|

---

IL259414D0|2018-07-31|

---

JP6151707B2|2017-06-21|

---

PE20150041A1|2015-01-28|

---

KR102272498B1|2021-07-06|

---

AU2017265103B2|2019-11-28|

---

JP2021181463A|2021-11-25|

---

JP2014534220A|2014-12-18|

---

WO2013063468A8|2014-03-06|

---

AU2017265103A1|2017-12-14|

---

EA201891809A1|2019-05-31|

---

US20180036333A9|2018-02-08|

---

CA3119789A1|2013-05-02|

---

US20170165290A1|2017-06-15|

---

US20200330501A1|2020-10-22|

---

US9512073B2|2016-12-06|

---

IL250740D0|2017-04-30|

---

AU2020201387A1|2020-03-12|

---

CN104136419B|2017-11-03|

---

HK1201525A1|2015-09-04|

---

JP2019182867A|2019-10-24|

---

KR20210082570A|2021-07-05|

---

CN107522664B|2021-03-16|

---

CN104136419A|2014-11-05|

---

UA119028C2|2019-04-25|

---

CL2014001070A1|2014-11-21|

---

ZA201802716B|2020-08-26|

---

KR20150000461A|2015-01-02|

---

AU2021257964A1|2021-11-25|

---

IL268756A|2020-08-31|

---

CN107522664A|2017-12-29|

---

WO2013063468A1|2013-05-02|

---

IL232158D0|2014-05-28|

---

EP2771319A1|2014-09-03|

---

KR20200037431A|2020-04-08|

---

NZ624223A|2016-06-24|

---

EA032088B1|2019-04-30|

---

IL250740A|2018-06-28|

---

EP2771319B1|2022-03-02|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US2844629A|1956-04-25|1958-07-22|American Home Prod|Fatty acid amides and derivatives thereof|

---

US3127372A|1960-10-05|1964-03-31|Stabilization of polyolefevs |

---

DE1155118B|1961-12-30|1963-10-03|Basf Ag|Process for the preparation of sulfonamides substituted on the nitrogen atom|

---

DE1191629B|1962-03-16|1965-04-22|Basf Ag|Fungicides|

---

BE642774A|1963-04-02|1964-07-22|

---

US3542581A|1968-11-05|1970-11-24|Eastman Kodak Co|Method of de-aggregating oxonol dye-containing gelatin layers|

---

GB1361627A|1970-08-04|1974-07-30|Marumo H|Detergent composition|

---

US4258061A|1970-08-07|1981-03-24|Pfizer Inc.|Interferon induction in animals by amines|

---

US4022833A|1973-02-14|1977-05-10|Sterling Drug Inc.|N,N'-bridged-bis[2-alkyl-2-hydroxyethylamines]|

---

JPS5120639B1|1971-05-10|1976-06-26|

---

JPS515430B1|1971-05-10|1976-02-19|

---

JPS49127908A|1973-04-20|1974-12-07|

---

JPS5123537A|1974-04-26|1976-02-25|Adeka Argus Chemical Co Ltd| Kasozaisoseibutsu |

---

JPS5813576B2|1974-12-27|1983-03-14|Adeka Argus Chemical Co Ltd|

---

DE2520814A1|1975-05-09|1976-11-18|Bayer Ag|Light stabilisation of polyurethanes - using polymeric tert. amines from aliphatic diamines and acrylic esters or amides|

---

JPS5514113B2|1975-12-30|1980-04-14|

---

US4265745A|1977-05-25|1981-05-05|Teijin Limited|Permselective membrane|

---

US4308085A|1980-07-28|1981-12-29|Jenoptik Jena Gmbh|Process for the preparation of high molecular thermoplastic epoxide-amine-polyadducts|

---

JPS6129632B2|1980-10-27|1986-07-08|Nippon Paint Co Ltd|

---

DE3143726C2|1981-11-04|1987-02-05|Degussa Ag, 6000 Frankfurt, De|

---

US4897355A|1985-01-07|1990-01-30|Syntex Inc.|N[ω,-dialkyloxy]- and N-[ω,-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor|

---

US4762915A|1985-01-18|1988-08-09|Liposome Technology, Inc.|Protein-liposome conjugates|

---

CA1320724C|1985-07-19|1993-07-27|Koichi Kanehira|Terpene amino alcohols and medicinal uses thereof|

---

AT77806T|1985-08-05|1992-07-15|Miyoshi Yushi Kk|METHOD FOR DEPOSITING METALS.|

---

DE3616824A1|1986-05-17|1987-11-19|Schering Ag|USE OF CURABLE RESIN MIXTURES FOR SURFACE COATINGS AND PRINTING INKS AND METHOD FOR THE PRODUCTION THEREOF|

---

JPH07115545B2|1986-08-05|1995-12-13|株式会社リコー|Reversible thermosensitive recording material|

---

US4873370A|1987-03-03|1989-10-10|Pennzoil Products Company|Alkylene diamines for use in friction and wear reducing compositions|

---

US4782105A|1987-04-10|1988-11-01|Ciba-Geigy Corporation|Long chain N,N,-dialkylhydroxylamines and stabilized compositions|

---

JPH0832856B2|1987-05-15|1996-03-29|日本ペイント株式会社|Paint composition|

---

JPH07116064B2|1987-07-21|1995-12-13|三菱化学株式会社|Separation agent|

---

ZA899436B|1988-12-12|1990-08-29|Ciba Geigy|Piperidine derivatives|

---

FR2645866B1|1989-04-17|1991-07-05|Centre Nat Rech Scient|NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE|

---

JPH04225954A|1990-05-02|1992-08-14|Yoshitomi Pharmaceut Ind Ltd|Amide compound, its pharmaceutical use and new 1-substituted pyrrolidinemethylamines|

---

JPH04364112A|1991-06-11|1992-12-16|Mitsubishi Petrochem Co Ltd|Aqueous liquid detergent composition|

---

JP2684276B2|1991-11-27|1997-12-03|富士写真フイルム株式会社|Silver halide color photographic materials|

---

US5352461A|1992-03-11|1994-10-04|Pharmaceutical Discovery Corporation|Self assembling diketopiperazine drug delivery system|

---

DE4218744C2|1992-06-04|1997-11-06|Schering Ag|Process for the preparation of N-β-hydroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecane and N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane derivatives and their metal complexes|

---

US5334761A|1992-08-28|1994-08-02|Life Technologies, Inc.|Cationic lipids|

---

US5380778A|1992-09-30|1995-01-10|Minnesota Mining And Manufacturing Company|Fluorochemical aminoalcohols|

---

JPH06211978A|1992-10-28|1994-08-02|Takeda Chem Ind Ltd|New polyether polyol and production of polyurethane foam therefrom|

---

AT187713T|1993-02-19|2000-01-15|Nippon Shinyaku Co Ltd|GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION|

---

FR2707289B1|1993-07-06|1995-08-11|Chemoxal Sa|Process for the preparation of a hydroxylated compound of secondary or tertiary amine.|

---

CA2176714A1|1993-11-24|1995-06-01|Timothy D. Heath|Amphiphilic derivatives of piperazine|

---

US5464924A|1994-01-07|1995-11-07|The Dow Chemical Company|Flexible poly for barrier packaging|

---

FR2714830B1|1994-01-10|1996-03-22|Rhone Poulenc Rorer Sa|Composition containing nucleic acids, preparation and uses.|

---

US5624976A|1994-03-25|1997-04-29|Dentsply Gmbh|Dental filling composition and method|

---

US5693338A|1994-09-29|1997-12-02|Emisphere Technologies, Inc.|Diketopiperazine-based delivery systems|

---

US6331318B1|1994-09-30|2001-12-18|Emisphere Technologies Inc.|Carbon-substituted diketopiperazine delivery systems|

---

US5885613A|1994-09-30|1999-03-23|The University Of British Columbia|Bilayer stabilizing components and their use in forming programmable fusogenic liposomes|

---

GB9524630D0|1994-12-24|1996-01-31|Zeneca Ltd|Chemical compounds|

---

FR2730637B1|1995-02-17|1997-03-28|Rhone Poulenc Rorer Sa|PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF|

---

US5830430A|1995-02-21|1998-11-03|Imarx Pharmaceutical Corp.|Cationic lipids and the use thereof|

---

US6428771B1|1995-05-15|2002-08-06|Pharmaceutical Discovery Corporation|Method for drug delivery to the pulmonary system|

---

US5679852A|1995-06-02|1997-10-21|Schering Aktiengesellschaft|Process for the production of DTPA-monoamides of the central carboxylic acid and their use as pharmaceutical agents|

---

JPH0913066A|1995-06-26|1997-01-14|Kao Corp|Lubricating oil additive for diesel engine and lubricating oil composition|

---

US5728844A|1995-08-29|1998-03-17|Celgene Corporation|Immunotherapeutic agents|

---

JPH0995691A|1995-09-28|1997-04-08|Sony Corp|Lubricant and magnetic recording medium using the same|

---

FR2741066B1|1995-11-14|1997-12-12|Rhone Poulenc Rorer Sa|NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS|

---

US6344436B1|1996-01-08|2002-02-05|Baylor College Of Medicine|Lipophilic peptides for macromolecule delivery|

---

NL1003008C2|1996-05-03|1997-11-06|Dsm Nv|Cyclopentadiene compound substituted with a heteroatom-containing group.|

---

TW520297B|1996-10-11|2003-02-11|Sequus Pharm Inc|Fusogenic liposome composition and method|

---

JPH10197978A|1997-01-09|1998-07-31|Mitsubishi Paper Mills Ltd|Silver halide photographic sensitive material|

---

AU7173698A|1997-05-02|1998-11-27|Baylor College Of Medicine|Lipophilic and/or lytic peptides for specific delivery of nucleic acids to ce lls|

---

JPH115786A|1997-06-13|1999-01-12|Pola Chem Ind Inc|Novel aminohydroxypropylpiperazine derivative|

---

JPH11241095A|1997-08-04|1999-09-07|Ajinomoto Co Inc|Hair cosmetic composition|

---

JPH11106329A|1997-08-04|1999-04-20|Ajinomoto Co Inc|Cosmetic composition|

---

JPH1180142A|1997-09-05|1999-03-26|Pola Chem Ind Inc|Production of diphenylalkyl compound|

---

WO1999015129A2|1997-09-23|1999-04-01|Bristol-Myers Squibb Company|SELECTIVE cPLA2 INHIBITORS|

---

FR2774092B1|1998-01-26|2000-02-18|Air Liquide|PROCESS FOR THE PREPARATION OF GRAFT POLYAZACYCLOALCANES ON SILICA GEL AND USE OF THE GRAFT COMPOUNDS|

---

DE19822602A1|1998-05-20|1999-11-25|Goldschmidt Ag Th|Process for the preparation of polyamino acid esters by esterification of acidic polyamino acids or transesterification of polyamino acid esters|

---

DE19911509A1|1999-03-15|2000-09-21|Boehringer Ingelheim Pharma|Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation|

---

US6696424B1|1999-05-28|2004-02-24|Vical Incorporated|Cytofectin dimers and methods of use thereof|

---

PT1808438E|1999-06-29|2015-01-14|Mannkind Corp|Purification and stabilization of peptide and proteins in pharmaceutical agents|

---

DE19937721A1|1999-08-10|2001-02-15|Max Planck Gesellschaft|New diketopiperazines|

---

AU3366901A|1999-12-30|2001-07-16|Novartis Ag|Novel colloid synthetic vectors for gene therapy|

---

IL138474D0|2000-09-14|2001-10-31|Epox Ltd|Highly branched water-soluble polyamine oligomers, process for their preparation and applications thereof|

---

USRE43612E1|2000-10-10|2012-08-28|Massachusetts Institute Of Technology|Biodegradable poly and uses thereof|

---

US6998115B2|2000-10-10|2006-02-14|Massachusetts Institute Of Technology|Biodegradable poly and uses thereof|

---

US7427394B2|2000-10-10|2008-09-23|Massachusetts Institute Of Technology|Biodegradable poly and uses thereof|

---

US7776315B2|2000-10-31|2010-08-17|Boehringer Ingelheim Pharma Gmbh & Co. Kg|Pharmaceutical compositions based on anticholinergics and additional active ingredients|

---

US6656977B2|2001-07-20|2003-12-02|Air Products And Chemical, Inc.|Alkyl glycidyl ether-capped polyamine foam control agents|

---

US7601367B2|2002-05-28|2009-10-13|Mirus Bio Llc|Compositions and processes using siRNA, amphipathic compounds and polycations|

---

WO2003024401A2|2001-09-18|2003-03-27|Bristol-Myers Squibb Company|Piperizinones as modulators of chemokine receptor activity|

---

EP2428571B1|2001-09-28|2018-07-18|Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.|MicroRNA molecules|

---

DE10207178A1|2002-02-19|2003-09-04|Novosom Ag|Components for the production of amphoteric liposomes|

---

US20030215395A1|2002-05-14|2003-11-20|Lei Yu|Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier|

---

CN100457804C|2002-11-04|2009-02-04|Ge拜尔硅股份有限公司|Linear polyamino and/or polyammonium polysiloxane copolymers I|

---

JP2006515574A|2002-11-22|2006-06-01|ノボ・ノルデイスク・エー／エス|Compounds used in the treatment of obesity|

---

US6998508B2|2003-03-10|2006-02-14|Air Products And Chemicals, Inc.|Tertiary alkanolamines containing surface active alkyl groups|

---

EP1644479A4|2003-06-16|2008-04-23|Mark W Grinstaff|Functional synthetic molecules and macromolecules for gene delivery|

---

US20050123596A1|2003-09-23|2005-06-09|Kohane Daniel S.|pH-triggered microparticles|

---

JP4510881B2|2004-04-20|2010-07-28|デンドリティックナノテクノロジーズ，インコーポレイテッド|Dendritic polymers with enhanced expandability and internal functionality|

---

CA2569664C|2004-06-07|2013-07-16|Protiva Biotherapeutics, Inc.|Lipid encapsulated interfering rna|

---

US20060035893A1|2004-08-07|2006-02-16|Boehringer Ingelheim International Gmbh|Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders|

---

BRPI0514293A|2004-08-23|2008-06-10|Mannkind Corp|diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug administration|

---

DE102004043342A1|2004-09-08|2006-03-09|Bayer Materialscience Ag|Blocked polyurethane prepolymers as adhesives|

---

GB0502482D0|2005-02-07|2005-03-16|Glaxo Group Ltd|Novel compounds|

---

BRPI0606905B1|2005-02-23|2021-06-01|Shionogi & Co., Ltd.|QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION INCLUDING THEM|

---

US7977452B2|2005-03-28|2011-07-12|Dendritic Nanotechnologies, Inc.|Janus dendrimers and dendrons|

---

AU2006259415B2|2005-06-15|2012-08-30|Massachusetts Institute Of Technology|Amine-containing lipids and uses thereof|

---

RU2394550C2|2005-09-14|2010-07-20|Маннкайнд Корпорейшн|Method of obtaining medical composition, based on increase of crystal micro particles surface affinity to active agents|

---

WO2007073489A2|2005-12-22|2007-06-28|Trustees Of Boston University|Molecules for gene delivery and gene therapy, and methods of use thereof|

---

CN100569877C|2005-12-30|2009-12-16|财团法人工业技术研究院|Contain the dendritic structural compounds of branch and the application thereof of many UV crosslinking reactive group|

---

MX2008010721A|2006-02-22|2008-09-01|Mannkind Corp|A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent.|

---

CA2643744A1|2006-02-27|2007-08-30|Technische Universitaet Muenchen|Cancer imaging and treatment|

---

US20070275923A1|2006-05-25|2007-11-29|Nastech Pharmaceutical Company Inc.|CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY|

---

WO2007143659A2|2006-06-05|2007-12-13|Massachusetts Institute Of Technology|Crosslinked, degradable polymers and uses thereof|

---

ES2293834B1|2006-07-20|2009-02-16|Consejo Superior Investig. Cientificas|COMPOSED WITH INHIBITING ACTIVITY OF UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS THERAPEUTIC APPLICATIONS.|

---

CA2658768C|2006-07-21|2016-05-17|Massachusetts Institute Of Technology|End-modified poly and uses thereof|

---

JP5552313B2|2006-11-01|2014-07-16|プロノヴァ・バイオファーマ・ノルゲ・アーエス|Lipid compounds|

---

WO2008092091A2|2007-01-26|2008-07-31|Jenrin Discovery|Mao inhibiting n-benzyl-n-propargyl-amines useful for treating obesity|

---

EP2139461A2|2007-03-20|2010-01-06|Recepticon Aps|Amino derivatives to prevent nephrotoxicity and cancer|

---

JP5186126B2|2007-03-29|2013-04-17|公益財団法人地球環境産業技術研究機構|Novel triazine derivatives, their production and their use as gas separation membranes|

---

WO2008137470A1|2007-05-01|2008-11-13|Pgr-Solutions|Multi-chain lipophilic polyamines|

---

JP5446119B2|2007-05-08|2014-03-19|公立大学法人大阪府立大学|Polyamidoamine dendron lipids containing lower acyl groups|

---

GB0716897D0|2007-08-30|2007-10-10|Univ Muenchen Tech|Cancer imaging and treatment|

---

JP2009087966A|2007-09-27|2009-04-23|Fujifilm Corp|Polishing liquid for metal and polishing method employing the same|

---

CA2701274A1|2007-10-02|2009-04-09|Mdrna, Inc.|Lipopeptides for delivery of nucleic acids|

---

WO2009086547A1|2008-01-03|2009-07-09|Cedars-Sinai Medical Center|Antioxidant nanosphere comprising [1,2]-dithiolane moieties|

---

KR101492672B1|2008-02-13|2015-02-16|브리스톨-마이어스 스큅 컴퍼니|Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors|

---

DE102008013500A1|2008-03-10|2009-09-17|Evonik Degussa Gmbh|New chiral selectors and stationary phases for the separation of enantiomeric mixtures|

---

EP2350043B9|2008-10-09|2014-08-20|TEKMIRA Pharmaceuticals Corporation|Improved amino lipids and methods for the delivery of nucleic acids|

---

AU2009305639B2|2008-10-16|2016-06-23|Marina Biotech, Inc.|Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics|

---

US20120009222A1|2008-10-27|2012-01-12|Massachusetts Institute Of Technology|Modulation of the immune response|

---

WO2010053572A2|2008-11-07|2010-05-14|Massachusetts Institute Of Technology|Aminoalcohol lipidoids and uses thereof|

---

US8518994B2|2008-12-26|2013-08-27|Nof Corporation|Arginine derivative and cosmetic containing the same|

---

US8314106B2|2008-12-29|2012-11-20|Mannkind Corporation|Substituted diketopiperazine analogs for use as drug delivery agents|

---

DK2379511T3|2008-12-29|2015-01-12|Mannkind Corp|Substituted diketopiperazinanaloger for use as pharmaceutical management funds|

---

CA2752500A1|2009-02-18|2010-08-26|The Lubrizol Corporation|Compounds and a method of lubricating an internal combustion engine|

---

US20100222489A1|2009-02-27|2010-09-02|Jiang Dayue D|Copolymer composition, membrane article, and methods thereof|

---

WO2010114789A1|2009-04-02|2010-10-07|The Siemon Company|Telecommunications patch panel|

---

CA2760776C|2009-05-05|2019-07-09|Alnylam Pharmaceuticals, Inc.|Lipid compositions for the delivery of therapeutic agents|

---

US20120196923A1|2009-05-15|2012-08-02|Kaushal Rege|Polymers for delivering a substance into a cell|

---

CN104721825B|2009-06-12|2019-04-12|曼金德公司|With the diketopiperazine particle for determining specific surface area|

---

CA2769408C|2009-07-30|2017-09-05|Laboratorios Salvat, S.A.|Apaf-1 inhibitor compounds|

---

ES2734973T3|2009-12-01|2019-12-13|Translate Bio Inc|Administration of mRNA for the increase of proteins and enzymes in human genetic diseases|

---

GB0921871D0|2009-12-15|2010-01-27|Univ Leuven Kath|Novel antifungal compounds|

---

CN101863544B|2010-06-29|2011-09-28|湖南科技大学|Cyanuric acid-based heavy metal chelating flocculant and preparation method thereof|

---

WO2012027675A2|2010-08-26|2012-03-01|Massachusetts Institute Of Technology|Poly, their preparation, and uses thereof|

---

WO2012135025A2|2011-03-28|2012-10-04|Massachusetts Institute Of Technology|Conjugated lipomers and uses thereof|

---

WO2012133737A1|2011-03-31|2012-10-04|公益財団法人地球環境産業技術研究機構|Crosslinkable amine compound, polymer membrane using crosslinkable amine compound, and method for producing polymer membrane|

---

EP2532649B1|2011-06-07|2015-04-08|Incella GmbH|Amino lipids, their synthesis and uses thereof|

---

WO2012170889A1|2011-06-08|2012-12-13|Shire Human Genetic Therapies, Inc.|Cleavable lipids|

---

RU2013154295A|2011-06-08|2015-07-20|Шир Хьюман Дженетик Терапис, Инк.|COMPOSITIONS OF LIPID NANOPARTICLES AND METHODS FOR DELIVERY OF mRNA|

---

KR102272498B1|2011-10-27|2021-07-06|메사추세츠 인스티튜트 오브 테크놀로지|Amino acid derivatives functionalized on the n-terminal capable of forming drug incapsulating microspheres|

---

EP2882706A1|2012-08-13|2015-06-17|Massachusetts Institute of Technology|Amine-containing lipidoids and uses thereof|

---

JP5991937B2|2013-03-06|2016-09-14|Ｊｘエネルギー株式会社|Friction modifier and lubricating oil composition|

---

WO2014179562A1|2013-05-01|2014-11-06|Massachusetts Institute Of Technology|1,3,5-triazinane-2,4,6-trione derivatives and uses thereof|

---

US9895443B2|2013-06-26|2018-02-20|Massachusetts Institute Of Technology|Multi-tailed lipids and uses thereof|

---

KR101355583B1|2013-10-04|2014-01-24|한국지질자원연구원|Simplicity valuable mineral decollator and valuable mineral separating method using thereof|

---

KR102096796B1|2013-10-22|2020-05-27|샤이어 휴먼 지네틱 테라피즈 인크.|Lipid formulations for delivery of messenger rna|

---

EP3164379A1|2014-07-02|2017-05-10|Massachusetts Institute of Technology|Polyamine-fatty acid derived lipidoids and uses thereof|

---

EP3310764A1|2015-06-19|2018-04-25|Massachusetts Institute of Technology|Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell|AT512674T|2003-01-06|2011-07-15|Angiochem Inc|ANGIOPEP-1, RELATED CONNECTIONS AND THEIR USES|

---

US9365634B2|2007-05-29|2016-06-14|Angiochem Inc.|Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues|

---

AU2006259415B2|2005-06-15|2012-08-30|Massachusetts Institute Of Technology|Amine-containing lipids and uses thereof|

---

BRPI0910557A2|2008-04-18|2015-09-29|Angiochem Inc|paclitaxel pharmaceutical compositions, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use.|

---

US8828925B2|2008-10-15|2014-09-09|Angiochem Inc.|Etoposide and doxorubicin conjugates for drug delivery|

---

MX2011004017A|2008-10-15|2011-06-24|Angiochem Inc|Conjugates of glp-1 agonists and uses thereof.|

---

WO2010053572A2|2008-11-07|2010-05-14|Massachusetts Institute Of Technology|Aminoalcohol lipidoids and uses thereof|

---

CN102307904A|2008-12-05|2012-01-04|安吉奥开米公司|Conjugates of neurotensin or neurotensin analogs and uses thereof|

---

BRPI0922611A2|2008-12-17|2018-11-06|Angiochem Inc|type 1 membrane matrix metalloprotein inhibitors and uses thereof|

---

WO2010121379A1|2009-04-20|2010-10-28|Angiochem Inc|Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog|

---

WO2011000095A1|2009-07-02|2011-01-06|Angiochem Inc.|Multimeric peptide conjugates and uses thereof|

---

ES2734973T3|2009-12-01|2019-12-13|Translate Bio Inc|Administration of mRNA for the increase of proteins and enzymes in human genetic diseases|

---

US8822663B2|2010-08-06|2014-09-02|Moderna Therapeutics, Inc.|Engineered nucleic acids and methods of use thereof|

---

WO2012027675A2|2010-08-26|2012-03-01|Massachusetts Institute Of Technology|Poly, their preparation, and uses thereof|

---

EP2625189B1|2010-10-01|2018-06-27|ModernaTX, Inc.|Engineered nucleic acids and methods of use thereof|

---

WO2012135025A2|2011-03-28|2012-10-04|Massachusetts Institute Of Technology|Conjugated lipomers and uses thereof|

---

WO2012135805A2|2011-03-31|2012-10-04|modeRNA Therapeutics|Delivery and formulation of engineered nucleic acids|

---

RU2013154295A|2011-06-08|2015-07-20|Шир Хьюман Дженетик Терапис, Инк.|COMPOSITIONS OF LIPID NANOPARTICLES AND METHODS FOR DELIVERY OF mRNA|

---

WO2012170889A1|2011-06-08|2012-12-13|Shire Human Genetic Therapies, Inc.|Cleavable lipids|

---

US9464124B2|2011-09-12|2016-10-11|Moderna Therapeutics, Inc.|Engineered nucleic acids and methods of use thereof|

---

AU2012352180A1|2011-12-16|2014-07-31|Moderna Therapeutics, Inc.|Modified nucleoside, nucleotide, and nucleic acid compositions|

---

CN110511939A|2011-10-03|2019-11-29|现代泰克斯公司|Nucleosides, nucleotide and nucleic acid of modification and application thereof|

---

KR102272498B1|2011-10-27|2021-07-06|메사추세츠 인스티튜트 오브 테크놀로지|Amino acid derivatives functionalized on the n-terminal capable of forming drug incapsulating microspheres|

---

US9283287B2|2012-04-02|2016-03-15|Moderna Therapeutics, Inc.|Modified polynucleotides for the production of nuclear proteins|

---

US9878056B2|2012-04-02|2018-01-30|Modernatx, Inc.|Modified polynucleotides for the production of cosmetic proteins and peptides|

---

US9572897B2|2012-04-02|2017-02-21|Modernatx, Inc.|Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins|

---

AU2013243955B2|2012-04-02|2018-02-22|Modernatx, Inc.|Modified polynucleotides for the production of oncology-related proteins and peptides|

---

WO2013185067A1|2012-06-08|2013-12-12|Shire Human Genetic Therapies, Inc.|Nuclease resistant polynucleotides and uses thereof|

---

EP2882706A1|2012-08-13|2015-06-17|Massachusetts Institute of Technology|Amine-containing lipidoids and uses thereof|

---

EP2922554B1|2012-11-26|2022-02-23|ModernaTX, Inc.|Terminally modified rna|

---

US10258698B2|2013-03-14|2019-04-16|Modernatx, Inc.|Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions|

---

EA201591229A1|2013-03-14|2016-01-29|Шир Хьюман Дженетик Терапис, Инк.|METHODS OF CLEANING MATRIX RNA|

---

PT2968586T|2013-03-14|2018-11-13|Ethris Gmbh|Cftr mrna compositions and related methods and uses|

---

BR112015022855A2|2013-03-14|2017-11-07|Shire Human Genetic Therapies|compositions and method for producing an in vitro antibody|

---

US8980864B2|2013-03-15|2015-03-17|Moderna Therapeutics, Inc.|Compositions and methods of altering cholesterol levels|

---

US10077439B2|2013-03-15|2018-09-18|Modernatx, Inc.|Removal of DNA fragments in mRNA production process|

---

WO2014179562A1|2013-05-01|2014-11-06|Massachusetts Institute Of Technology|1,3,5-triazinane-2,4,6-trione derivatives and uses thereof|

---

EP3041938A1|2013-09-03|2016-07-13|Moderna Therapeutics, Inc.|Circular polynucleotides|

---

AU2014315287A1|2013-09-03|2015-03-12|Moderna Therapeutics, Inc.|Chimeric polynucleotides|

---

WO2015048744A2|2013-09-30|2015-04-02|Moderna Therapeutics, Inc.|Polynucleotides encoding immune modulating polypeptides|

---

US10323076B2|2013-10-03|2019-06-18|Modernatx, Inc.|Polynucleotides encoding low density lipoprotein receptor|

---

EA201690588A1|2013-10-22|2016-09-30|Шир Хьюман Дженетик Терапис, Инк.|DELIVERY OF MRNA IN THE CNS AND ITS APPLICATION|

---

KR102096796B1|2013-10-22|2020-05-27|샤이어 휴먼 지네틱 테라피즈 인크.|Lipid formulations for delivery of messenger rna|

---

EP3501605A1|2013-10-22|2019-06-26|Translate Bio, Inc.|Mrna therapy for argininosuccinate synthetase deficiency|

---

EA201992208A1|2013-10-22|2020-07-31|Транслейт Био, Инк.|TREATMENT OF PHENYLKETONURIA USING mRNA|

---

MX2016011686A|2014-03-09|2016-11-07|Univ Pennsylvania|Compositions useful in treatment of ornithine transcarbamylasedeficiency.|

---

JP6372118B2|2014-03-18|2018-08-15|東洋インキＳｃホールディングス株式会社|Amphoteric surfactant and process for producing the same|

---

ES2774552T3|2014-03-24|2020-07-21|Translate Bio Inc|MRNA therapy for treating eye diseases|

---

BR112016024644A2|2014-04-23|2017-10-10|Modernatx Inc|nucleic acid vaccines|

---

JP6571679B2|2014-04-25|2019-09-04|トランスレイト バイオ， インコーポレイテッド|Method for purifying messenger RNA|

---

EP3587409A1|2014-05-30|2020-01-01|Translate Bio, Inc.|Biodegradable lipids for delivery of nucleic acids|

---

CA2951707A1|2014-06-10|2015-12-17|Massachusetts Institute Of Technology|Method for gene editing|

---

EP3160959A4|2014-06-24|2018-02-28|Translate Bio, Inc.|Stereochemically enriched compositions for delivery of nucleic acids|

---

EP3164379A1|2014-07-02|2017-05-10|Massachusetts Institute of Technology|Polyamine-fatty acid derived lipidoids and uses thereof|

---

CN114146063A|2014-07-02|2022-03-08|川斯勒佰尔公司|Encapsulation of messenger RNA|

---

EP3171895A1|2014-07-23|2017-05-31|Modernatx, Inc.|Modified polynucleotides for the production of intrabodies|

---

US10736966B2|2014-08-12|2020-08-11|Massachusetts Institute Of Technology|Brush-poly -lipids and uses thereof|

---

EP3884964A1|2014-12-05|2021-09-29|Translate Bio, Inc.|Messenger rna therapy for treatment of articular disease|

---

US10172924B2|2015-03-19|2019-01-08|Translate Bio, Inc.|MRNA therapy for pompe disease|

---

EP3297637B1|2015-05-21|2021-05-26|Ohio State Innovation Foundation|Benzene-1,3,5-tricarboxamide derivatives and uses thereof|

---

WO2016205367A1|2015-06-15|2016-12-22|Angiochem Inc.|Methods for the treatment of leptomeningeal carcinomatosis|

---

EP3310764A1|2015-06-19|2018-04-25|Massachusetts Institute of Technology|Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell|

---

CA3002922A1|2015-10-22|2017-04-27|Modernatx, Inc.|Human cytomegalovirus vaccine|

---

EP3394093B1|2015-12-23|2022-01-26|Modernatx, Inc.|Methods of using ox40 ligand encoding polynucleotides|

---

US20190241658A1|2016-01-10|2019-08-08|Modernatx, Inc.|Therapeutic mRNAs encoding anti CTLA-4 antibodies|

---

WO2017177169A1|2016-04-08|2017-10-12|Rana Therapeutics, Inc.|Multimeric coding nucleic acid and uses thereof|

---

RU2018142589A3|2016-05-18|2020-09-18|

---

EP3464336B1|2016-06-01|2022-03-16|Athira Pharma, Inc.|Compounds|

---

CN109312313A|2016-06-13|2019-02-05|川斯勒佰尔公司|For treating the mRNA therapy of ornithine transcarbamylase deficiency disease|

---

DK3436054T3|2016-09-13|2019-11-11|Allergan Inc|STABILIZED NON-PROTEIN CLOSTRID TOXIN COMPOSITIONS|

---

CA3041307A1|2016-10-21|2018-04-26|Giuseppe Ciaramella|Human cytomegalovirus vaccine|

---

US20180153822A1|2016-11-10|2018-06-07|Translate Bio, Inc.|Process of Preparing mRNA-Loaded Lipid Nanoparticles|

---

AU2017356190A1|2016-11-10|2019-05-16|Translate Bio, Inc.|Subcutaneous delivery of messenger RNA|

---

US20200149026A1|2016-12-08|2020-05-14|Curevac Ag|Rnas for wound healing|

---

WO2018104538A1|2016-12-08|2018-06-14|Curevac Ag|Rna for treatment or prophylaxis of a liver disease|

---

CA3054323A1|2017-02-27|2018-08-30|Translate Bio, Inc.|Methods for purification of messenger rna|

---

AU2018224843A1|2017-02-27|2019-09-19|Translate Bio, Inc.|Methods for purification of messenger RNA|

---

AU2018224326A1|2017-02-27|2019-09-19|Translate Bio, Inc.|Novel codon-optimized CFTR mRNA|

---

US10961184B2|2017-03-07|2021-03-30|Translate Bio, Inc.|Polyanionic delivery of nucleic acids|

---

CA3063531A1|2017-05-16|2018-11-22|Translate Bio, Inc.|Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr|

---

EP3641834A1|2017-06-19|2020-04-29|Translate Bio, Inc.|Messenger rna therapy for the treatment of friedreich's ataxia|

---

EP3681900A4|2017-09-11|2021-09-08|Protagonist Therapeutics, Inc.|Opioid agonist peptides and uses thereof|

---

EP3461487A1|2017-09-29|2019-04-03|Nlife Therapeutics S.L.|Compositions and methods for the delivery of mrna to hepatic cells|

---

WO2019079367A1|2017-10-17|2019-04-25|Sarepta Therapeutics, Inc.|Bicyclic peptide oligonucleotide conjugates|

---

US20200316210A1|2017-10-17|2020-10-08|Sarepta Therapeutics, Inc.|Cell-Penetrating Peptides For Antisense Delivery|

---

CN111386105A|2017-11-06|2020-07-07|日东电工株式会社|Membrane fusion compounds for delivery of bioactive molecules|

---

EP3727428A1|2017-12-20|2020-10-28|Translate Bio, Inc.|Improved composition and methods for treatment of ornithine transcarbamylase deficiency|

---

KR102128951B1|2017-12-21|2020-07-01|탑월드|Cosmetic composition including beeswax with animal oil and vegetable oil|

---

WO2019152802A1|2018-02-02|2019-08-08|Translate Bio, Inc.|Cationic polymers|

---

CN108467475B|2018-03-08|2020-02-14|山西大学|Cyclic polymer and preparation method and application thereof|

---

MA52148A|2018-03-16|2021-01-20|Sarepta Therapeutics Inc|PEPTIDES CHIMÈRES FOR ADMINISTRATION OF ANTISENS|

---

US20210220449A1|2018-05-15|2021-07-22|Translate Bio, Inc.|Subcutaneous Delivery of Messenger RNA|

---

CN112384523A|2018-05-16|2021-02-19|川斯勒佰尔公司|Cationic lipid of ribose|

---

CA3100254A1|2018-05-24|2019-11-28|Translate Bio, Inc.|Thioester cationic lipids|

---

EP3801467A1|2018-05-30|2021-04-14|Translate Bio, Inc.|Messenger rna vaccines and uses thereof|

---

AU2019278813A1|2018-05-30|2020-12-03|Translate Bio, Inc.|Cationic lipids comprising a steroidal moiety|

---

EP3802507A1|2018-05-30|2021-04-14|Translate Bio, Inc.|Vitamin cationic lipids|

---

CN112672761A|2018-05-30|2021-04-16|川斯勒佰尔公司|Phosphate cationic lipids|

---

CN108727209A|2018-06-20|2018-11-02|复旦大学|With N, the compound and preparation method thereof of N- dialkyl group leucine structures|

---

WO2019246405A1|2018-06-21|2019-12-26|Merck Sharp & Dohme Corp.|Cyclic polypeptides for pcsk9 inhibition|

---

EP3826608A1|2018-07-23|2021-06-02|Translate Bio, Inc.|Dry power formulations for messenger rna|

---

EP3833762A1|2018-08-09|2021-06-16|Verseau Therapeutics, Inc.|Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof|

---

KR20210060480A|2018-08-24|2021-05-26|트랜슬레이트 바이오 인코포레이티드|Method for purifying messenger RNA|

---

EP3843709A1|2018-08-29|2021-07-07|Translate Bio, Inc.|Improved process of preparing mrna-loaded lipid nanoparticles|

---

JP2022513308A|2018-08-30|2022-02-07|テナヤ セラピューティクス， インコーポレイテッド|Cardiac cell reprogramming with myocardin and ASCL1|

---

WO2020056294A1|2018-09-14|2020-03-19|Translate Bio, Inc.|Composition and methods for treatment of methylmalonic acidemia|

---

EP3866825A1|2018-10-19|2021-08-25|Translate Bio, Inc.|Pumpless encapsulation of messenger rna|

---

US20210388338A1|2018-11-08|2021-12-16|Translate Bio, Inc.|Methods and Compositions for Messenger RNA Purification|

---

EP3876914A2|2018-11-09|2021-09-15|Translate Bio, Inc.|Messenger rna therapy for treatment of ocular diseases|

---

AU2019377525A1|2018-11-09|2021-05-27|Translate Bio, Inc.|Multi-PEG lipid compounds|

---

US20220071905A1|2018-11-09|2022-03-10|Translate Bio, Inc.|Peg lipidoid compounds|

---

WO2020097384A1|2018-11-09|2020-05-14|Translate Bio, Inc.|2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities|

---

WO2020102172A2|2018-11-12|2020-05-22|Translate Bio, Inc.|Methods for inducing immune tolerance|

---

CA3119976A1|2018-11-21|2020-05-28|Translate Bio, Inc.|Cationic lipid compounds|

---

AU2019384557A1|2018-11-21|2021-06-10|Translate Bio, Inc.|Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR|

---

CA3118034A1|2018-12-21|2020-06-25|Curevac Ag|Rna for malaria vaccines|

---

CA3125588A1|2019-01-07|2020-07-16|Translate Bio, Inc.|Composition and methods for treatment of primary ciliary dyskinesia|

---

EP3920950A1|2019-02-08|2021-12-15|CureVac AG|Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases|

---

EP3956303A1|2019-04-18|2022-02-23|Translate Bio, Inc.|Cystine cationic lipids|

---

EP3959195A1|2019-04-22|2022-03-02|Translate Bio, Inc.|Thioester cationic lipids|

---

EP3962902A1|2019-05-03|2022-03-09|Translate Bio, Inc.|Di-thioester cationic lipids|

---

AU2020274758A1|2019-05-14|2021-12-23|Translate Bio, Inc.|Improved process of preparing mRNA-loaded lipid nanoparticles|

---

WO2020243540A1|2019-05-31|2020-12-03|Translate Bio, Inc.|Macrocyclic lipids|

---

WO2020254535A1|2019-06-18|2020-12-24|Curevac Ag|Rotavirus mrna vaccine|

---

CA3144457A1|2019-06-21|2020-12-24|Translate Bio, Inc.|Tricine and citric acid lipids|

---

WO2020257611A1|2019-06-21|2020-12-24|Translate Bio, Inc.|Cationic lipids comprising an hydroxy moiety|

---

CA3146369A1|2019-07-08|2021-01-14|Translate Bio, Inc.|Improved mrna-loaded lipid nanoparticles and processes of making the same|

---

WO2021007515A1|2019-07-11|2021-01-14|Tenaya Therapeutics, Inc.|Cardiac cell reprogramming with micrornas and other factors|

---

WO2021016430A1|2019-07-23|2021-01-28|Translate Bio, Inc.|Stable compositions of mrna-loaded lipid nanoparticles and processes of making|

---

WO2021021988A1|2019-07-30|2021-02-04|Translate Bio, Inc.|Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr|

---

WO2021028439A1|2019-08-14|2021-02-18|Curevac Ag|Rna combinations and compositions with decreased immunostimulatory properties|

---

WO2021055609A1|2019-09-20|2021-03-25|Translate Bio, Inc.|Mrna encoding engineered cftr|

---

WO2021061707A1|2019-09-23|2021-04-01|Omega Therapeutics, Inc.|Compositions and methods for modulating apolipoprotein bgene expression|

---

WO2021061815A1|2019-09-23|2021-04-01|Omega Therapeutics, Inc.|COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHAGENE EXPRESSION|

---

US20210106527A1|2019-10-09|2021-04-15|Translate Bio, Inc.|Compositions, methods and uses of messenger rna|

---

WO2021081058A1|2019-10-21|2021-04-29|Translate Bio, Inc.|Compositions, methods and uses of messenger rna|

---

WO2021123332A1|2019-12-20|2021-06-24|Curevac Ag|Lipid nanoparticles for delivery of nucleic acids|

---

WO2021127394A2|2019-12-20|2021-06-24|Translate Bio, Inc.|Rectal delivery of messenger rna|

---

US20210186890A1|2019-12-20|2021-06-24|Translate Bio, Inc.|Process of preparing mrna-loaded lipid nanoparticles|

---

WO2021142245A1|2020-01-10|2021-07-15|Translate Bio, Inc.|Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues|

---

WO2021156267A1|2020-02-04|2021-08-12|Curevac Ag|Coronavirus vaccine|

---

US20210275689A1|2020-02-25|2021-09-09|Translate Bio, Inc.|Processes of preparing mrna-loaded lipid nanoparticles|

---

WO2021178246A1|2020-03-02|2021-09-10|Tenaya Therapeutics, Inc.|Gene vector control by cardiomyocyte-expressed micrornas|

---

WO2021183720A1|2020-03-11|2021-09-16|Omega Therapeutics, Inc.|Compositions and methods for modulating forkhead box p3gene expression|

---

WO2021189355A1|2020-03-26|2021-09-30|Chinese Institute For Brain Research, Beijing|Amino acid mediated gene delivery and its uses|

---

WO2021226463A1|2020-05-07|2021-11-11|Translate Bio, Inc.|Composition and methods for treatment of primary ciliary dyskinesia|

---

WO2021226468A1|2020-05-07|2021-11-11|Translate Bio, Inc.|Improved compositions for cftr mrna therapy|

---

WO2021226436A1|2020-05-07|2021-11-11|Translate Bio, Inc.|Optimized nucleotide sequences encoding sars-cov-2 antigens|

---

WO2021231697A1|2020-05-14|2021-11-18|Translate Bio, Inc.|Peg lipidoid compounds|

---

US20210353556A1|2020-05-15|2021-11-18|Translate Bio, Inc.|Lipid Nanoparticle Formulations for mRNA Delivery|

---

WO2021236930A1|2020-05-20|2021-11-25|Flagship Pioneering Innovations Vi, Llc|Immunogenic compositions and uses thereof|

---

WO2021236980A1|2020-05-20|2021-11-25|Flagship Pioneering Innovations Vi, Llc|Coronavirus antigen compositions and their uses|

---

CN111517974A|2020-05-28|2020-08-11|浙江昂拓莱司生物技术有限公司|Amino acid N-terminal alkylated derivative and preparation method and application thereof|

---

WO2021243290A1|2020-05-29|2021-12-02|Flagship Pioneering Innovations Vi, Llc|Trem compositions and methods relating thereto|

---

WO2021243301A2|2020-05-29|2021-12-02|Flagship Pioneering Innovations Vi, Llc.|Trem compositions and methods relating thereto|

---

WO2021239880A1|2020-05-29|2021-12-02|Curevac Ag|Nucleic acid based combination vaccines|

---

WO2022006527A1|2020-07-02|2022-01-06|Maritime Therapeutics, Inc.|Compositions and methods for reverse gene therapy|

---

WO2022023559A1|2020-07-31|2022-02-03|Curevac Ag|Nucleic acid encoded antibody mixtures|

---

WO2022043551A2|2020-08-31|2022-03-03|Curevac Ag|Multivalent nucleic acid based coronavirus vaccines|

法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-03-27| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-04-24| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-07-09| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2021-06-01| B350| Update of information on the portal [chapter 15.35 patent gazette]|

---

2021-08-24| B15K| Others concerning applications: alteration of classification|Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 207/16 , C07D 209/20 , C07D 233/64 , C07D 241/08 , C07D 403/06 , C07D 487/06 , C07C 227/18 , C07C 229/12 , C07C 229/16 , C07C 229/22 , C07C 229/26 , C07C 229/28 , A61K 48/00 , C12N 15/87 Ipc: C07D 207/16 (2006.01), C07D 209/20 (2006.01), C07D |

---

2021-11-03| B350| Update of information on the portal [chapter 15.35 patent gazette]|

---

2021-12-07| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161552423P| true| 2011-10-27|2011-10-27|

---

US61/552,423|2011-10-27|

---

PCT/US2012/062222|WO2013063468A1|2011-10-27|2012-10-26|Amino acid derivates functionalized on the n- terminal capable of forming drug incapsulating microspheres|

---